0000049071-24-000023.txt : 20240424 0000049071-24-000023.hdr.sgml : 20240424 20240424154725 ACCESSION NUMBER: 0000049071-24-000023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240424 DATE AS OF CHANGE: 20240424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANA INC CENTRAL INDEX KEY: 0000049071 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 610647538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-05975 FILM NUMBER: 24870416 BUSINESS ADDRESS: STREET 1: 500 W MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 5025801000 MAIL ADDRESS: STREET 1: 500 W. MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 FORMER COMPANY: FORMER CONFORMED NAME: EXTENDICARE INC DATE OF NAME CHANGE: 19740404 FORMER COMPANY: FORMER CONFORMED NAME: HERITAGE HOUSE OF AMERICA INC DATE OF NAME CHANGE: 19671129 10-Q 1 hum-20240331.htm 10-Q hum-20240331
0000049071--12-312024Q1false0.16670.1667http://fasb.org/us-gaap/2023#HealthCareMemberhttp://fasb.org/us-gaap/2023#HealthCareMemberP1Y00000490712024-01-012024-03-3100000490712024-03-31xbrli:sharesiso4217:USD00000490712023-12-31iso4217:USDxbrli:shares00000490712023-01-012023-03-310000049071us-gaap:CommonStockMember2023-12-310000049071us-gaap:AdditionalPaidInCapitalMember2023-12-310000049071us-gaap:RetainedEarningsMember2023-12-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000049071us-gaap:TreasuryStockCommonMember2023-12-310000049071us-gaap:ParentMember2023-12-310000049071us-gaap:NoncontrollingInterestMember2023-12-310000049071us-gaap:RetainedEarningsMember2024-01-012024-03-310000049071us-gaap:ParentMember2024-01-012024-03-310000049071us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000049071us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000049071us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000049071us-gaap:CommonStockMember2024-01-012024-03-310000049071us-gaap:CommonStockMember2024-03-310000049071us-gaap:AdditionalPaidInCapitalMember2024-03-310000049071us-gaap:RetainedEarningsMember2024-03-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000049071us-gaap:TreasuryStockCommonMember2024-03-310000049071us-gaap:ParentMember2024-03-310000049071us-gaap:NoncontrollingInterestMember2024-03-310000049071us-gaap:CommonStockMember2022-12-310000049071us-gaap:AdditionalPaidInCapitalMember2022-12-310000049071us-gaap:RetainedEarningsMember2022-12-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000049071us-gaap:TreasuryStockCommonMember2022-12-310000049071us-gaap:ParentMember2022-12-310000049071us-gaap:NoncontrollingInterestMember2022-12-3100000490712022-12-310000049071us-gaap:RetainedEarningsMember2023-01-012023-03-310000049071us-gaap:ParentMember2023-01-012023-03-310000049071us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000049071us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000049071us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000049071us-gaap:CommonStockMember2023-03-310000049071us-gaap:AdditionalPaidInCapitalMember2023-03-310000049071us-gaap:RetainedEarningsMember2023-03-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000049071us-gaap:TreasuryStockCommonMember2023-03-310000049071us-gaap:ParentMember2023-03-310000049071us-gaap:NoncontrollingInterestMember2023-03-3100000490712023-03-310000049071hum:ValueCreationInitiativesMember2024-01-012024-03-310000049071us-gaap:ServiceMember2024-03-310000049071us-gaap:USTreasuryAndGovernmentMember2024-03-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-03-310000049071us-gaap:NontaxableMunicipalNotesMember2024-03-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMember2024-03-310000049071us-gaap:CommercialMortgageBackedSecuritiesMember2024-03-310000049071us-gaap:AssetBackedSecuritiesMember2024-03-310000049071us-gaap:CorporateDebtSecuritiesMember2024-03-310000049071us-gaap:USTreasuryAndGovernmentMember2023-12-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000049071us-gaap:NontaxableMunicipalNotesMember2023-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:AssetBackedSecuritiesMember2023-12-310000049071us-gaap:CorporateDebtSecuritiesMember2023-12-310000049071hum:GentivaHospiceMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2024-03-310000049071hum:GentivaHospiceMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-12-310000049071srt:StandardPoorsAAMinusRatingMember2024-03-31xbrli:purehum:position0000049071us-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310000049071us-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:InvestmentsMemberhum:FairValueRiskMemberus-gaap:FairValueInputsLevel3Member2024-01-012024-03-310000049071us-gaap:InvestmentsMemberhum:FairValueRiskMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-12-310000049071us-gaap:InterestRateSwapMember2024-03-310000049071us-gaap:SeniorNotesMemberhum:A5875PercentSeniorNotesDueMarch2033Member2024-03-310000049071us-gaap:InterestRateSwapMemberhum:InterestRateSwapMaturing2033Member2024-03-310000049071us-gaap:InterestRateSwapMemberhum:InterestRateSwapMaturing2033Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5.950PercentSeniorNotesDueMarch2034Member2024-03-310000049071hum:InterestRateSwapMaturing2034Memberus-gaap:InterestRateSwapMember2024-03-310000049071hum:InterestRateSwapMaturing2034Memberus-gaap:InterestRateSwapMember2023-12-310000049071us-gaap:SeniorNotesMemberhum:A395PercentSeniorNotesDueAugust2049Member2024-03-310000049071us-gaap:InterestRateSwapMemberhum:InterestRateSwapMaturing2049Member2024-03-310000049071us-gaap:InterestRateSwapMemberhum:InterestRateSwapMaturing2049Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A550PercentSeniorNotesDueMarch2053Member2024-03-310000049071hum:InterestRateSwapMaturing2053Memberus-gaap:InterestRateSwapMember2024-03-310000049071hum:InterestRateSwapMaturing2053Memberus-gaap:InterestRateSwapMember2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5.750PercentSeniorNotesDueApril2054Member2024-03-310000049071hum:InterestRateSwapMaturing2054Memberus-gaap:InterestRateSwapMember2024-03-310000049071hum:InterestRateSwapMaturing2054Memberus-gaap:InterestRateSwapMember2023-12-310000049071us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310000049071us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000049071us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000049071us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000049071hum:TermLoanAndCommercialPaperMember2024-03-310000049071hum:TermLoanAndCommercialPaperMember2023-12-310000049071us-gaap:PutOptionMember2024-03-310000049071us-gaap:CallOptionMember2024-03-310000049071us-gaap:PutOptionMember2023-12-310000049071us-gaap:CallOptionMember2023-12-310000049071us-gaap:MeasurementInputOptionVolatilityMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071us-gaap:MeasurementInputOptionVolatilityMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071us-gaap:MeasurementInputOptionVolatilityMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071us-gaap:MeasurementInputOptionVolatilityMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071us-gaap:CreditSpreadOptionMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071srt:MaximumMemberus-gaap:CreditSpreadOptionMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071us-gaap:CreditSpreadOptionMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071srt:MaximumMemberus-gaap:CreditSpreadOptionMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071hum:RevenueExitMultipleMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071srt:MaximumMemberhum:RevenueExitMultipleMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071hum:RevenueExitMultipleMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071srt:MaximumMemberhum:RevenueExitMultipleMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071us-gaap:MeasurementInputLongTermRevenueGrowthRateMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310000049071us-gaap:MeasurementInputLongTermRevenueGrowthRateMemberus-gaap:OptionOnSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000049071hum:RiskCorridorSettlementsMedicarePartDMember2024-03-310000049071hum:CmsSubsidiesOrDiscountsMember2024-03-310000049071hum:RiskCorridorSettlementsMedicarePartDMember2023-12-310000049071hum:CmsSubsidiesOrDiscountsMember2023-12-310000049071hum:InsuranceSegmentMember2023-12-310000049071hum:CenterWellSegmentMember2023-12-310000049071hum:InsuranceSegmentMember2024-01-012024-03-310000049071hum:CenterWellSegmentMember2024-01-012024-03-310000049071hum:InsuranceSegmentMember2024-03-310000049071hum:CenterWellSegmentMember2024-03-310000049071hum:CertificateOfNeedMember2024-03-310000049071hum:CertificateOfNeedMember2023-12-310000049071us-gaap:LicensingAgreementsMember2024-03-310000049071us-gaap:LicensingAgreementsMember2023-12-310000049071us-gaap:CustomerContractsMember2024-03-310000049071us-gaap:CustomerContractsMember2023-12-310000049071us-gaap:TradeNamesMember2024-03-310000049071us-gaap:TradeNamesMember2023-12-310000049071us-gaap:ContractualRightsMember2024-03-310000049071us-gaap:ContractualRightsMember2023-12-310000049071hum:NoncompetesAndOtherMember2024-03-310000049071hum:NoncompetesAndOtherMember2023-12-310000049071us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000049071us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000049071us-gaap:RestrictedStockMember2024-01-012024-03-310000049071us-gaap:RestrictedStockMember2023-01-012023-03-3100000490712024-01-262024-01-2600000490712024-02-012024-02-290000049071us-gaap:SubsequentEventMember2024-04-012024-04-300000049071hum:A2023ShareRepurchaseAuthorizationMember2024-02-160000049071hum:A2024ShareRepurchaseAuthorizationMember2024-02-160000049071hum:A2023And2024ShareRepurchaseAuthorizationMember2024-01-012024-03-310000049071hum:A2023ShareRepurchaseAuthorizationMember2023-01-012023-03-310000049071us-gaap:SubsequentEventMember2024-04-230000049071us-gaap:CommercialPaperMember2024-03-310000049071us-gaap:CommercialPaperMember2023-12-310000049071us-gaap:SeniorNotesMemberhum:A3.85PercentSeniorNotesDueOctober2024Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A3.85PercentSeniorNotesDueOctober2024Member2023-12-310000049071us-gaap:SeniorNotesMember2024-03-310000049071us-gaap:SeniorNotesMember2023-12-310000049071us-gaap:SeniorNotesMemberhum:A450PercentSeniorNotesDueApril2025Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A450PercentSeniorNotesDueApril2025Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A570PercentSeniorNotesDueMarch2026Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A570PercentSeniorNotesDueMarch2026Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A135PercentSeniorNotesDueFebruary2027Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A135PercentSeniorNotesDueFebruary2027Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A3.95PercentSeniorNotesDueMarch2027Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A3.95PercentSeniorNotesDueMarch2027Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5750PercentSeniorNotesDueMarch2028Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A5750PercentSeniorNotesDueMarch2028Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5.750PercentSeniorNotesDueDecember2028Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A5.750PercentSeniorNotesDueDecember2028Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A3700PercentSeniorNotesDueMarch2029Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A3700PercentSeniorNotesDueMarch2029Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A3125PercentSeniorNotesDueAugust2029Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A3125PercentSeniorNotesDueAugust2029Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A4875PercentSeniorNotesDueApril2030Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A4875PercentSeniorNotesDueApril2030Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5.375PercentSeniorNotesDueApril2031Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A5.375PercentSeniorNotesDueApril2031Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A215PercentSeniorNotesDueFebruary2032Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A215PercentSeniorNotesDueFebruary2032Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5875PercentSeniorNotesDueMarch2033Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5.950PercentSeniorNotesDueMarch2034Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A8.15PercentSeniorNotesDueJune2038Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A8.15PercentSeniorNotesDueJune2038Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A4.625PercentSeniorNotesDueDecember2042Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A4.625PercentSeniorNotesDueDecember2042Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A4.95PercentSeniorNotesDueOctober2044Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A4.95PercentSeniorNotesDueOctober2044Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A4.80PercentSeniorNotesDueMarch2047Member2024-03-310000049071us-gaap:SeniorNotesMemberhum:A4.80PercentSeniorNotesDueMarch2047Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A395PercentSeniorNotesDueAugust2049Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A550PercentSeniorNotesDueMarch2053Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5.750PercentSeniorNotesDueApril2054Member2023-12-310000049071us-gaap:SeniorNotesMemberhum:A5.375PercentSeniorNotesDueApril2031And5.750PercentSeniorNotesDueApril2054Member2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2023-06-012023-06-300000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2023-06-300000049071hum:RevolvingCreditAgreementJune2021FiveYearMemberus-gaap:RevolvingCreditFacilityMember2021-06-012021-06-300000049071hum:RevolvingCreditAgreementJune2021FiveYearMemberus-gaap:RevolvingCreditFacilityMember2021-06-300000049071hum:RevolvingCreditAgreementJune2023OneYearMemberus-gaap:RevolvingCreditFacilityMember2023-06-012023-06-300000049071hum:RevolvingCreditAgreementJune2023OneYearMemberus-gaap:RevolvingCreditFacilityMember2023-06-300000049071hum:RevolvingCreditAgreementJune2022OneYearMemberus-gaap:RevolvingCreditFacilityMember2022-06-012022-06-300000049071hum:RevolvingCreditAgreementJune2022OneYearMemberus-gaap:RevolvingCreditFacilityMember2022-06-300000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberhum:SecuredOvernightFinancingRateSOFRMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023OneYearMemberhum:SecuredOvernightFinancingRateSOFRMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023OneYearMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberhum:SecuredOvernightFinancingRateSOFRMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMembersrt:MaximumMemberhum:SecuredOvernightFinancingRateSOFRMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023OneYearMemberhum:SecuredOvernightFinancingRateSOFRMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071srt:MaximumMemberhum:RevolvingCreditAgreementJune2023OneYearMemberhum:SecuredOvernightFinancingRateSOFRMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071hum:RevolvingCreditAgreementJune2023OneYearMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071srt:MaximumMemberhum:RevolvingCreditAgreementJune2023OneYearMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000049071us-gaap:RevolvingCreditFacilityMember2024-03-310000049071us-gaap:LoansPayableMember2024-03-310000049071us-gaap:LetterOfCreditMember2024-03-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2024-03-310000049071hum:RevolvingCreditAgreementJune2023OneYearMemberus-gaap:RevolvingCreditFacilityMember2024-03-310000049071us-gaap:CommercialPaperMember2024-01-012024-03-310000049071us-gaap:FederalHomeLoanBankAdvancesMember2024-03-310000049071hum:MedicareMember2024-01-012024-03-310000049071hum:MedicaidMember2024-01-012024-03-310000049071hum:MilitaryServiceMemberhum:TRICARE2017EastRegionContractMember2024-01-012024-03-310000049071hum:TRICARE2017EastRegionContractMember2024-03-31hum:state0000049071hum:TRICARE2017EastRegionContractMember2024-01-012024-03-31hum:beneficiary0000049071hum:TRICAREManagedCareSupportContractEffective2024Member2022-12-310000049071hum:TRICAREManagedCareSupportContractEffective2024Member2022-12-012022-12-31hum:option_periodhum:segment0000049071hum:MedicareAdvantageMemberus-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:MedicareAdvantageMemberus-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:MedicareAdvantageMemberus-gaap:ProductMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberhum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberhum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:GroupMedicareAdvantageMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2024-01-012024-03-310000049071hum:MedicareMemberus-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:MedicareMemberus-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:MedicareMemberus-gaap:ProductMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberhum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberhum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:CommercialFullyInsuredMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:SpecialtyBenefitsMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:SpecialtyBenefitsMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:SpecialtyBenefitsMemberus-gaap:ProductMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareSupplementProductMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareSupplementProductMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:MedicareSupplementProductMember2024-01-012024-03-310000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ProductMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:InsuranceSegmentMemberhum:HomeSolutionsMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberhum:HomeSolutionsMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:HomeSolutionsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:PrimaryCareMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:PrimaryCareMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:PrimaryCareMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:InsuranceSegmentMemberhum:CommercialASOMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberhum:CommercialASOMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:CommercialASOMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:MilitaryAndOtherMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:MilitaryAndOtherMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:MilitaryAndOtherMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMemberhum:PharmacySolutionsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMemberhum:PharmacySolutionsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:PharmacySolutionsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071us-gaap:ServiceMember2024-01-012024-03-310000049071hum:ExternalRevenuesMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:ExternalRevenuesMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:ExternalRevenuesMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2024-01-012024-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberhum:CorporateAndEliminationsMember2024-01-012024-03-310000049071us-gaap:ServiceMemberus-gaap:IntersegmentEliminationMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2024-01-012024-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberhum:CorporateAndEliminationsMember2024-01-012024-03-310000049071us-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2024-01-012024-03-310000049071hum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2024-01-012024-03-310000049071hum:CenterWellSegmentMemberhum:CorporateAndEliminationsMember2024-01-012024-03-310000049071us-gaap:IntersegmentEliminationMember2024-01-012024-03-310000049071hum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000049071hum:CorporateAndEliminationsMember2024-01-012024-03-310000049071hum:MedicareAdvantageMemberus-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:MedicareAdvantageMemberus-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:MedicareAdvantageMemberus-gaap:ProductMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberhum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberhum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:GroupMedicareAdvantageMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2023-01-012023-03-310000049071hum:MedicareMemberus-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:MedicareMemberus-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:MedicareMemberus-gaap:ProductMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberhum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberhum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:CommercialFullyInsuredMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:SpecialtyBenefitsMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:SpecialtyBenefitsMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:SpecialtyBenefitsMemberus-gaap:ProductMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareSupplementProductMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareSupplementProductMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:MedicareSupplementProductMember2023-01-012023-03-310000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ProductMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:InsuranceSegmentMemberhum:HomeSolutionsMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberhum:HomeSolutionsMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:HomeSolutionsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:PrimaryCareMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:PrimaryCareMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:PrimaryCareMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:InsuranceSegmentMemberhum:CommercialASOMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberhum:CommercialASOMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:CommercialASOMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:MilitaryAndOtherMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:MilitaryAndOtherMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:MilitaryAndOtherMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMemberhum:PharmacySolutionsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMemberhum:PharmacySolutionsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:PharmacySolutionsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071us-gaap:ServiceMember2023-01-012023-03-310000049071hum:ExternalRevenuesMemberhum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:ExternalRevenuesMemberhum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:ExternalRevenuesMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2023-01-012023-03-310000049071us-gaap:ServiceMemberhum:CenterWellSegmentMemberhum:CorporateAndEliminationsMember2023-01-012023-03-310000049071us-gaap:ServiceMemberus-gaap:IntersegmentEliminationMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2023-01-012023-03-310000049071us-gaap:ProductMemberhum:CenterWellSegmentMemberhum:CorporateAndEliminationsMember2023-01-012023-03-310000049071us-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2023-01-012023-03-310000049071hum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2023-01-012023-03-310000049071hum:CenterWellSegmentMemberhum:CorporateAndEliminationsMember2023-01-012023-03-310000049071us-gaap:IntersegmentEliminationMember2023-01-012023-03-310000049071hum:InsuranceSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:CenterWellSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000049071hum:CorporateAndEliminationsMember2023-01-012023-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number 1-5975
HUMANA INC.
(Exact name of registrant as specified in its charter)
Delaware61-0647538
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
500 West Main Street
Louisville, Kentucky 40202
(Address of principal executive offices, including zip code)
(502) 580-1000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common stock, $0.16 2/3 par valueHUMNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.
Class of Common Stock
Outstanding at March 31, 2024
$0.16 2/3 par value120,500,635 shares

Humana Inc.
FORM 10-Q
MARCH 31, 2024
INDEX
 Page
Part I: Financial Information
Item 1.Financial Statements
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
Certifications


Humana Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
March 31,
2024		December 31, 2023
(in millions, except share amounts)
ASSETS
Current assets:
Cash and cash equivalents$5,910 $4,694 
Investment securities16,697 16,626 
Receivables, net of allowances of $85 in 2024
    and $88 in 2023
3,925 2,035 
Other current assets6,264 6,631 
Total current assets32,796 29,986 
Property and equipment, net2,979 3,030 
Long-term investment securities380 382 
Equity method investments730 740 
Goodwill9,563 9,550 
Other long-term assets3,643 3,377 
Total assets$50,091 $47,065 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Benefits payable$11,729 $10,241 
Trade accounts payable and accrued expenses6,504 6,569 
Book overdraft333 353 
Unearned revenues301 266 
Short-term debt822 1,443 
Total current liabilities19,689 18,872 
Long-term debt12,390 10,213 
Other long-term liabilities1,826 1,662 
Total liabilities33,905 30,747 
Commitments and Contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued
— — 
Common stock, $0.16 2/3 par; 300,000,000 shares authorized;
  198,690,593 shares issued at March 31, 2024 and 198,690,082 shares issued at December 31, 2023
33 33 
Capital in excess of par value3,369 3,346 
Retained earnings28,173 27,540 
Accumulated other comprehensive loss(1,086)(999)
Treasury stock, at cost, 78,189,958 shares at March 31, 2024 and
    76,465,862 shares at December 31, 2023
(14,359)(13,658)
Total stockholders' equity16,130 16,262 
Noncontrolling interests56 56 
Total equity16,186 16,318 
Total liabilities and equity$50,091 $47,065 

See accompanying notes to condensed consolidated financial statements.

3

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
 
Three Months Ended March 31,
 20242023
 (in millions, except per share results)
Revenues:
Premiums$28,261 $25,550 
Services1,062 999 
Investment income288 193 
Total revenues29,611 26,742 
Operating expenses:
Benefits25,124 21,858 
Operating costs3,042 2,979 
Depreciation and amortization209 186 
Total operating expenses28,375 25,023 
Income from operations1,236 1,719 
Interest expense159 113 
Other expense (income), net63 (8)
Income before income taxes and equity in net losses1,014 1,614 
Provision for income taxes251 359 
Equity in net losses(24)(17)
Net income$739 $1,238 
Net loss attributable to noncontrolling interests2 1 
Net income attributable to Humana$741 $1,239 
Basic earnings per common share$6.13 $9.91 
Diluted earnings per common share$6.11 $9.87 
See accompanying notes to condensed consolidated financial statements.

4

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Three Months Ended March 31,
 20242023
 (in millions)
Net income attributable to Humana$741 $1,239 
Other comprehensive income (loss):
Change in gross unrealized investment (losses) gains(114)188 
Effect of income taxes28 (43)
Total change in unrealized investment (losses) gains, net of tax(86)145 
Reclassification adjustment for net realized (gains) losses(1)61 
Effect of income taxes— (15)
Total reclassification adjustment, net of tax(1)46 
Other comprehensive (loss) income, net of tax(87)191 
Comprehensive income attributable to Humana$654 $1,430 
See accompanying notes to condensed consolidated financial statements.

5

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
 Common StockCapital In
Excess of
Par Value		Retained
Earnings		Accumulated
Other
Comprehensive
Income (Loss)		Treasury
Stock		Total Stockholders' EquityNoncontrolling InterestsTotal
Equity
 Issued
Shares		Amount
(dollars in millions, share amounts in thousands)
Three months ended March 31, 2024
Balances, December 31, 2023198,690 $33 $3,346 $27,540 $(999)$(13,658)$16,262 $56 $16,318 
Net income741 741 (2)739 
Distribution from noncontrolling interest holders, net2 2 
Other comprehensive loss(87)(87)(87)
Common stock repurchases— (723)(723)(723)
Dividends and dividend
   equivalents		— (108)(108)(108)
Stock-based compensation45 45 45 
Restricted stock unit vesting1 — (22)22 — — 
Balances, March 31, 2024198,691 $33 $3,369 $28,173 $(1,086)$(14,359)$16,130 $56 $16,186 
Three months ended March 31, 2023
Balances, December 31, 2022198,667 $33 $3,246 $25,492 $(1,304)$(12,156)$15,311 $59 $15,370 
Net income1,239 1,239 (1)1,238 
Distribution from noncontrolling interest holders, net4 4 
Acquisition(5)(5)
Other comprehensive income191 191 191 
Common stock repurchases— (94)(94)(94)
Dividends and dividend
   equivalents		— (112)(112)(112)
Stock-based compensation38 38 38 
Restricted stock unit vesting— — (24)24 — — 
Stock option exercises— — 2 2 4 4 
Balances, March 31, 2023198,667 $33 $3,262 $26,619 $(1,113)$(12,224)$16,577 $57 $16,634 
See accompanying notes to condensed consolidated financial statements.
    



6

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 For the three months ended March 31,
 20242023
 (in millions)
Cash flows from operating activities
Net income$739 $1,238 
Adjustments to reconcile net income to net cash provided by operating activities:
(Gain) loss on investment securities, net(1)60 
Equity in net losses24 17 
Stock-based compensation45 38 
Depreciation226 200 
Amortization16 18 
Impairment of property and equipment33 — 
Changes in operating assets and liabilities, net of effect of
    businesses acquired and disposed:
Receivables(1,890)(1,433)
Other assets97 (907)
Benefits payable1,488 754 
Other liabilities(422)(238)
Unearned revenues35 6,934 
Other33 6 
Net cash provided by operating activities423 6,687 
Cash flows from investing activities
Acquisitions, net of cash and cash equivalents acquired(14)(73)
Purchases of property and equipment, net(177)(223)
Purchases of investment securities(1,259)(1,313)
Proceeds from maturities of investment securities645 267 
Proceeds from sales of investment securities391 50 
Net cash used in investing activities(414)(1,292)
Cash flows from financing activities
Receipts from contract deposits, net499 2,997 
Proceeds from issuance of senior notes, net2,232 1,215 
Repayments of senior notes— (60)
Repayments of commercial paper, net(644)(177)
Repayment of term loan— (500)
Debt issue costs(5)(4)
Change in book overdraft(20)108 
Common stock repurchases(717)(94)
Dividends paid(109)(100)
Other(29)(106)
Net cash provided by financing activities1,207 3,279 
Increase in cash and cash equivalents1,216 8,674 
Cash and cash equivalents at beginning of period4,694 5,061 
Cash and cash equivalents at end of period$5,910 $13,735 






7

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)
(Unaudited)
For the three months ended March 31,
20242023
(in millions)
Supplemental cash flow disclosures:
Interest payments$158 $97 
Income tax payments, net$1 $6 
Details of businesses acquired in purchase transactions:
Fair value of assets acquired, net of cash and cash equivalents acquired$22 $73 
Less: Fair value of liabilities assumed(8)(5)
Less: Noncontrolling interests acquired— 5 
Cash paid for acquired businesses, net of cash and cash equivalents acquired$14 $73 
See accompanying notes to condensed consolidated financial statements.

8


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT EVENTS
The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.
The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
Employer Group Commercial Medical Products Business Exit
In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.

Value Creation Initiatives
Beginning in 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges, primarily in asset impairments, of $29 million for the three months ended March 31, 2024 within operating costs in the consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. We did not record any charges for the three months ended March 31, 2023.
Revenue Recognition
Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are

9


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
At March 31, 2024, accounts receivable related to services were $390 million. For the three months ended March 31, 2024, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at March 31, 2024.
For the three months ended March 31, 2024, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.

2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Accounting Pronouncements Effective in Future Periods
In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

3. ACQUISITIONS
During the first quarter of 2024 and 2023, respectively, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in the first quarter of 2024 and 2023, respectively, have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in the first quarter of 2024 and 2023, were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the quarter of acquisition, were not material for disclosure purposes.

10


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
4. INVESTMENT SECURITIES
Investment securities classified as current and long-term were as follows at March 31, 2024 and December 31, 2023, respectively:
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
 (in millions)
March 31, 2024
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,928 $— $(84)$2,844 
Mortgage-backed securities3,925 — (486)3,439 
Tax-exempt municipal securities850 — (24)826 
Mortgage-backed securities:
Residential462 — (68)394 
Commercial1,420 1 (113)1,308 
Asset-backed securities1,552 2 (37)1,517 
Corporate debt securities7,348 24 (623)6,749 
Total debt securities$18,485 $27 $(1,435)17,077 
December 31, 2023
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,717 $1 $(51)$2,667 
Mortgage-backed securities3,946 1 (425)3,522 
Tax-exempt municipal securities879 1 (22)858 
Mortgage-backed securities:
Residential465 1 (66)400 
Commercial1,471 — (126)1,345 
Asset-backed securities1,813 2 (44)1,771 
Corporate debt securities7,011 28 (594)6,445 
Total debt securities$18,302 $34 $(1,328)17,008 

11


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $379 million and $397 million, respectively, at March 31, 2024. The book value and fair value were $379 million and $398 million, respectively, at December 31, 2023.
Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at March 31, 2024 and December 31, 2023, respectively:
 Less than 12 months12 months or moreTotal
 Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
 (in millions)
March 31, 2024
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$2,301 $(43)$447 $(41)$2,748 $(84)
Mortgage-backed securities862 (15)2,513 (471)3,375 (486)
Tax-exempt municipal securities261 (1)508 (23)769 (24)
Mortgage-backed securities:
Residential9 — 365 (68)374 (68)
Commercial— — 1,242 (113)1,242 (113)
Asset-backed securities447 (2)787 (35)1,234 (37)
Corporate debt securities824 (7)4,702 (616)5,526 (623)
Total debt securities$4,704 $(68)$10,564 $(1,367)$15,268 $(1,435)
December 31, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$1,899 $(12)$431 $(39)$2,330 $(51)
Mortgage-backed securities958 (12)2,269 (413)3,227 (425)
Tax-exempt municipal securities160 (1)523 (21)683 (22)
Mortgage-backed securities:
Residential— — 373 (66)373 (66)
Commercial18 — 1,303 (126)1,321 (126)
Asset-backed securities120 (1)1,364 (43)1,484 (44)
Corporate debt securities466 (2)4,783 (592)5,249 (594)
Total debt securities$3,621 $(28)$11,046 $(1,300)$14,667 $(1,328)

Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by Standard & Poor's Rating Service, or S&P, at March 31, 2024. Our remaining debt securities below investment-grade were primarily rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.
Our unrealized losses from all debt securities were generated from approximately 1,685 positions out of a total of approximately 2,100 positions at March 31, 2024. All issuers of debt securities we own that were trading at an

12


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
unrealized loss at March 31, 2024 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At March 31, 2024, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three months ended March 31, 2024 or 2023.
The detail of gains (losses) related to investment securities and included within investment income was as follows for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
 20242023
 (in millions)
Gross gains on investment securities$2 $— 
Gross losses on investment securities(1)(61)
Gross gains on equity securities— 1 
Gross losses on equity securities— — 
Net recognized gains (losses) on investment securities$1 $(60)
The gains and losses related to equity securities for the three months ended March 31, 2024 and 2023 was as follows:
Three Months Ended March 31,
20242023
(in millions)
Net gains (losses) recognized on equity securities during the period$— $1 
Less: Net gains (losses) recognized on equity securities sold during the period— 1 
Unrealized gains (losses) recognized on equity securities still held at the end of the period$— $— 
The contractual maturities of debt securities available for sale at March 31, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.
Amortized
Cost		Fair
Value
 (in millions)
Due within one year$1,235 $1,229 
Due after one year through five years5,402 5,199 
Due after five years through ten years3,259 2,954 
Due after ten years1,230 1,037 
Mortgage and asset-backed securities7,359 6,658 
Total debt securities$18,485 $17,077 

For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

13


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
5. FAIR VALUE
Financial Assets
The following table summarizes our fair value measurements at March 31, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:
 Fair Value Measurements Using
 Fair
Value		Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)
 (in millions)
March 31, 2024
Cash equivalents$5,594 $5,594 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,844 — 2,844 — 
Mortgage-backed securities3,439 — 3,439 — 
Tax-exempt municipal securities826 — 826 — 
Mortgage-backed securities:
Residential394 — 391 3 
Commercial1,308 — 1,308 — 
Asset-backed securities1,517 — 1,479 38 
Corporate debt securities6,749 — 6,564 185 
Total debt securities17,077 — 16,851 226 
Total invested assets$22,671 $5,594 $16,851 $226 
December 31, 2023
Cash equivalents$4,582 $4,582 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,667 — 2,667 — 
Mortgage-backed securities3,522 — 3,522 — 
Tax-exempt municipal securities858 — 858 — 
Mortgage-backed securities:
Residential400 — 396 4 
Commercial1,345 — 1,345 — 
Asset-backed securities1,771 — 1,733 38 
Corporate debt securities6,445 — 6,269 176 
Total debt securities17,008 — 16,790 218 
Total invested assets$21,590 $4,582 $16,790 $218 
Our Level 3 assets had a fair value of $226 million, or 1.0% of total invested assets, and $218 million, or 1.0% or total invested assets, at March 31, 2024 and December 31, 2023, respectively. During the three months ended

14


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
March 31, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    
For the three months ended March 31, 2024For the three months ended March 31, 2023
Private Placements
(in millions)
Beginning balance at January 1$218 $101 
Total gains or losses:
Realized in earnings— — 
Unrealized in other comprehensive income(2)1 
Purchases11 1 
Sales— — 
Settlements(1)— 
Transfer out— (4)
Balance at March 31$226 $99 
Interest Rate Swaps

We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on SOFR, to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our condensed consolidated balance sheets at fair value as of the reporting date. Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy. The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $17 million at March 31, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheets, were approximately $20 million and $68 million at March 31, 2024 and December 31, 2023, respectively. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three months ended March 31, 2024. We did not enter into interest-rate swap agreements for the three months ended March 31, 2023. The following table summarizes the notional amounts at March 31, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:

March 31, 2024December 31, 2023
(in millions)
$750 million, 5.875% due March 1, 2033
$650 $650 
$850 million, 5.950% due March 15, 2034
800 400 
$500 million, 3.950% due August 15, 2049
450 450 
$750 million, 5.500% due March 15, 2053
700 300 
$1,000 million, 5.750% due April 15, 2054
400 — 

Financial Liabilities
Our debt is recorded at carrying value in our condensed consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $13.0 billion at March 31, 2024 and $10.8 billion at December 31, 2023. The fair value of our senior notes debt was $12.6 billion at March 31, 2024 and $10.6 billion at December 31, 2023. The fair value of our senior notes debt is determined based on Level 2 inputs,

15


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our commercial paper borrowings. The commercial paper borrowings were $0.3 billion and $0.9 billion at March 31, 2024 and December 31, 2023, respectively.
Put and Call Options Measured at Fair Value
Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.
The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $731 million and $22 million, respectively, at March 31, 2024. The put and call options fair values, derived from the Monte Carlo simulation, were $595 million and $18 million, respectively, at December 31, 2023. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.
The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.
March 31, 2024December 31, 2023
Annualized volatility
17.0% - 18.8%
16.1% - 17.8%
Credit spread
1.0% - 1.3%
0.9% - 1.1%
Revenue exit multiple
1.5x - 2.5x
1.5x - 2.5x
Weighted average cost of capital
11.0% - 12.5%
11.0% - 12.5%
Long term growth rate3.0 %3.0 %
The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.
Other Assets and Liabilities Measured at Fair Value
Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2024 and 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.
Other than the assets and liabilities acquired during 2024 and 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2024 and 2023.

16


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
6. MEDICARE PART D
We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at March 31, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

 March 31, 2024December 31, 2023
Risk
Corridor
Settlement		CMS
Subsidies/
Discounts		Risk
Corridor
Settlement		CMS
Subsidies/
Discounts
 (in millions)
Other current assets$100 $592 $224 $514 
Trade accounts payable and accrued expenses(108)(2,472)(232)(1,825)
Net current liability(8)(1,880)(8)(1,311)
Other long-term assets293 — 17 — 
Other long-term liabilities(81)— (77)— 
Net long-term asset (liability)212 — (60)— 
Total net asset (liability)$204 $(1,880)$(68)$(1,311)

7. GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the carrying amount of goodwill for our reportable segments for the three months ended March 31, 2024 were as follows:
InsuranceCenterWellTotal
 (in millions)
Balance at January 1, 2024$2,663 $6,887 $9,550 
Acquisitions— 13 13 
Balance at March 31, 2024$2,663 $6,900 $9,563 

17


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at March 31, 2024 and December 31, 2023:
 March 31, 2024December 31, 2023
Weighted
Average
Life		CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
 ($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,092 $— $1,092 $1,092 $— $1,092 
Medicare licensesIndefinite288 — 288 288 — 288 
Customer contracts/
    relationships		9.4 years956 728 228 956 718 238 
Trade names and
    technology		6.7 years139 111 28 139 109 30 
Provider contracts11.9 years67 63 4 67 62 5 
Noncompetes and
    other		8.4 years85 46 39 84 44 40 
Total other intangible
    assets		9.2 years$2,627 $948 $1,679 $2,626 $933 $1,693 
    For the three months ended March 31, 2024 and 2023, amortization expense for other intangible assets was approximately $16 million and $18 million, respectively. The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at March 31, 2024:
 (in millions)
For the years ending December 31,
2024$44 
202558 
202643 
202733 
202829 
202927 
For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

18


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
8. BENEFITS PAYABLE
On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the three months ended March 31, 2024 and 2023:
For the three months ended March 31,
20242023
(in millions)
Balances, beginning of period$10,241 $9,264 
Incurred related to:
Current year25,659 22,380 
Prior years(535)(522)
Total incurred25,124 21,858 
Paid related to:
Current year(16,061)(14,203)
Prior years(7,575)(6,901)
Total paid(23,636)(21,104)
Balances, end of period$11,729 $10,018 
The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At March 31, 2024, benefits payable included IBNR of approximately $7.3 billion, primarily associated with claims incurred in 2024.
Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).
Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.


19


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
9. EARNINGS PER COMMON SHARE COMPUTATION
Detail supporting the computation of basic and diluted earnings per common share was as follows for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders$741 $1,239 
Weighted average outstanding shares of common stock
    used to compute basic earnings per common share		120,978 125,005 
Dilutive effect of:
Employee stock options6 34 
Restricted stock284 525 
Shares used to compute diluted earnings per common share121,268 125,564 
Basic earnings per common share$6.13 $9.91 
Diluted earnings per common share$6.11 $9.87 
Number of antidilutive stock options and restricted stock
    excluded from computation		1,165 538 

For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

10. STOCKHOLDERS’ EQUITY
Dividends
The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:
Record
Date		Payment
Date		Amount
per Share		Total
Amount
(in millions)
2024 payments
12/29/20231/26/2024$0.8850 $108 
In February 2024, the Board declared a cash dividend of $0.885 per share payable on April 26, 2024 to stockholders of record on March 29, 2024. In April 2024, the Board declared a cash dividend of $0.885 per share payable on July 26, 2024 to stockholders of record as of the close of business on June 28, 2024. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.

Stock Repurchases
Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as

20


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.
Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. During the three months ended March 31, 2024, we repurchased 1.8 million shares in open market transactions for $702 million at an average price of $388.78 under the February 2023 and 2024 share repurchase authorizations. During the three months ended March 31, 2023, we repurchased 0.1 million shares in open market transactions for $67 million at an average price of $495.68 under the February 2023 share repurchase authorization.

Our remaining repurchase authorization was $2.96 billion as of April 23, 2024.
In connection with employee stock plans, we acquired 0.04 million common shares for $15 million and 0.05 million common shares for $27 million during the three months ended March 31, 2024 and 2023, respectively.
For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

11. INCOME TAXES
The effective income tax rate was 25.3% and 22.5% for the three months ended March 31, 2024 and 2023, respectively. The year-over-year increase in the effective income tax rate is primarily due to a change in the mix of current year earnings between our Insurance segment and our CenterWell health services segment, as the latter incurs a higher effective domestic tax rate than the former. In addition, the prior year income tax rate was favorably impacted by the recognition of a non-taxable gain.

For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.



21


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
12.  DEBT
The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at March 31, 2024 and December 31, 2023:
March 31, 2024December 31, 2023
(in millions)
Short-term debt:
Commercial paper$250 $871 
Senior notes:
$600 million, 3.850% due October 1, 2024
572 572 
Total senior notes572 572 
Total short-term debt$822 $1,443 
Long-term debt:
Senior notes:
$600 million, 4.500% due April 1, 2025
$599 $598 
$500 million, 5.700% due March 13, 2026
498 498 
$750 million, 1.350% due February 3, 2027
688 688 
$600 million, 3.950% due March 15, 2027
537 537 
$500 million, 5.750% due March 1, 2028
495 495 
$500 million, 5.750% due December 1, 2028
495 495 
$750 million, 3.700% due March 23, 2029
590 590 
$500 million, 3.125% due August 15, 2029
433 433 
$500 million, 4.875% due April 1, 2030
496 496 
$1,250 million, 5.375% due April 15, 2031
1,238 — 
$750 million, 2.150% due February 3, 2032
744 743 
$750 million, 5.875% due March 1, 2033
735 750 
$850 million, 5.950% due March 15, 2034
826 840 
$250 million, 8.150% due June 15, 2038
261 261 
$400 million, 4.625% due December 1, 2042
396 396 
$750 million, 4.950% due October 1, 2044
740 740 
$400 million, 4.800% due March 15, 2047
396 396 
$500 million, 3.950% due August 15, 2049
514 529 
$750 million, 5.500% due March 15, 2053
720 728 
$1,000 million, 5.750% due April 15, 2054
989 — 
Total senior notes12,390 10,213 
Total long-term debt$12,390 $10,213 
Senior Notes
In March 2024, we issued $1.3 billion of 5.375% unsecured senior notes due April 15, 2031 and $1.0 billion of 5.750% unsecured senior notes due April 15, 2054. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $2.2 billion. We used the net proceeds for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.
We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on SOFR, to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value

22


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $17 million at March 31, 2024.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Revolving Credit Agreements
In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021) and entered into a 364-day $1.5 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2022, which expired in accordance with its terms).
Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.
The SOFR spread, currently 114.0 basis points under the 5-year revolving credit agreement and 116.0 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 11.0 basis points, under the 5-year revolving credit agreement and 15.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.
Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 45.1% as measured in accordance with the revolving credit agreements as of March 31, 2024.
At March 31, 2024, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of March 31, 2024, we had $2.482 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement.
For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Commercial Paper
Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the three months ended March 31, 2024 was $2.7 billion, with $0.3 billion outstanding at March 31, 2024 compared to $0.9

23


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
billion outstanding at December 31, 2023. The outstanding commercial paper at March 31, 2024 had a weighted average annual interest rate of 5.46%.
For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Other Short-term Borrowings
We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At March 31, 2024 we had no outstanding short-term FHLB borrowings.
13. COMMITMENTS, GUARANTEES AND CONTINGENCIES
Government Contracts
Our Medicare products, which accounted for approximately 86% of our total premiums and services revenue for the three months ended March 31, 2024, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.
CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.
CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.
In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would

24


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.
In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”
We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.
On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

Our state-based Medicaid business, which accounted for approximately 7% of our total premiums and services revenue for the three months ended March 31, 2024 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states.
At March 31, 2024, our Military services business, which accounted for approximately 1% of our total premiums and services revenue for the three months ended March 31, 2024, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2024, unless further extended.
In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region

25


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
contract comprises 24 states, and Washington D.C., and covers approximately 4.6 million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is one transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.
The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.
Legal Proceedings and Certain Regulatory Matters
As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020.
As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana Inc., currently pending in United States District Court, Western District of Kentucky, Louisville division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. During 2023, we accrued certain anticipated expenses in connection with this matter.
On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.

Other Lawsuits and Regulatory Matters
Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.

26


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.
As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.
A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.
We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.
The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.
14. SEGMENT INFORMATION
Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.
The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration,

27


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.
The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.
Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics.
In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.
We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $3.7 billion and $4.0 billion for the three months ended March 31, 2024 and 2023, respectively. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $32 million and $33 million for the three months ended March 31, 2024 and 2023, respectively.
Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.
Our segment results were as follows for the three months ended March 31, 2024 and 2023:

28


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended March 31, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$22,448 $— $— $22,448 
Group Medicare Advantage1,989 — — 1,989 
Medicare stand-alone PDP821 — — 821 
Total Medicare25,258 — — 25,258 
Commercial fully-insured256 — — 256 
Specialty benefits239 — — 239 
Medicare Supplement197 — — 197 
State-based contracts and other2,311 — — 2,311 
Total premiums28,261 — — 28,261 
Services revenue:
Home solutions— 335 — 335 
Primary care— 241 — 241 
Commercial ASO24 — — 24 
Military services and other251 — — 251 
Pharmacy solutions— 211 — 211 
Total services revenue275 787 — 1,062 
Total external revenues 28,536 787 — 29,323 
Intersegment revenues
Services1 1,414 (1,415)— 
Products— 2,617 (2,617)— 
Total intersegment revenues1 4,031 (4,032)— 
Investment income162 — 126 288 
Total revenues28,699 4,818 (3,906)29,611 
Operating expenses:
Benefits25,251 — (127)25,124 
Operating costs2,364 4,483 (3,805)3,042 
Depreciation and amortization186 53 (30)209 
Total operating expenses27,801 4,536 (3,962)28,375 
Income from operations898 282 56 1,236 
Interest expense— 1 158 159 
Other expense, net— — 63 63 
Income (loss) before income taxes and equity in net earnings 898 281 (165)1,014 
Equity in net losses(2)(22)— (24)
Segment earnings (loss)$896 $259 $(165)$990 
Net loss attributable to noncontrolling interests2 — — 2 
Segment earnings (loss) attributable to Humana$898 $259 $(165)$992 

29


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended March 31, 2023(in millions)
External revenues
Premiums:
Individual Medicare Advantage$19,809 $— $— $19,809 
Group Medicare Advantage1,765 — — 1,765 
Medicare stand-alone PDP616 — — 616 
Total Medicare22,190 — — 22,190 
Commercial fully-insured1,018 — — 1,018 
Specialty benefits254 — — 254 
Medicare Supplement179 — — 179 
State-based contracts and other1,909 — — 1,909 
Total premiums25,550 — — 25,550 
Services revenue:
Home solutions— 314 — 314 
Primary care— 201 — 201 
Commercial ASO71 — — 71 
Military services and other171 — — 171 
Pharmacy solutions— 242 — 242 
Total services revenue242 757 — 999 
Total external revenues 25,792 757 — 26,549 
Intersegment revenues
Services14 1,133 (1,147)— 
Products— 2,615 (2,615)— 
Total intersegment revenues14 3,748 (3,762)— 
Investment income 97 — 96 193 
Total revenues25,903 4,505 (3,666)26,742 
Operating expenses:
Benefits21,993 — (135)21,858 
Operating costs2,418 4,126 (3,565)2,979 
Depreciation and amortization165 49 (28)186 
Total operating expenses24,576 4,175 (3,728)25,023 
Income from operations1,327 330 62 1,719 
Interest expense— — 113 113 
Other income, net— — (8)(8)
Income (loss) before income taxes and equity in net earnings 1,327 330 (43)1,614 
Equity in net losses(3)(14)— (17)
Segment earnings (loss)$1,324 $316 $(43)$1,597 
Net loss attributable to noncontrolling interests1 — — 1 
Segment earnings (loss) attributable to Humana$1,325 $316 $(43)$1,598 


30


Humana Inc.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The condensed consolidated financial statements of Humana Inc. in this document present the Company’s financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the Securities and Exchange Commission, or SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like “believes,” “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward–looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our 2023 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February 15, 2024, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward–looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.
Executive Overview
General
Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large.
Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking
total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.
Employer Group Commercial Medical Products Business Exit
In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.
Value Creation Initiatives
Beginning in 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges, primarily in asset impairments, of $29 million for the three months ended March 31, 2024 within operating costs in the consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. We did not record any charges for the three months ended March 31, 2023.


31
Business Segments
Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.
The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.
The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.
The results of each segment are measured by income (loss) from operations. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.
Seasonality
One of the product offerings of our Insurance segment is Medicare stand-alone prescription drug plans, or PDP, under the Medicare Part D program. Our quarterly Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.
The Insurance segment also experiences seasonality in the commercial fully-insured product offering. The effect on the Insurance segment benefit ratio is opposite of the Medicare stand-alone PDP impact, with the benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses. The Employer Group Commercial Fully-Insured business decreased the Insurance segment benefit ratio by 10 basis points and decreased the Insurance segment benefit ratio by 30 basis points for the three months ended March 31, 2024 and 2023, respectively.

32
The Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season. The Insurance segment may experience adverse impacts in the operating cost ratio as a result of our Employer Group Commercial Medical Products exit phased over the 18-24 months following our February 2023 announcement. The Employer Group Commercial Fully-Insured business increased the Insurance segment operating cost ratio by 10 basis points and increased the Insurance segment operating cost ratio by 40 basis points for the three months ended March 31, 2024 and 2023, respectively.
2024 Highlights
•Our strategy offers our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At March 31, 2024, approximately 3,837,300 members, or 69%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,505,100 members, or 68%, at March 31, 2023.
•Net income attributable to Humana was $0.7 billion, or $6.11 per diluted common share, and $1.2 billion, or $9.87 per diluted common share, for the three months ended March 31, 2024 and 2023, respectively. These comparisons were significantly impacted by put/call valuation adjustments associated with non-consolidating minority interest investments, transaction and integration costs, and charges associated with value creation initiatives. The impact of these adjustments to our consolidated income before income taxes and equity in net earnings and diluted earnings per common share was as follows for the 2024 and 2023 quarter:

33
For the three months ended March 31,
20242023
(in millions)
Consolidated income before income taxes and equity in net earnings:
Put/call valuation adjustments associated with our non consolidating minority interest investments$131 $53 
Transaction and integration costs— (51)
Value creation initiatives29 — 
Total$160 $2 
For the three months ended March 31,
20242023
Diluted earnings per common share:
Put/call valuation adjustments associated with our non consolidating minority interest investments$1.08 $0.42 
Transaction and integration costs— (0.41)
Value creation initiatives0.24 — 
Net tax impact of transactions(0.31)(0.11)
Total$1.01 $(0.10)




































34
Regulatory Environment

We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Health Care Reform Law, the Families First Act, the CARES Act, and the Inflation Reduction Act, and related regulations, are examples of laws which have enacted significant reforms to various aspects of the U.S. health insurance industry, including, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with insurance products, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial values, and changes to the Part D prescription drug benefit design.
It is reasonably possible that these laws and regulations, as well as other current or future legislative, judicial or regulatory changes including restrictions on our ability to manage our provider network, manage and sell our products, or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, increases in regulation of our prescription drug benefit businesses, or changes to the Part D prescription drug benefit design (and uncertainty arising from the implementation of these changes) in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.
In March 2024, the United States Securities and Exchange Commission issued its final regulation on climate-related disclosures. The regulation requires certain disclosures in registration statements and annual reports, including financial impact and climate-related impact metrics. On April 4, 2024, the SEC exercised its discretion to stay the Final Rules pending the completion of judicial review. The new regulation is effective for us beginning with the annual report for the year ended December 31, 2025. We are evaluating the final rule and its impact on our disclosures.

We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers and are described in Note 14 to the condensed consolidated financial statements included in this report.


35
Comparison of Results of Operations for 2024 and 2023
The following discussion primarily details our results of operations for the three months ended March 31, 2024, or the 2024 quarter and the three months ended March 31, 2023, or the 2023 quarter.
Change
Three Months Ended March 31,Three Months Ended March 31, 2024 vs 2023
20242023$%
($ in millions, except per common share results)
Revenues:
Insurance premiums$28,261 $25,550 $2,711 10.6 %
Services:
Insurance275 242 33 13.6 %
CenterWell787 757 30 4.0 %
Total services revenue1,062 999 63 6.3 %
Investment income288 193 95 49.2 %
Total revenues29,611 26,742 2,869 10.7 %
Operating expenses:
Benefits25,124 21,858 3,266 14.9 %
Operating costs3,042 2,979 63 2.1 %
Depreciation and amortization209 186 23 12.4 %
Total operating expenses28,375 25,023 3,352 13.4 %
Income from operations1,236 1,719 (483)(28.1)%
Interest expense159 113 46 40.7 %
Other expense (income), net63 (8)71 887.5 %
Income before income taxes and equity in net earnings1,014 1,614 (600)(37.2)%
Provision for income taxes251 359 (108)(30.1)%
Equity in net losses(24)(17)7 41.2 %
Net income$739 $1,238 $(499)(40.3)%
Diluted earnings per common share$6.11 $9.87 $(3.76)(38.1)%
Benefit ratio (a)88.9 %85.5 %3.4 %
Operating cost ratio (b)10.4 %11.2 %(0.8)%
Effective tax rate25.3 %22.5 %2.8 %
(a)Represents benefits expense as a percentage of premiums revenue.
(b)Represents operating costs as a percentage of total revenues less investment income.

Premiums Revenue

Consolidated premiums revenue increased $2.7 billion, or 10.6%, from $25.6 billion in the 2023 quarter to $28.3 billion in the 2024 quarter primarily due to higher per member Medicare premiums and individual and group Medicare Advantage membership growth. These factors were partially offset by the continued decline in the our group commercial medical and stand-alone PDP membership, as well as a decline in state-based contracts membership as a result of the end of the suspension of state eligibility redetermination efforts previously enacted as part of the Public Health Emergency.



36
Services Revenue
Consolidated services revenue increased $0.1 billion, or 6.3%, from $1.0 billion in the 2023 quarter to $1.1 billion in the 2024 quarter.
Investment Income
Investment income increased $95 million, or 49.2%, from $193 million in the 2023 quarter to $288 million in the 2024 quarter primarily due to increase in interest income on our debt securities.
Benefit Expense    
Consolidated benefits expense increased $3.3 billion, or 14.9%, from $21.9 billion in the 2023 quarter to $25.1 billion in the 2024 quarter. The consolidated benefit ratio increased 340 basis points from 85.5% for the 2023 quarter to 88.9% for the 2024 quarter primarily due to higher Medicare Advantage medical cost trends in the 2024 quarter compared to the 2023 quarter partially offset by the impact of pricing and benefit design of our 2024 Medicare Advantage products, which included a reduction in benefits in response to the net impact of the final rate notice and the initial emergence of increased medical cost trends. Further, the year-over-year comparison continues to reflect a shift in line of business mix, with growth in Medicare Advantage and state-based contracts and other membership, which can carry a higher benefit ratio.
Consolidated benefits expense included $535 million of favorable prior-period medical claims reserve development in the 2024 quarter and $522 million of favorable prior-period medical claims development in the 2023 quarter. Prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 190 basis points in the 2024 quarter and decreased the consolidated benefit ratio by approximately 200 basis points in the 2023 quarter.
Operating Costs
Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.
Consolidated operating costs increased $0.06 billion, or 2.1%, from $2.98 billion in the 2023 quarter to $3.04 billion in the 2024 quarter. The consolidated operating cost ratio decreased 80 basis points from 11.2% for the 2023 quarter to 10.4% for the 2024 quarter primarily due to scale efficiencies associated with growth in our individual Medicare Advantage membership, administrative cost efficiencies resulting from our value creation initiatives, and lower commission expense for brokers in the 2024 quarter compared to the 2023 quarter as a result of significant individual Medicare Advantage membership growth in 2023. These factors were partially offset by the impact from charges related to value creation initiatives in the 2024 quarter.
Depreciation and Amortization
Depreciation and amortization increased $23 million, or 12.4%, from $186 million in the 2023 quarter to $209 million in the 2024 quarter primarily due to capital expenditures.
Interest Expense
Interest expense increased $46 million, or 40.7%, from $113 million in the 2023 quarter to $159 million in the 2024 quarter primarily due to increase in interest rates and higher average debt balances.
Income Taxes
The effective income tax rate was 25.3% and 22.5% for the three months ended March 31, 2024, and 2023, respectively. The year-over-year increase in the effective income tax rate is primarily due to a change in the mix of current year earnings between our Insurance segment and our CenterWell health services segment, as the latter incurs a higher effective domestic tax rate than the former. In addition, the prior year income tax rate was favorably impacted by the recognition of a non-taxable gain.

37
Insurance Segment
 March 31,Change
 20242023Members%
Membership:
Individual Medicare Advantage5,548,900 5,153,000 395,900 7.7 %
Group Medicare Advantage551,500 511,200 40,300 7.9 %
Medicare stand-alone PDP2,347,000 2,956,300 (609,300)(20.6)%
Total Medicare8,447,400 8,620,500 (173,100)(2.0)%
Medicare Supplement323,200 294,000 29,200 9.9 %
Commercial fully-insured109,700 522,600 (412,900)(79.0)%
State-based contracts and other1,261,400 1,371,500 (110,100)(8.0)%
Military services 5,955,300 5,930,700 24,600 0.4 %
Commercial ASO77,700 414,800 (337,100)(81.3)%
Total Medical Membership16,174,700 17,154,100 (979,400)(5.7)%
Total Specialty Membership (a)
4,653,200 5,114,700 (461,500)(9.0)%
(a) We provide a full range of insured specialty products including dental, vision, and life insurance benefits marketed to individuals and groups. Members included in these products may not be unique to each product since members have the ability to enroll in a medical product and one or more specialty products.
Change
Three Months Ended March 31,Three Months Ended March 31, 2024 vs 2023
20242023$%
($ in millions)
Premiums and Services Revenue:
Premiums:
Individual Medicare Advantage$22,448 $19,809 $2,639 13.3 %
Group Medicare Advantage1,989 1,765 224 12.7 %
Medicare stand-alone PDP821 616 205 33.3 %
Total Medicare25,258 22,190 3,068 13.8 %
Commercial fully-insured 256 1,018 (762)(74.9)%
Specialty benefits239 254 (15)(5.9)%
Medicare Supplement197 179 18 10.1 %
State-based contracts and other2,311 1,909 402 21.1 %
Total premiums revenue28,261 25,550 2,711 10.6 %
Commercial ASO 24 71 (47)(66.2)%
Military services and other251 171 80 46.8 %
Services revenue275 242 33 13.6 %
Total premiums and services revenue$28,536 $25,792 $2,744 10.6 %
Income from operations$898 $1,327 $(429)(32.3)%
Benefit ratio89.3 %86.1 %3.2 %
Operating cost ratio8.3 %9.4 %(1.1)%




38
Income from operations
Insurance segment income from operations decreased $0.4 billion, or 32.3%, from $1.3 billion in the 2023 quarter to $0.9 billion in the 2024 quarter primarily due to the same factors impacting the segment's higher benefit ratio partially offset by the lower operating cost ratio as more fully described below.
Enrollment
Individual Medicare Advantage membership increased 395,900 members, or 7.7%, from March 31, 2023 to March 31, 2024 primarily due to membership additions associated with the most recent Annual Election Period, or AEP. Individual Medicare Advantage membership includes 922,200 D-SNP members as of March 31, 2024, a net increase of 140,100 D-SNP members, or 18%, from 782,100 D-SNP members as of March 31, 2023.
Group Medicare Advantage membership increased 40,300 members, or 7.9%, from March 31, 2023 to March 31, 2024 primarily due to growth in small and medium group accounts.
Medicare stand-alone PDP membership decreased 609,300 members, or 20.6%, from March 31, 2023 to March 31, 2024 primarily due to continued intensified competition for Medicare stand-alone PDP offerings.
State-based contracts and other membership decreased 110,100 members, or 8.0%, from March 31, 2023 to March 31, 2024 primarily due to the end of the suspension of state eligibility redetermination efforts previously enacted as part of the Public Health Emergency.

Commercial fully-insured medical membership decreased 412,900 members, or 79.0%, from March 31, 2023 to March 31, 2024 and commercial ASO medical membership decreased 337,100 members, or 81.3%, from March 31, 2023 to March 31, 2024. These decreases reflect our planned exit of the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.
Specialty membership decreased 461,500 members, or 9.0%, from March 31, 2023 to March 31, 2024 primarily due to non-renewal of dental and vision plans as a result of exit from the Employer Group Commercial Medical Products business partially offset by growth in dental and vision plans as a result of Medicare Advantage enrollment.

Premiums Revenue
Insurance segment premiums revenue increased $2.7 billion, or 10.6%, from $25.6 billion in the 2023 quarter to $28.3 billion in the 2024 quarter primarily due to higher per member Medicare premiums and individual and group Medicare Advantage membership growth. These factors were partially offset by the continued decline in the our group commercial medical and stand-alone PDP membership, as well as a decline in state-based contracts membership as a result of the end of the suspension of state eligibility redetermination efforts previously enacted as part of the Public Health Emergency.
Services Revenue
Insurance segment services revenue increased $33 million, or 13.6%, from $242 million in the 2023 quarter to $275 million in the 2024 quarter.
Benefits Expense
The Insurance segment benefit ratio increased 320 basis points from 86.1% for the 2023 quarter to 89.3% for the 2024 quarter primarily due to higher Medicare Advantage medical cost trends in the 2024 quarter compared to the 2023 quarter partially offset by the impact of pricing and benefit design of our 2024 Medicare Advantage products, which included a reduction in benefits in response to the net impact of the final rate notice and the initial emergence of increased medical cost trends. Further, the year-over-year comparison continues to reflect a shift in

39
line of business mix, with growth in Medicare Advantage and state-based contracts and other membership, which can carry a higher benefit ratio.
The Insurance segment benefits expense included $535 million of favorable prior-period medical claims reserve development in the 2024 quarter and $522 million of favorable prior-period medical claims reserve development in the 2023 quarter. Prior-period medical claims reserve development decreased the Insurance segment benefit ratio by approximately 190 basis points in the 2024 quarter and decreased the Insurance segment benefit ratio by approximately 200 basis points in the 2023 quarter.
Operating Costs
The Insurance segment operating cost ratio decreased 110 basis points from 9.4% for the 2023 quarter to 8.3% for the 2024 quarter primarily due to scale efficiencies associated with growth in our individual Medicare Advantage membership, administrative cost efficiencies resulting from our value creation initiatives, and lower commission expense for brokers in the 2024 quarter compared to the 2023 quarter as a result of significant individual Medicare Advantage membership growth in 2023.






















40
CenterWell Segment
Change
Three Months Ended March 31,Three Months Ended March 31, 2024 vs 2023
20242023$%
($ in millions)
Revenues:
Services:
Home solutions$335 $314 $21 6.7 %
Pharmacy solutions211 242 (31)(12.8)%
Primary care241 201 40 19.9 %
Total services revenue787 757 30 4.0 %
Intersegment revenues:
Home solutions485 314 171 54.5 %
Pharmacy solutions2,617 2,615 2 0.1 %
Primary care929 819 110 13.4 %
Total intersegment revenues4,031 3,748 283 7.6 %
Total services and intersegment revenues$4,818 $4,505 $313 6.9 %
Income from operations$282 $330 $(48)(14.5)%
Operating cost ratio93.0 %91.6 %1.4 %

Income from operations
CenterWell income from operations decreased $48 million, or 14.5%, from $330 million in the 2023 quarter to $282 million in the 2024 quarter primarily due to the same factors impacting the segment's higher operating cost ratio as more fully described below.
Services Revenue
CenterWell services revenue increased $30 million, or 4.0%, from $757 million in the 2023 quarter to $787 million in the 2024 quarter primarily due to higher revenues associated with growth in the primary care and home solutions businesses partially offset by a decline in revenues associated with the pharmacy solutions business and the impact of the v28 risk model revision.
Intersegment Revenues
CenterWell intersegment revenues increased $0.3 billion, or 7.6%, from $3.7 billion in the 2023 quarter to $4.0 billion in the 2024 quarter primarily due to greater intersegment revenues associated with the home solutions business in the 2024 quarter as compared to the 2023 quarter as a result of the expansion of the value-based care home model and higher intersegment revenues associated with growth in the primary care business, partially offset by the impact of the v28 risk model revision.
Operating Costs
The CenterWell segment operating cost ratio increased 140 basis points from 91.6% for the 2023 quarter to 93.0% for the 2024 quarter primarily due to the unfavorable impact of the v28 risk model revision to the primary care business.



41
Liquidity
Historically, our primary sources of cash have included receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities, and borrowings. Our primary uses of cash historically have included disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. As premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including premiums receivable, benefits payable, and other receivables and payables. Our cash flows are impacted by the timing of payments to and receipts from CMS associated with Medicare Part D subsidies for which we do not assume risk. The use of cash flows may be limited by regulatory requirements of state departments of insurance (or comparable state regulators) which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of cash flows derived from our non-insurance subsidiaries, such as in our CenterWell segment, is generally not restricted by state departments of insurance (or comparable state regulators).
For additional information regarding our liquidity risk, refer to Part I, Item 1A, "Risk Factors" in our 2023 Form 10-K and Part II, Item 1A, "Risk Factors" of this Form 10-Q.
Cash and cash equivalents increased to approximately $5.9 billion at March 31, 2024 from $4.7 billion at December 31, 2023. The change in cash and cash equivalents for the three months ended March 31, 2024 and 2023 is summarized as follows:
Three Months Ended
20242023
 (in millions)
Net cash provided by operating activities$423 $6,687 
Net cash used in investing activities(414)(1,292)
Net cash provided by financing activities1,207 3,279 
Increase in cash and cash equivalents$1,216 $8,674 
Cash Flow from Operating Activities
Cash flows provided by operations of $423 million in the 2024 quarter decreased $6.3 billion from cash flows provided by operations of $6.7 billion in the 2023 quarter. Our operating cash flows for the 2023 quarter were significantly impacted by the early receipt of the Medicare premium remittance of $6.6 billion in March 2023 because the payment date for April 2023 fell on a weekend. Generally, when the first day of a month falls on a weekend or holiday, with the exception of January 1 (New Year's Day), we receive this payment at the end of the previous month. This also resulted in an increase to unearned revenues in our condensed consolidated balance sheet at March 31, 2023.
The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.
The detail of total net receivables at March 31, 2024 and December 31, 2023 and reconciliation to cash flow for the three months ended March 31, 2024 and 2023 was as follows:

42
March 31, 2024December 31, 20232024 Quarter Change2023 Quarter Change
 (in millions)
Medicare$3,288 $1,426 $1,862 $1,398 
Commercial and other553 549 4 66 
Military services169 148 21 (32)
Allowances(85)(88)3 1 
Total net receivables$3,925 $2,035 $1,890 $1,433 

The changes in Medicare receivables for both the 2024 quarter and the 2023 period reflect individual Medicare Advantage membership growth and the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model. Significant collections occur with the mid-year and final settlements with CMS in the second and third quarter.
Cash Flow from Investing Activities
During the 2024 quarter and 2023 quarter, we acquired various businesses for approximately $14 million and $73 million, net of cash and cash equivalents received, respectively.
Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our primary care operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Total net capital expenditures, excluding acquisitions, were $177 million in the 2024 quarter and $223 million in the 2023 quarter.
Net purchases of investment securities were $223 million and $996 million in the 2024 quarter and 2023 quarter, respectively.
Cash Flow from Financing Activities
Receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were higher than claim payments by $569 million and $3.03 billion in the 2024 and 2023 quarters, respectively.

Under our administrative services only TRICARE contracts, health care costs payments for which we do not assume risk exceeded reimbursements from the federal government by $70 million and $29 million in the 2024 and 2023 quarters, respectively.
In March 2024, we issued $1.3 billion of 5.375% unsecured senior notes due April 15, 2031 and $1.0 billion of 5.750% unsecured senior notes due April 15, 2054. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $2.2 billion. We used the net proceeds for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.
In March 2023, we issued $500 million of 5.700% unsecured senior notes due March 13, 2026 and $750 million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion. We used the net proceeds to repay outstanding amounts under our $500 million Delayed Draw Term Loan. The remaining net proceeds will be used for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.
In March 2023, we entered into a Rule 10b5-1 Repurchase Plan, or the Plan, to repurchase a portion of our $1.5 billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600 million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the Plan period beginning on March 13, 2023 and ending on June 15, 2023. At March 31, 2023, we repurchased $61 million, for cash totaling approximately $60 million.

43
Net repayments from the issuance of commercial paper were $644 million in the 2024 quarter and net repayments from the issuance of commercial paper were $177 million in the 2023 quarter. The maximum principal amount outstanding at any one time during the 2024 period was $2.7 billion.
We repurchased common shares for $702 million and $67 million in the 2024 quarter and 2023 quarter, respectively, under share repurchase plans authorized by the Board of Directors. We also acquired common shares in connection with employee stock plans for $15 million and $27 million in the 2024 quarter and 2023 quarter, respectively.
We paid dividends to stockholders of $109 million and $100 million during the 2024 quarter and 2023 quarter, respectively.

Future Sources and Uses of Liquidity
Dividends
For additional information regarding our dividends to stockholders, refer to Note 10 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Stock Repurchases
For additional information regarding stock repurchases, refer to Note 10 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Debt
For additional information regarding debt, including our senior notes, term loans, revolving credit agreements, commercial paper program and other short-term borrowings, refer to Note 12 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Acquisitions
For additional information regarding acquisitions, refer to Note 3 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Liquidity Requirements
We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement and our commercial paper program or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.
Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at March 31, 2024 was BBB according to Standard & Poor’s Rating Services, or S&P, and Baa2 according to Moody’s Investors Services, Inc., or Moody’s. A downgrade by S&P to BB+ or by Moody’s to Ba1 triggers an interest rate increase of 25 basis points with respect to $250 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by $1 million, up to a maximum 100 basis points, or annual interest expense by $3 million.
In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent

44
company were $509 million at March 31, 2024, remaining relatively unchanged compared to $510 million at December 31, 2023.
Regulatory Requirements
Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity’s level of statutory income and statutory capital and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required.
Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Based on the most recently filed statutory financial statements as of December 31, 2023, our state regulated subsidiaries had aggregate statutory capital and surplus of approximately $12.2 billion, which exceeded aggregate minimum regulatory requirements of $9.8 billion. The amount of ordinary dividends that may be paid to our parent company in 2024 is approximately $1.1 billion in the aggregate. Actual dividends paid to our parent company were approximately $1.8 billion in 2023. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.


45
Item 3.    Quantitative and Qualitative Disclosures about Market Risk
Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.4
Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&P credit rating of AA- at March 31, 2024. Our net unrealized position increased $114 million from a net unrealized loss position of $1.3 billion at December 31, 2023 to a net unrealized loss position of $1.4 billion at March 31, 2024. At March 31, 2024, we had gross unrealized losses of $1.4 billion on our investment portfolio primarily due to an increase in market interest rates since the time the securities were purchased. There were no material credit allowances during the three months ended March 31, 2024. While we believe that these securities in an unrealized loss will recover in value over time and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or credit allowances may be recorded in future periods.
Duration is the time-weighted average of the present value of the bond portfolio’s cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately 3 years as of March 31, 2024 and December 31, 2023. Based on the duration, including cash equivalents, a 1% increase in interest rates would generally decrease the fair value of our securities by approximately $688 million at March 31, 2024.
Item 4.    Controls and Procedures
Under the supervision and with the participation of our Chief Executive Officer, or CEO, our Chief Financial Officer, or CFO, and our Principal Accounting Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for the quarter ended March 31, 2024.
Based on our evaluation, our CEO, CFO, and our Principal Accounting Officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information the Company is required to disclose in its reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including, without limitation, ensuring that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
There have been no changes in the Company’s internal control over financial reporting during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.


46
Part II. Other Information

Item 1.     Legal Proceedings
For additional information regarding legal proceedings pending against us and certain other pending or threatened litigation, investigations or other matters, refer to “Legal Proceedings and Certain Regulatory Matters” in Note 13 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Item 1A. Risk Factors
There have been no changes to the risk factors included in our 2023 Form 10-K.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
(a)None.
(b)N/A
(c)The following table provides information about our purchases of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, during the three months ended March 31, 2024:
PeriodTotal Number
of Shares
Purchased (1)(2)		Average
Price Paid
per Share		Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs (1)(2)		Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs (1) (2)
January 20241,572,566 $392.11 1,572,566 $883,530,302 
February 2024181,648 371.58 181,648 2,992,126,583 
March 202450,431 346.94 50,431 2,974,630,293 
Total1,804,645 $388.78 1,804,645 
(1)Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. Our remaining repurchase authorization was $2.96 billion as of April 23, 2024.
(2)Excludes 0.04 million shares repurchased in connection with employee stock plans.
Item 3.     Defaults Upon Senior Securities
None.

Item 4.     Mine Safety Disclosures
Not applicable.


47
Item 5.     Other Information
a.None.
b.None.
c.During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.


48
Item 6:     Exhibits
3(i)
Restated Certificate of Incorporation of Humana Inc. filed with the Secretary of State of Delaware on November 9, 1989, as restated to incorporate the amendment of January 9, 1992, and the correction of March 23, 1992 (incorporated herein by reference to Exhibit 4(i) to Humana Inc.’s Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (Reg. No. 33-49305) filed February 2, 1994).
Humana Inc. Amended and Restated By-laws, effective as of December 8, 2022 (incorporated herein by reference to Exhibit 3(b) to Humana Inc.’s Current Report on Form 8-K filed on December 8, 2022).
Twenty-Eighth Supplemental Indenture, dated March 13, 2024, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.’s Current Report on Form 8-K filed on March 13, 2024).
Twenty-Ninth Supplemental Indenture, dated March 13, 2024, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.’s Current Report on Form 8-K filed on March 13, 2024).
Principal Executive Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.
Principal Financial Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.
Principal Executive Officer and Principal Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101The following materials from Humana Inc.'s Quarterly Report on Form 10-Q formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets at March 31, 2024 and December 31, 2023; (ii) the Condensed Consolidated Statements of Income for the three months ended March 31, 2024 and 2023; (iii) the Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2024 and 2023; (iv) the Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2024 and 2023; (v) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023; and (vi) Notes to Condensed Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.

49
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HUMANA INC.
(Registrant)
Date:April 24, 2024By:/s/ JOHN-PAUL W. FELTER
John-Paul W. Felter
Senior Vice President, Chief Accounting Officer and Controller (Principal Accounting Officer)

50
 EX-31.1 2 hum-20240331xex31x1.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002
I, Bruce D. Broussard, principal executive officer of Humana Inc., certify that:
1. I have reviewed this Report of Humana Inc. (the "Company") on Form 10-Q for the period ending March 31, 2024;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:April 24, 2024
Signature:/s/ Bruce D. Broussard
Bruce D. Broussard
Principal Executive Officer

 EX-31.2 3 hum-20240331xex31.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002
I, Susan M. Diamond, principal financial officer of Humana Inc., certify that:
1. I have reviewed this Report of Humana Inc. (the "Company") on Form 10-Q for the period ending March 31, 2024;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: April 24, 2024
Signature: /s/ Susan M. Diamond
 Susan M. Diamond
Principal Financial Officer

 EX-32 4 hum-20240331xex32.htm EX-32 Document

Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Report of Humana Inc. (the "Company") on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, in their capacity as an officer of Humana Inc., that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ Bruce D. Broussard
Bruce D. Broussard
Principal Executive Officer
April 24, 2024
/s/ Susan M. Diamond
Susan M. Diamond
Principal Financial Officer
April 24, 2024
A signed original of this written statement required by Section 906 has been provided to Humana Inc. and will be retained by Humana Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.SCH 5 hum-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - INVESTMENT SECURITIES link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - MEDICARE PART D link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - BENEFITS PAYABLE link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - INVESTMENT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - MEDICARE PART D (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - BENEFITS PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - INVESTMENT SECURITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - FAIR VALUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - FAIR VALUE - Fair Value of Swap Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - MEDICARE PART D (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - STOCKHOLDERS' EQUITY - Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - DEBT - Debt Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - DEBT - Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - DEBT - Revolving Credit Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - DEBT - Commercial Paper and Other Short-term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - SEGMENT INFORMATION - Segment Results (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hum-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hum-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hum-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Proceeds from sales of investment securities Proceeds from Sale of Debt Securities, Available-for-Sale Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Changes in operating assets and liabilities, net of effect of businesses acquired and disposed: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent 5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 [Member] 5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 Award Type [Domain] Award Type [Domain] Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Fair Value as of Grant Date Award Grant Date Fair Value T2017 East Region TRICARE 2017 East Region Contract [Member] TRICARE 2017 East Region Contract DEBT Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Revolving credit facility Revolving Credit Facility [Member] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Investment Securities Classified as Current and Long-Term Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Significant unobservable inputs Derivative Asset (Liability) Net, Measurement Input MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Transfer out Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Mortgage and asset-backed securities Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value Restatement Determination Date: Restatement Determination Date [Axis] Medicare stand-alone PDP Medicare Stand Alone Prescription Drug Plan [Member] Medicare Stand Alone Prescription Drug Plan [Member] Corporate debt securities Corporate debt securities Corporate Debt Securities [Member] Beginning balance at January 1 Balance at March 31 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value T-5, Effective 2024 TRICARE Managed Care Support Contract, Effective 2024 [Member] TRICARE Managed Care Support Contract, Effective 2024 Commitments and Contingencies (Note 13) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] STOCKHOLDERS' EQUITY Equity [Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Maximum amount outstanding during period Short-Term Debt, Maximum Amount Outstanding During Period Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] INCOME TAXES Income Tax Disclosure [Text Block] Benefits payable Balances, beginning of period Balances, end of period Liability for Claims and Claims Adjustment Expense Unearned revenues Increase (Decrease) in Contract with Customer, Liability $750 million, 1.350% due February 3, 2027 1.35 Percent Senior Notes Due February 2027 [Member] 1.35 Percent Senior Notes Due February 2027 Member co-share amounts and government subsidies Government And Health Plan Member Subsidies Amount Amount of member co-share amounts and government subsidies that are excluded from benefits expense because the health plans do not bear responsibility. Fair value of financial liability Financial Liabilities Fair Value Disclosure Revenue Recognition Revenue [Policy Text Block] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Net loss (income) attributable to noncontrolling interests Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Noncontrolling Interest Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Noncontrolling Interest Preferred stock, par (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $1 par; 10,000,000 shares authorized; none issued Preferred Stock, Value, Issued Intersegment Eliminations Intersegment Eliminations [Member] Credit spread Credit Spread Option [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted earnings per common share (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Goodwill Goodwill [Roll Forward] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Unobservable Inputs (Level 3) Level 3 fair value measurement Fair Value, Inputs, Level 3 [Member] Treasury stock, shares (in shares) Treasury Stock, Common, Shares $500 million, 4.875% due April 1, 2030 4.875 Percent Senior Notes Due April 2030 [Member] A 4.875 Percent Senior Notes Due April 2030 [Member] Due after five years through ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Stock option exercises Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Receipts from contract deposits, net Payments For Proceeds From Contract Deposits Payments For Proceeds From Contract Deposits Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Investment income Investment Income, Interest and Dividend Net income attributable to Humana Net income attributable to Humana Net income available for common stockholders Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] $500 million, 3.950% due August 15, 2049 3.95 Percent Senior Notes Due August 2049 [Member] 3.95 Percent Senior Notes Due August 2049 [Member] Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five $500 million, 3.125% due August 15, 2029 3.125 Percent Senior Notes Due August 2029 [Member] A 3.125 Percent Senior Notes Due August 2029 [Member] Total other intangible assets, cost Intangible Assets, Gross (Excluding Goodwill) LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Acquired Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] INVESTMENT SECURITIES Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax $600 million, 3.850% due October 1, 2024 3.85 Percent Senior Notes Due October 2024 [Member] 3.85 Percent Senior Notes Due October 2024 [Member] Receivables Increase (Decrease) in Receivables Schedule of Details Supporting Computation of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] $400 million, 4.625% due December 1, 2042 4.625 Percent Senior Notes Due December 2042 [Member] 4.625 Percent Senior Notes Due December 2042 [Member] Gross gains on investment securities Debt And Equity Securities, Realized Gain Debt And Equity Securities, Realized Gain Military services Military Service [Member] Military Service [Member] Executive Category: Executive Category [Axis] Schedule of Other Intangible Assets, Indefinite-Lived Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Carrying Value Reported Value Measurement [Member] Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] State-based contracts and other State-Based Contracts and Other [Member] State-Based Contracts and Other Current year Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Measurement Basis [Axis] Measurement Basis [Axis] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Prior years Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Local Phone Number Local Phone Number Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of credit Letter of Credit [Member] Dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Derivative, notional amount Derivative, Notional Amount Total change in unrealized investment (losses) gains, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Frequency [Axis] Measurement Frequency [Axis] Incurred related to: Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract] Schedule of Contractual Maturity of Debt Securities Available for Sale Investments Classified by Contractual Maturity Date [Table Text Block] Commercial ASO Commercial ASO [Member] Commercial ASO Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt instrument term (in years) Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Depreciation Depreciation Debt issue costs Payments of Debt Issuance Costs Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Line of Credit Facility [Table] Line of Credit Facility [Table] Total gains or losses: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) [Abstract] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Number of TRICARE managed care support contract beneficiaries Number Of TRICARE Managed Care Support Contract Beneficiaries Number Of TRICARE Managed Care Support Contract Beneficiaries Repayments of senior notes Repayments of Senior Debt $850 million, 5.950% due March 15, 2034 5.950 Percent Senior Notes Due March 2034 [Member] 5.950 Percent Senior Notes Due March 2034 Due after ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 Total revenues Revenues Commercial Commercial Mortgage-Backed Securities [Member] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Securities, number of positions Debt, Securities, Available-For-Sale, Securities, Number Of Positions Debt Securities, Available-for-sale, Securities, Number Of Positions Depreciation and amortization classified as benefit expense Depreciation And Amortization Classified As Benefit Expense Depreciation and amortization expense that has been reclassified to be included with benefit expenses. The reclassification is the result of depreciation and amortization expense associated primarily from the delivery of pharmacy services by our wholly-owned pharmacy business included in our Healthcare Services segment. Short-term Debt [Line Items] Short-Term Debt [Line Items] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Debt to capitalization percentage, maximum Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Benefits Policyholder Benefits and Claims Incurred, Net, Health Number of antidilutive stock options and restricted stock excluded from computation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Document Quarterly Report Document Quarterly Report Interest Rate Swap Maturing 2053 Interest Rate Swap Maturing 2053 [Member] Interest Rate Swap Maturing 2053 Details of businesses acquired in purchase transactions: Noncash Investing and Financing Items [Abstract] Interest expense Interest Expense Total paid Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Goodwill [Line Items] Goodwill [Line Items] 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Schedule of Details of Dividend Payments Dividends Declared [Table Text Block] Trading Arrangement: Trading Arrangement [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Weighted average cost of capital Measurement Input, Discount Rate [Member] Common shares acquired in connection with employee stock plans, amount Share Repurchases Related To Employee Stock Based Compensation Awards Value Cost of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares. Eliminations/ Corporate Corporate And Eliminations [Member] Corporate And Eliminations [Member] Amortization Amortization of Intangible Assets Entity Shell Company Entity Shell Company Amortizable intangible assets, net Finite-Lived Intangible Assets, Net Accounting Pronouncements Effective in Future Periods New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Stock repurchase average price (in dollars per share) Shares Acquired, Average Cost Per Share Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amortizable intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization $500 million, 5.700% due March 13, 2026 5.70 Percent Senior Notes Due March 2026 [Member] 5.70 Percent Senior Notes Due March 2026 Gross losses on equity securities Equity Securities, FV-NI, Realized Loss Insurance [Abstract] Insurance [Abstract] Debt outstanding Debt Instrument, Fair Value Disclosure Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Total external revenues External Revenues [Member] External Revenues TRICARE Contract [Domain] TRICARE Contract [Domain] TRICARE Contract [Domain] Term Loan Loans Payable [Member] 12 months or more Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Facility fee (percent) Line of Credit Facility, Commitment Fee Percentage Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Schedule of Gross Unrealized Losses and Fair Value of Securities Unrealized Gain (Loss) on Investments [Table Text Block] Unearned revenues Contract with Customer, Liability, Current Treasury stock, at cost, 78,189,958 shares at March 31, 2024 and 76,465,862 shares at December 31, 2023 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Total invested assets Assets, fair value disclosure Assets, Fair Value Disclosure Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Operating costs Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Employee stock options Employee Stock Option [Member] $600 million, 3.950% due March 15, 2027 3.95 Percent Senior Notes Due March 2027 [Member] 3.95 Percent Senior Notes Due March 2027 [Member] Actual debt to capitalization percentage Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual Other Proceeds from (Payments for) Other Financing Activities $600 million, 4.500% due April 1, 2025 4.50 Percent Senior Notes Due April 2025 [Member] A 4.50 Percent Senior Notes Due April 2025 [Member] Maximum Maximum [Member] Comprehensive income attributable to Humana Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Acquisitions Goodwill, Acquired During Period Total operating expenses Benefits, Losses and Expenses External Credit Rating, Standard & Poor's [Domain] External Credit Rating, Standard & Poor's [Domain] Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Common stock repurchases Stock repurchases Treasury Stock, Value, Acquired, Cost Method Number of states comprising TRICARE beneficiaries Number Of States Comprising TRICARE Beneficiaries Number Of States Comprising TRICARE Beneficiaries (Gain) loss on investment securities, net Net recognized gains (losses) on investment securities Debt and Equity Securities, Gain (Loss) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Purchases of investment securities Payments to Acquire Debt Securities, Available-for-Sale Common shares acquired in connection with employee stock plans (in shares) Share Repurchases Related To Employee Stock Based Compensation Awards Shares Number of shares of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares. Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Receivables, net of allowances Accounts Receivable, Allowance for Credit Loss, Current Subsequent Event Subsequent Event [Member] Schedule of Other Intangible Assets, Amortizable Schedule of Finite-Lived Intangible Assets [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Services Services revenue Revenue from Contract with Customer, Including Assessed Tax Investment income Net Investment Income Options Option on Securities [Member] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Investment Securities, Available-for-sale Amortized Cost to Fair Value Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Financing Receivable, Credit Quality Indicator [Line Items] Financing Receivable, Credit Quality Indicator [Line Items] ACQUISITIONS Business Combination Disclosure [Text Block] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] For the years ending December 31, Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Operating segments Operating Segments [Member] Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Less: Fair value of liabilities assumed Liabilities Assumed Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Activity in Benefits Payable Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Effect of income taxes OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Entity Tax Identification Number Entity Tax Identification Number Equity method investments Equity Method Investments $750 million, 3.700% due March 23, 2029 3.700 Percent Senior Notes Due March 2029 [Member] 3.700 Percent Senior Notes Due March 2029 Statistical Measurement [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Customer contracts/ relationships Customer Contracts [Member] Entity Interactive Data Current Entity Interactive Data Current Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income Schedule of Realized Gain (Loss) [Table Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Products Product [Member] Common stock repurchases Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Restructuring and impairment charge Restructuring Costs and Asset Impairment Charges Book overdraft Book Overdraft Liability Book Overdraft Liability Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Total Stockholders' Equity Parent [Member] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Long term growth rate Measurement Input, Long-Term Revenue Growth Rate [Member] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Restricted stock unit vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Name Outstanding Recovery, Individual Name BENEFITS PAYABLE Insurance Disclosure [Text Block] Aggregate principal Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Tax-exempt municipal securities Nontaxable Municipal Notes [Member] Current assets: Assets, Current [Abstract] Prior years Prior Year Claims and Claims Adjustment Expense Net long-term asset (liability) Net Noncurrent Asset (Liability) Net Noncurrent Asset (Liability) Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Residential Residential Mortgage-Backed Securities [Member] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Proceeds from maturities of investment securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Total Amount Dividends Disposal Group Name [Domain] Disposal Group Name [Domain] Number of states comprising of TRICARE managed care support contract beneficiaries Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries Investments Investments [Member] PEO PEO [Member] 2023 Share Repurchase Authorization 2023 Share Repurchase Authorization [Member] 2023 Share Repurchase Authorization Other Other Operating Activities, Cash Flow Statement Call option Call Option [Member] Common stock, par (in dollars per share) Common Stock, Par or Stated Value Per Share Effect of income taxes Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Interest rate swaps Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Securities in unrealized loss positions, number of positions Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate (percent) Effective Income Tax Rate Reconciliation, Percent Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Change in gross unrealized investment (losses) gains OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Total liabilities Liabilities Services Service [Member] BASIS OF PRESENTATION AND SIGNIFICANT EVENTS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Repayments of commercial paper, net Proceeds from (Repayments of) Commercial Paper Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Fair Value Risk Fair Value Risk [Member] Fair Value Risk Total Debt Securities, Available-for-Sale, Unrealized Loss Position CMS Subsidies/ Discounts Cms Subsidies Or Discounts [Member] CMS Subsidies Or Discounts [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Amortized Cost Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Dispositions Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Proceeds from issuance of senior notes, net Proceeds from Issuance of Senior Long-Term Debt Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,593 shares issued at March 31, 2024 and 198,690,082 shares issued at December 31, 2023 Common Stock, Value, Issued $750 million, 2.150% due February 3, 2032 2.15 Percent Senior Notes Due February 2032 [Member] 2.15 Percent Senior Notes Due February 2032 Annualized volatility Measurement Input, Option Volatility [Member] Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade names and technology Trade Names [Member] Weighted average annual interest rate (percent) Short-Term Debt, Weighted Average Interest Rate, at Point in Time Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current Mortgage-backed securities Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member] All Individuals All Individuals [Member] $1,250 million, $5.375% due April 15, 2031 5.375 Percent Senior Notes Due April 2031 [Member] 5.375 Percent Senior Notes Due April 2031 Supplemental cash flow disclosures: Supplemental Cash Flow Information [Abstract] Individual Medicare Advantage Medicare Advantage [Member] Medicare Advantage [Member] Amortization Amortization Other expense (income), net Other expense (income), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category S&P AA- rating Standard & Poor's, AA- Rating [Member] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Share repurchase authorization Stock Repurchase Program, Authorized Amount GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] PEO Name PEO Name Concentration risk (percent) Concentration Risk, Percentage Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five U.S. Treasury and agency obligations US Treasury and Government [Member] Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments Schedule of Goodwill [Table Text Block] Asset-backed securities Asset-backed securities Asset-Backed Securities [Member] Provider contracts Contractual Rights [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Unrealized in other comprehensive income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Outstanding borrowings Line of Credit, Current Receivables and Other [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Stated interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Trade accounts payable and accrued expenses Trade accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Percentage of debt securities considered to be of investment-grade (percent) Percentage Of Total Debt Securities, Investment Grade Quality Percentage Of Total Debt Securities, Investment Grade Quality Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Total stockholders' equity Equity, Attributable to Parent $750 million, 5.500% due March 15, 2053 5.50 Percent Senior Notes Due March 2053 [Member] 5.50 Percent Senior Notes Due March 2053 Consolidation Items [Axis] Consolidation Items [Axis] Commercial paper Commercial Paper [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Premiums Premiums Earned, Net Restricted stock Restricted Stock [Member] Fair value of financial asset Financial Assets, Fair Value Disclosure Financial Assets, Fair Value Disclosure Percentage of premiums and services revenue Percentage Of Total Premium And Services Revenues Percentage Of Total Premium And Services Revenues Schedule of Assumptions Used For Inputs In Fair Value Measurement Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Contract base term TRICARE Managed Care Support Contract, Base Term TRICARE Managed Care Support Contract, Base Term 364-day unsecured revolving credit agreement June 2022 Revolving Credit Agreement June 2022 One Year [Member] Revolving Credit Agreement June 2022 One Year Concentration Risk Type [Axis] Concentration Risk Type [Axis] Segment earnings (loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Maximum individual state general bond obligation as a percentage of total debt securities (percent) Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items] Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] Interest Rate Swap Maturing 2033 Interest Rate Swap Maturing 2033 [Member] Interest Rate Swap Maturing 2033 Impairment of property and equipment Tangible Asset Impairment Charges Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Current year Current Year Claims and Claims Adjustment Expense Credit Rating, Standard & Poor's [Axis] Credit Rating, Standard & Poor's [Axis] Entity Emerging Growth Company Entity Emerging Growth Company Pharmacy solutions Pharmacy Solutions [Member] Pharmacy Solutions Put option Put Option [Member] Total other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Disposal Group Classification [Domain] Disposal Group Classification [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Home solutions Home Solutions [Member] Home Solutions Document Fiscal Period Focus Document Fiscal Period Focus Weighted average life (in years) Finite-Lived Intangible Asset, Useful Life Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense 364-day unsecured revolving credit agreement June 2023 Revolving Credit Agreement June 2023 One Year [Member] Revolving Credit Agreement June 2023 One Year Common Stock Common Stock [Member] Interest Rate Swap Maturing 2054 Interest Rate Swap Maturing 2054 [Member] Interest Rate Swap Maturing 2054 Long-term investment securities Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] EARNINGS PER COMMON SHARE COMPUTATION Earnings Per Share [Text Block] Fair Value Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Share Repurchase Program [Domain] Share Repurchase Program [Domain] Schedule of Balance Sheet Amounts Associated With Medicare Part D Balance Sheet Account Associated With Medicare Part D Table [Table Text Block] Balance Sheet Account Associated With Medicare Part D 2024 Share Repurchase Authorization 2024 Share Repurchase Authorization [Member] 2024 Share Repurchase Authorization Receivables, net of allowances of $85 in 2024 and $88 in 2023 Receivables, Net, Current Exercise Price Award Exercise Price Amount per Share (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Dividends and dividend equivalents Dividends, Common Stock, Cash ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Total incurred Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Due after ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] MEDICARE PART D Medicare Part D Disclosure [Text Block] Balance sheet amounts associated with Medicare Part D. Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income tax payments, net Income Taxes Paid, Net Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Schedule of Financial Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] COMMITMENTS, GUARANTEES AND CONTINGENCIES Commitments Contingencies and Guarantees [Text Block] Retained Earnings Retained Earnings [Member] Total senior notes Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and equity Liabilities and Equity Amortized Cost Book value Debt Securities, Available-for-Sale, Amortized Cost Other long-term assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic earnings per common share (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Interest Rate Swap Maturing 2049 Interest Rate Swap Maturing 2049 [Member] Interest Rate Swap Maturing 2049 Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Arrangement Duration Trading Arrangement Duration SOFR Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Segment earnings (loss) attributable to Humana Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Parent Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Parent Specialty benefits Specialty Benefits [Member] Specialty [Member] Schedule of Segment Results Schedule of Segment Reporting Information, by Segment [Table Text Block] Mortgage and asset-backed securities Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Fair Value Debt Securities, Available-for-Sale, Unrealized Gain (Loss) [Abstract] Number of TRICARE beneficiaries Number Of TRICARE Beneficiaries Number Of TRICARE Beneficiaries $400 million, 4.800% due March 15, 2047 4.80 Percent Senior Notes Due March 2047 [Member] 4.80 Percent Senior Notes Due March 2047 [Member] Term Loan And Commercial Paper Term Loan And Commercial Paper [Member] Term Loan And Commercial Paper Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Noncompetes and other Noncompetes And Other [Member] Noncompetes and Other [Member] Remaining authorized amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Acquisition Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Benefits payable Increase (Decrease) in Health Care Insurance Liabilities Fair Value Fair value Fair Value Total debt securities Debt Securities, Available-for-Sale Paid related to: Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] Insurance Insurance Segment [Member] Insurance Segment Short-term debt Short-term debt outstanding Short-Term Debt Contract term with exercises TRICARE Managed Care Support Contract, Term With Option Exercises TRICARE Managed Care Support Contract, Term With Option Exercises Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross gains on equity securities Equity Securities, FV-NI, Realized Gain Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Net gains (losses) recognized on equity securities during the period Equity Securities, FV-NI, Gain (Loss) FHLB borrowings Federal Home Loan Bank Advances [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Gross Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Due within one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One All Adjustments to Compensation All Adjustments to Compensation [Member] Swap asset Interest Rate Fair Value Hedge Asset at Fair Value Award Timing Disclosures [Line Items] Risk Corridor Settlement Risk Corridor Settlements Medicare Part D [Member] Risk Corridor Settlements - Medicare Part D [Member] Medicare Total Medicare Medicare [Member] Medicare [Member] Compensation Amount Outstanding Recovery Compensation Amount Gentiva Hospice Gentiva Hospice [Member] Gentiva Hospice Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Less: Noncontrolling interests acquired Noncash or Part Noncash Acquisition, Noncontrolling Interest Acquired Noncash or Part Noncash Acquisition, Noncontrolling Interest Acquired $250 million, 8.150% due June 15, 2038 8.15 Percent Senior Notes Due June 2038 [Member] 8.15 Percent Senior Notes Due June 2038 [Member] Due after five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Restricted stock unit vesting Stock Issued During Period, Value, Restricted Stock Award, Gross Subsequent Event Type [Axis] Subsequent Event Type [Axis] Restructuring Plan [Axis] Restructuring Plan [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table] Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table] Uncommitted incremental loan facility Line Of Credit Facility, Uncommitted Incremental Capacity Line Of Credit Facility, Uncommitted Incremental Capacity Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Short-term debt Total short-term debt Debt, Current 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Insider Trading Arrangements [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Registrant Name Entity Registrant Name Value Creation Initiatives Value Creation Initiatives [Member] Value Creation Initiatives Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Dilutive effect of employee stock options and restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Other assets Increase (Decrease) in Other Operating Assets 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Unrealized gains (losses) recognized on equity securities still held at the end of the period Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Noncontrolling interests Equity, Attributable to Noncontrolling Interest Change in book overdraft Increase (Decrease) in Book Overdrafts Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Total IBNR included in benefits payable Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] $500 million, 5.750% due December 1, 2028 5.750 Percent Senior Notes Due December 2028 [Member] 5.750 Percent Senior Notes Due December 2028 Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Realized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortizable intangible assets, cost Finite-Lived Intangible Assets, Gross Provision for income taxes Income Tax Expense (Benefit) Primary care Primary Care [Member] Primary Care Group Medicare Advantage Group Medicare Advantage [Member] Group Medicare Advantage FAIR VALUE Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Other comprehensive (loss) income, net of tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 5-year unsecured revolving credit agreement June 2021 Revolving Credit Agreement June 2021 Five Year [Member] Revolving Credit Agreement June 2021 Five Year 12 months or more Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Total reclassification adjustment, net of tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Military services and other Military And Other [Member] Military And Other Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Reclassification adjustment for net realized (gains) losses Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax Gross losses on investment securities Debt And Equity Securities, Realized Loss Debt And Equity Securities, Realized Loss $750 million, 4.950% due October 1, 2044 4.95 Percent Senior Notes Due October 2044 [Member] 4.95 Percent Senior Notes Due October 2044 [Member] Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Acquisitions, net of cash and cash equivalents acquired Cash paid for acquired businesses, net of cash and cash equivalents acquired Payments to Acquire Businesses, Net of Cash Acquired Medicare licenses Licensing Agreements [Member] Interest payments Interest Paid, Excluding Capitalized Interest, Operating Activities Financing Receivable, Credit Quality Indicator [Table] Financing Receivable, Credit Quality Indicator [Table] Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Credit Facility [Domain] Credit Facility [Domain] Stock repurchases (in shares) Treasury Stock, Shares, Acquired Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Interest Rate Swap Maturing 2034 Interest Rate Swap Maturing 2034 [Member] Interest Rate Swap Maturing 2034 Basis points spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Schedule of Gain (Loss) on Equity Securities Gain (Loss) on Securities [Table Text Block] Shares used to compute diluted earnings per common share (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Certificates of need Certificate Of Need [Member] Certificate Of Need Other intangible assets: Intangible Assets, Net (Excluding Goodwill) [Abstract] Operating expenses: Operating Expenses [Abstract] Total net asset (liability) Net Asset (Liability) Net Asset (Liability) Purchases of property and equipment, net Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Capital in excess of par value Additional Paid in Capital, Common Stock Fair value of assets acquired, net of cash and cash equivalents acquired Fair Value of Assets Acquired Capital In Excess of Par Value Additional Paid-in Capital [Member] 5-year unsecured revolving credit agreement June 2023 Revolving Credit Agreement June 2023 Five Year [Member] Revolving Credit Agreement June 2023 Five Year Less: Net gains (losses) recognized on equity securities sold during the period Equity Securities, FV-NI, Realized Gain (Loss) Repayment of term loan Repayments of Unsecured Debt Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Equity in net losses Equity in net losses Equity in net losses Income (Loss) from Equity Method Investments Share Repurchase Program [Axis] Share Repurchase Program [Axis] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] CenterWell CenterWell Segment [Member] CenterWell Segment Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Recurring Basis Fair Value, Recurring [Member] 2023 And 2024 Share Repurchase Authorization 2023 And 2024 Share Repurchase Authorization [Member] 2023 And 2024 Share Repurchase Authorization Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Dividends paid Payments of Dividends Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Medicare Supplement Medicare Supplement Product [Member] Medicare Supplement Product Investment securities Short-Term Investments TRICARE Contract [Axis] TRICARE Contract [Axis] TRICARE Contract Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net current liability Net Current (Liability) Asset Net current (liability) asset Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Income (loss) before income taxes and equity in net losses Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Medicaid Medicaid [Member] Medicaid [Member] Cumulative, aggregate adjustment Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Revenue exit multiple Revenue Exit Multiple [Member] Revenue Exit Multiple Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average outstanding shares of common stock used to compute basic earnings per common share (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Income from operations Operating Income (Loss) Schedule of Short-term Debt [Table] Schedule of Short-Term Debt [Table] $1,000 million, $5.750% due April 15, 2054 5.750 Percent Senior Notes Due April 2054 [Member] 5.750 Percent Senior Notes Due April 2054 Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Revenues: Revenues [Abstract] Distribution from noncontrolling interest holders, net Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions From Noncontrolling Interest Holders Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions From Noncontrolling Interest Holders $750 million, 5.875% due March 1, 2033 5.875 Percent Senior Notes Due March 2033 [Member] 5.875 Percent Senior Notes Due March 2033 Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Fair Value Estimate of Fair Value Measurement [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] $500 million, 5.750% due March 1, 2028 5.750 Percent Senior Notes Due March 2028 [Member] 5.750 Percent Senior Notes Due March 2028 Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of Carrying Value of Debt Outstanding Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Annual option periods TRICARE Managed Care Support Contract, Number Of Option Periods TRICARE Managed Care Support Contract, Number Of Option Periods Noncontrolling Interests Noncontrolling Interest [Member] Commercial fully-insured Commercial Fully-Insured [Member] Commercial Fully-Insured Health Care [Member] EX-101.PRE 9 hum-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
 3 Months Ended
Mar. 31, 2024
shares
Cover [Abstract]  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Mar. 31, 2024
Document Transition Report false
Entity File Number 1-5975
Entity Registrant Name HUMANA INC
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 61-0647538
Entity Address, Address Line One 500 West Main Street
Entity Address, City or Town Louisville
Entity Address, State or Province KY
Entity Address, Postal Zip Code 40202
City Area Code 502
Local Phone Number 580-1000
Title of 12(b) Security Common stock, $0.16 2/3 par value
Trading Symbol HUM
Security Exchange Name NYSE
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 120,500,635
Entity Central Index Key 0000049071
Current Fiscal Year End Date --12-31
Document Fiscal Year Focus 2024
Document Fiscal Period Focus Q1
Amendment Flag false
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 5,910 $ 4,694
Investment securities 16,697 16,626
Receivables, net of allowances of $85 in 2024 and $88 in 2023 3,925 2,035
Other current assets 6,264 6,631
Total current assets 32,796 29,986
Property and equipment, net 2,979 3,030
Long-term investment securities 380 382
Equity method investments 730 740
Goodwill 9,563 9,550
Other long-term assets 3,643 3,377
Total assets 50,091 47,065
Current liabilities:    
Benefits payable 11,729 10,241
Trade accounts payable and accrued expenses 6,504 6,569
Book overdraft 333 353
Unearned revenues 301 266
Short-term debt 822 1,443
Total current liabilities 19,689 18,872
Long-term debt 12,390 10,213
Other long-term liabilities 1,826 1,662
Total liabilities 33,905 30,747
Commitments and Contingencies (Note 13)
Stockholders’ equity:    
Preferred stock, $1 par; 10,000,000 shares authorized; none issued 0 0
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,593 shares issued at March 31, 2024 and 198,690,082 shares issued at December 31, 2023 33 33
Capital in excess of par value 3,369 3,346
Retained earnings 28,173 27,540
Accumulated other comprehensive loss (1,086) (999)
Treasury stock, at cost, 78,189,958 shares at March 31, 2024 and 76,465,862 shares at December 31, 2023 (14,359) (13,658)
Total stockholders' equity 16,130 16,262
Noncontrolling interests 56 56
Total equity 16,186 16,318
Total liabilities and equity $ 50,091 $ 47,065
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Receivables, net of allowances $ 85 $ 88
Preferred stock, par (in dollars per share) $ 1 $ 1
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par (in dollars per share) $ 0.1667 $ 0.1667
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Common stock, shares issued (in shares) 198,690,593 198,690,082
Treasury stock, shares (in shares) 78,189,958 76,465,862
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Health Care [Member] Health Care [Member]
Revenues:    
Premiums $ 28,261 $ 25,550
Services 1,062 999
Investment income 288 193
Total revenues 29,611 26,742
Operating expenses:    
Benefits 25,124 21,858
Operating costs 3,042 2,979
Depreciation and amortization 209 186
Total operating expenses 28,375 25,023
Income from operations 1,236 1,719
Interest expense 159 113
Other expense (income), net 63 (8)
Income (loss) before income taxes and equity in net losses 1,014 1,614
Provision for income taxes 251 359
Equity in net losses (24) (17)
Net income 739 1,238
Net loss attributable to noncontrolling interests 2 1
Net income attributable to Humana $ 741 $ 1,239
Basic earnings per common share (in dollars per share) $ 6.13 $ 9.91
Diluted earnings per common share (in dollars per share) $ 6.11 $ 9.87
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net income attributable to Humana $ 741 $ 1,239
Other comprehensive income (loss):    
Change in gross unrealized investment (losses) gains (114) 188
Effect of income taxes 28 (43)
Total change in unrealized investment (losses) gains, net of tax (86) 145
Reclassification adjustment for net realized (gains) losses (1) 61
Effect of income taxes 0 (15)
Total reclassification adjustment, net of tax (1) 46
Other comprehensive (loss) income, net of tax (87) 191
Comprehensive income attributable to Humana $ 654 $ 1,430
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($)
shares in Thousands, $ in Millions
Total
Total Stockholders' Equity
Common Stock
Capital In Excess of Par Value
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Treasury Stock
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2022     198,667          
Beginning balance at Dec. 31, 2022 $ 15,370 $ 15,311 $ 33 $ 3,246 $ 25,492 $ (1,304) $ (12,156) $ 59
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 1,238 1,239     1,239     (1)
Distribution from noncontrolling interest holders, net 4             4
Acquisition (5)             (5)
Other comprehensive income (loss) 191 191       191    
Common stock repurchases (94) (94)         (94)  
Dividends and dividend equivalents (112) (112)     (112)      
Stock-based compensation 38 38   38        
Restricted stock unit vesting 0     (24)     24  
Stock option exercises 4 4   2     2  
Ending balance (in shares) at Mar. 31, 2023     198,667          
Ending balance at Mar. 31, 2023 16,634 16,577 $ 33 3,262 26,619 (1,113) (12,224) 57
Beginning balance (in shares) at Dec. 31, 2023     198,690          
Beginning balance at Dec. 31, 2023 16,318 16,262 $ 33 3,346 27,540 (999) (13,658) 56
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 739 741     741     (2)
Distribution from noncontrolling interest holders, net 2             2
Other comprehensive income (loss) (87) (87)       (87)    
Common stock repurchases (723) (723)         (723)  
Dividends and dividend equivalents (108) (108)     (108)      
Stock-based compensation 45 45   45        
Restricted stock unit vesting (in shares)     1          
Restricted stock unit vesting 0     (22)     22  
Ending balance (in shares) at Mar. 31, 2024     198,691          
Ending balance at Mar. 31, 2024 $ 16,186 $ 16,130 $ 33 $ 3,369 $ 28,173 $ (1,086) $ (14,359) $ 56
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities    
Net income $ 739 $ 1,238
Adjustments to reconcile net income to net cash provided by operating activities:    
(Gain) loss on investment securities, net (1) 60
Equity in net losses 24 17
Stock-based compensation 45 38
Depreciation 226 200
Amortization 16 18
Impairment of property and equipment 33 0
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:    
Receivables (1,890) (1,433)
Other assets 97 (907)
Benefits payable 1,488 754
Other liabilities (422) (238)
Unearned revenues 35 6,934
Other 33 6
Net cash provided by operating activities 423 6,687
Cash flows from investing activities    
Acquisitions, net of cash and cash equivalents acquired (14) (73)
Purchases of property and equipment, net (177) (223)
Purchases of investment securities (1,259) (1,313)
Proceeds from maturities of investment securities 645 267
Proceeds from sales of investment securities 391 50
Net cash used in investing activities (414) (1,292)
Cash flows from financing activities    
Receipts from contract deposits, net 499 2,997
Proceeds from issuance of senior notes, net 2,232 1,215
Repayments of senior notes 0 (60)
Repayments of commercial paper, net (644) (177)
Repayment of term loan 0 (500)
Debt issue costs (5) (4)
Change in book overdraft (20) 108
Common stock repurchases (717) (94)
Dividends paid (109) (100)
Other (29) (106)
Net cash provided by financing activities 1,207 3,279
Increase in cash and cash equivalents 1,216 8,674
Cash and cash equivalents at beginning of period 4,694 5,061
Cash and cash equivalents at end of period 5,910 13,735
Supplemental cash flow disclosures:    
Interest payments 158 97
Income tax payments, net 1 6
Details of businesses acquired in purchase transactions:    
Fair value of assets acquired, net of cash and cash equivalents acquired 22 73
Less: Fair value of liabilities assumed (8) (5)
Less: Noncontrolling interests acquired 0 5
Cash paid for acquired businesses, net of cash and cash equivalents acquired $ 14 $ 73
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS BASIS OF PRESENTATION AND SIGNIFICANT EVENTS
The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.
The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
Employer Group Commercial Medical Products Business Exit
In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.

Value Creation Initiatives
Beginning in 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges, primarily in asset impairments, of $29 million for the three months ended March 31, 2024 within operating costs in the consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. We did not record any charges for the three months ended March 31, 2023.
Revenue Recognition
Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are
recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
At March 31, 2024, accounts receivable related to services were $390 million. For the three months ended March 31, 2024, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at March 31, 2024.
For the three months ended March 31, 2024, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
 3 Months Ended
Mar. 31, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Accounting Pronouncements Effective in Future Periods
In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
ACQUISITIONS ACQUISITIONS
During the first quarter of 2024 and 2023, respectively, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in the first quarter of 2024 and 2023, respectively, have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in the first quarter of 2024 and 2023, were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the quarter of acquisition, were not material for disclosure purposes.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENT SECURITIES
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
INVESTMENT SECURITIES INVESTMENT SECURITIES
Investment securities classified as current and long-term were as follows at March 31, 2024 and December 31, 2023, respectively:
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
 (in millions)
March 31, 2024
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,928 $— $(84)$2,844 
Mortgage-backed securities3,925 — (486)3,439 
Tax-exempt municipal securities850 — (24)826 
Mortgage-backed securities:
Residential462 — (68)394 
Commercial1,420 1 (113)1,308 
Asset-backed securities1,552 2 (37)1,517 
Corporate debt securities7,348 24 (623)6,749 
Total debt securities$18,485 $27 $(1,435)17,077 
December 31, 2023
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,717 $1 $(51)$2,667 
Mortgage-backed securities3,946 1 (425)3,522 
Tax-exempt municipal securities879 1 (22)858 
Mortgage-backed securities:
Residential465 1 (66)400 
Commercial1,471 — (126)1,345 
Asset-backed securities1,813 2 (44)1,771 
Corporate debt securities7,011 28 (594)6,445 
Total debt securities$18,302 $34 $(1,328)17,008 
We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $379 million and $397 million, respectively, at March 31, 2024. The book value and fair value were $379 million and $398 million, respectively, at December 31, 2023.
Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at March 31, 2024 and December 31, 2023, respectively:
 Less than 12 months12 months or moreTotal
 Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
 (in millions)
March 31, 2024
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$2,301 $(43)$447 $(41)$2,748 $(84)
Mortgage-backed securities862 (15)2,513 (471)3,375 (486)
Tax-exempt municipal securities261 (1)508 (23)769 (24)
Mortgage-backed securities:
Residential9 — 365 (68)374 (68)
Commercial— — 1,242 (113)1,242 (113)
Asset-backed securities447 (2)787 (35)1,234 (37)
Corporate debt securities824 (7)4,702 (616)5,526 (623)
Total debt securities$4,704 $(68)$10,564 $(1,367)$15,268 $(1,435)
December 31, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$1,899 $(12)$431 $(39)$2,330 $(51)
Mortgage-backed securities958 (12)2,269 (413)3,227 (425)
Tax-exempt municipal securities160 (1)523 (21)683 (22)
Mortgage-backed securities:
Residential— — 373 (66)373 (66)
Commercial18 — 1,303 (126)1,321 (126)
Asset-backed securities120 (1)1,364 (43)1,484 (44)
Corporate debt securities466 (2)4,783 (592)5,249 (594)
Total debt securities$3,621 $(28)$11,046 $(1,300)$14,667 $(1,328)

Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by Standard & Poor's Rating Service, or S&P, at March 31, 2024. Our remaining debt securities below investment-grade were primarily rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.
Our unrealized losses from all debt securities were generated from approximately 1,685 positions out of a total of approximately 2,100 positions at March 31, 2024. All issuers of debt securities we own that were trading at an
unrealized loss at March 31, 2024 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At March 31, 2024, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three months ended March 31, 2024 or 2023.
The detail of gains (losses) related to investment securities and included within investment income was as follows for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
 20242023
 (in millions)
Gross gains on investment securities$2 $— 
Gross losses on investment securities(1)(61)
Gross gains on equity securities— 1 
Gross losses on equity securities— — 
Net recognized gains (losses) on investment securities$1 $(60)
The gains and losses related to equity securities for the three months ended March 31, 2024 and 2023 was as follows:
Three Months Ended March 31,
20242023
(in millions)
Net gains (losses) recognized on equity securities during the period$— $1 
Less: Net gains (losses) recognized on equity securities sold during the period— 1 
Unrealized gains (losses) recognized on equity securities still held at the end of the period$— $— 
The contractual maturities of debt securities available for sale at March 31, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.
Amortized
Cost		Fair
Value
 (in millions)
Due within one year$1,235 $1,229 
Due after one year through five years5,402 5,199 
Due after five years through ten years3,259 2,954 
Due after ten years1,230 1,037 
Mortgage and asset-backed securities7,359 6,658 
Total debt securities$18,485 $17,077 
For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE FAIR VALUE
Financial Assets
The following table summarizes our fair value measurements at March 31, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:
 Fair Value Measurements Using
 Fair
Value		Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)
 (in millions)
March 31, 2024
Cash equivalents$5,594 $5,594 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,844 — 2,844 — 
Mortgage-backed securities3,439 — 3,439 — 
Tax-exempt municipal securities826 — 826 — 
Mortgage-backed securities:
Residential394 — 391 3 
Commercial1,308 — 1,308 — 
Asset-backed securities1,517 — 1,479 38 
Corporate debt securities6,749 — 6,564 185 
Total debt securities17,077 — 16,851 226 
Total invested assets$22,671 $5,594 $16,851 $226 
December 31, 2023
Cash equivalents$4,582 $4,582 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,667 — 2,667 — 
Mortgage-backed securities3,522 — 3,522 — 
Tax-exempt municipal securities858 — 858 — 
Mortgage-backed securities:
Residential400 — 396 4 
Commercial1,345 — 1,345 — 
Asset-backed securities1,771 — 1,733 38 
Corporate debt securities6,445 — 6,269 176 
Total debt securities17,008 — 16,790 218 
Total invested assets$21,590 $4,582 $16,790 $218 
Our Level 3 assets had a fair value of $226 million, or 1.0% of total invested assets, and $218 million, or 1.0% or total invested assets, at March 31, 2024 and December 31, 2023, respectively. During the three months ended
March 31, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    
For the three months ended March 31, 2024For the three months ended March 31, 2023
Private Placements
(in millions)
Beginning balance at January 1$218 $101 
Total gains or losses:
Realized in earnings— — 
Unrealized in other comprehensive income(2)1 
Purchases11 1 
Sales— — 
Settlements(1)— 
Transfer out— (4)
Balance at March 31$226 $99 
Interest Rate Swaps

We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on SOFR, to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our condensed consolidated balance sheets at fair value as of the reporting date. Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy. The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $17 million at March 31, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheets, were approximately $20 million and $68 million at March 31, 2024 and December 31, 2023, respectively. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three months ended March 31, 2024. We did not enter into interest-rate swap agreements for the three months ended March 31, 2023. The following table summarizes the notional amounts at March 31, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:

March 31, 2024December 31, 2023
(in millions)
$750 million, 5.875% due March 1, 2033
$650 $650 
$850 million, 5.950% due March 15, 2034
800 400 
$500 million, 3.950% due August 15, 2049
450 450 
$750 million, 5.500% due March 15, 2053
700 300 
$1,000 million, 5.750% due April 15, 2054
400 — 

Financial Liabilities
Our debt is recorded at carrying value in our condensed consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $13.0 billion at March 31, 2024 and $10.8 billion at December 31, 2023. The fair value of our senior notes debt was $12.6 billion at March 31, 2024 and $10.6 billion at December 31, 2023. The fair value of our senior notes debt is determined based on Level 2 inputs,
including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our commercial paper borrowings. The commercial paper borrowings were $0.3 billion and $0.9 billion at March 31, 2024 and December 31, 2023, respectively.
Put and Call Options Measured at Fair Value
Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.
The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $731 million and $22 million, respectively, at March 31, 2024. The put and call options fair values, derived from the Monte Carlo simulation, were $595 million and $18 million, respectively, at December 31, 2023. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.
The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.
March 31, 2024December 31, 2023
Annualized volatility
17.0% - 18.8%
16.1% - 17.8%
Credit spread
1.0% - 1.3%
0.9% - 1.1%
Revenue exit multiple
1.5x - 2.5x
1.5x - 2.5x
Weighted average cost of capital
11.0% - 12.5%
11.0% - 12.5%
Long term growth rate3.0 %3.0 %
The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.
Other Assets and Liabilities Measured at Fair Value
Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2024 and 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.
Other than the assets and liabilities acquired during 2024 and 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2024 and 2023.
For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
MEDICARE PART D
 3 Months Ended
Mar. 31, 2024
Insurance [Abstract]  
MEDICARE PART D MEDICARE PART D
We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at March 31, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

 March 31, 2024December 31, 2023
Risk
Corridor
Settlement		CMS
Subsidies/
Discounts		Risk
Corridor
Settlement		CMS
Subsidies/
Discounts
 (in millions)
Other current assets$100 $592 $224 $514 
Trade accounts payable and accrued expenses(108)(2,472)(232)(1,825)
Net current liability(8)(1,880)(8)(1,311)
Other long-term assets293 — 17 — 
Other long-term liabilities(81)— (77)— 
Net long-term asset (liability)212 — (60)— 
Total net asset (liability)$204 $(1,880)$(68)$(1,311)
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the carrying amount of goodwill for our reportable segments for the three months ended March 31, 2024 were as follows:
InsuranceCenterWellTotal
 (in millions)
Balance at January 1, 2024$2,663 $6,887 $9,550 
Acquisitions— 13 13 
Balance at March 31, 2024$2,663 $6,900 $9,563 
The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at March 31, 2024 and December 31, 2023:
 March 31, 2024December 31, 2023
Weighted
Average
Life		CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
 ($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,092 $— $1,092 $1,092 $— $1,092 
Medicare licensesIndefinite288 — 288 288 — 288 
Customer contracts/
    relationships		9.4 years956 728 228 956 718 238 
Trade names and
    technology		6.7 years139 111 28 139 109 30 
Provider contracts11.9 years67 63 4 67 62 5 
Noncompetes and
    other		8.4 years85 46 39 84 44 40 
Total other intangible
    assets		9.2 years$2,627 $948 $1,679 $2,626 $933 $1,693 
    For the three months ended March 31, 2024 and 2023, amortization expense for other intangible assets was approximately $16 million and $18 million, respectively. The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at March 31, 2024:
 (in millions)
For the years ending December 31,
2024$44 
202558 
202643 
202733 
202829 
202927 
For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BENEFITS PAYABLE
 3 Months Ended
Mar. 31, 2024
Insurance [Abstract]  
BENEFITS PAYABLE BENEFITS PAYABLE
On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the three months ended March 31, 2024 and 2023:
For the three months ended March 31,
20242023
(in millions)
Balances, beginning of period$10,241 $9,264 
Incurred related to:
Current year25,659 22,380 
Prior years(535)(522)
Total incurred25,124 21,858 
Paid related to:
Current year(16,061)(14,203)
Prior years(7,575)(6,901)
Total paid(23,636)(21,104)
Balances, end of period$11,729 $10,018 
The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At March 31, 2024, benefits payable included IBNR of approximately $7.3 billion, primarily associated with claims incurred in 2024.
Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).
Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER COMMON SHARE COMPUTATION
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE COMPUTATION EARNINGS PER COMMON SHARE COMPUTATION
Detail supporting the computation of basic and diluted earnings per common share was as follows for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders$741 $1,239 
Weighted average outstanding shares of common stock
    used to compute basic earnings per common share		120,978 125,005 
Dilutive effect of:
Employee stock options6 34 
Restricted stock284 525 
Shares used to compute diluted earnings per common share121,268 125,564 
Basic earnings per common share$6.13 $9.91 
Diluted earnings per common share$6.11 $9.87 
Number of antidilutive stock options and restricted stock
    excluded from computation		1,165 538 
For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Dividends
The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:
Record
Date		Payment
Date		Amount
per Share		Total
Amount
(in millions)
2024 payments
12/29/20231/26/2024$0.8850 $108 
In February 2024, the Board declared a cash dividend of $0.885 per share payable on April 26, 2024 to stockholders of record on March 29, 2024. In April 2024, the Board declared a cash dividend of $0.885 per share payable on July 26, 2024 to stockholders of record as of the close of business on June 28, 2024. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.

Stock Repurchases
Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as
amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.
Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. During the three months ended March 31, 2024, we repurchased 1.8 million shares in open market transactions for $702 million at an average price of $388.78 under the February 2023 and 2024 share repurchase authorizations. During the three months ended March 31, 2023, we repurchased 0.1 million shares in open market transactions for $67 million at an average price of $495.68 under the February 2023 share repurchase authorization.

Our remaining repurchase authorization was $2.96 billion as of April 23, 2024.
In connection with employee stock plans, we acquired 0.04 million common shares for $15 million and 0.05 million common shares for $27 million during the three months ended March 31, 2024 and 2023, respectively.
For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The effective income tax rate was 25.3% and 22.5% for the three months ended March 31, 2024 and 2023, respectively. The year-over-year increase in the effective income tax rate is primarily due to a change in the mix of current year earnings between our Insurance segment and our CenterWell health services segment, as the latter incurs a higher effective domestic tax rate than the former. In addition, the prior year income tax rate was favorably impacted by the recognition of a non-taxable gain.

For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at March 31, 2024 and December 31, 2023:
March 31, 2024December 31, 2023
(in millions)
Short-term debt:
Commercial paper$250 $871 
Senior notes:
$600 million, 3.850% due October 1, 2024
572 572 
Total senior notes572 572 
Total short-term debt$822 $1,443 
Long-term debt:
Senior notes:
$600 million, 4.500% due April 1, 2025
$599 $598 
$500 million, 5.700% due March 13, 2026
498 498 
$750 million, 1.350% due February 3, 2027
688 688 
$600 million, 3.950% due March 15, 2027
537 537 
$500 million, 5.750% due March 1, 2028
495 495 
$500 million, 5.750% due December 1, 2028
495 495 
$750 million, 3.700% due March 23, 2029
590 590 
$500 million, 3.125% due August 15, 2029
433 433 
$500 million, 4.875% due April 1, 2030
496 496 
$1,250 million, 5.375% due April 15, 2031
1,238 — 
$750 million, 2.150% due February 3, 2032
744 743 
$750 million, 5.875% due March 1, 2033
735 750 
$850 million, 5.950% due March 15, 2034
826 840 
$250 million, 8.150% due June 15, 2038
261 261 
$400 million, 4.625% due December 1, 2042
396 396 
$750 million, 4.950% due October 1, 2044
740 740 
$400 million, 4.800% due March 15, 2047
396 396 
$500 million, 3.950% due August 15, 2049
514 529 
$750 million, 5.500% due March 15, 2053
720 728 
$1,000 million, 5.750% due April 15, 2054
989 — 
Total senior notes12,390 10,213 
Total long-term debt$12,390 $10,213 
Senior Notes
In March 2024, we issued $1.3 billion of 5.375% unsecured senior notes due April 15, 2031 and $1.0 billion of 5.750% unsecured senior notes due April 15, 2054. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $2.2 billion. We used the net proceeds for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.
We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on SOFR, to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value
caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $17 million at March 31, 2024.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Revolving Credit Agreements
In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021) and entered into a 364-day $1.5 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2022, which expired in accordance with its terms).
Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.
The SOFR spread, currently 114.0 basis points under the 5-year revolving credit agreement and 116.0 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 11.0 basis points, under the 5-year revolving credit agreement and 15.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.
Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 45.1% as measured in accordance with the revolving credit agreements as of March 31, 2024.
At March 31, 2024, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of March 31, 2024, we had $2.482 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement.
For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Commercial Paper
Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the three months ended March 31, 2024 was $2.7 billion, with $0.3 billion outstanding at March 31, 2024 compared to $0.9
billion outstanding at December 31, 2023. The outstanding commercial paper at March 31, 2024 had a weighted average annual interest rate of 5.46%.
For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Other Short-term Borrowings
We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At March 31, 2024 we had no outstanding short-term FHLB borrowings.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS, GUARANTEES AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS, GUARANTEES AND CONTINGENCIES COMMITMENTS, GUARANTEES AND CONTINGENCIES
Government Contracts
Our Medicare products, which accounted for approximately 86% of our total premiums and services revenue for the three months ended March 31, 2024, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.
CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.
CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.
In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would
be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.
In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”
We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.
On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

Our state-based Medicaid business, which accounted for approximately 7% of our total premiums and services revenue for the three months ended March 31, 2024 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states.
At March 31, 2024, our Military services business, which accounted for approximately 1% of our total premiums and services revenue for the three months ended March 31, 2024, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2024, unless further extended.
In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region
contract comprises 24 states, and Washington D.C., and covers approximately 4.6 million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is one transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.
The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.
Legal Proceedings and Certain Regulatory Matters
As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020.
As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana Inc., currently pending in United States District Court, Western District of Kentucky, Louisville division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. During 2023, we accrued certain anticipated expenses in connection with this matter.
On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.

Other Lawsuits and Regulatory Matters
Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.
We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.
As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.
A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.
We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.
The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.
The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration,
and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.
The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.
Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics.
In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.
We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $3.7 billion and $4.0 billion for the three months ended March 31, 2024 and 2023, respectively. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $32 million and $33 million for the three months ended March 31, 2024 and 2023, respectively.
Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.
Our segment results were as follows for the three months ended March 31, 2024 and 2023:
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended March 31, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$22,448 $— $— $22,448 
Group Medicare Advantage1,989 — — 1,989 
Medicare stand-alone PDP821 — — 821 
Total Medicare25,258 — — 25,258 
Commercial fully-insured256 — — 256 
Specialty benefits239 — — 239 
Medicare Supplement197 — — 197 
State-based contracts and other2,311 — — 2,311 
Total premiums28,261 — — 28,261 
Services revenue:
Home solutions— 335 — 335 
Primary care— 241 — 241 
Commercial ASO24 — — 24 
Military services and other251 — — 251 
Pharmacy solutions— 211 — 211 
Total services revenue275 787 — 1,062 
Total external revenues 28,536 787 — 29,323 
Intersegment revenues
Services1 1,414 (1,415)— 
Products— 2,617 (2,617)— 
Total intersegment revenues1 4,031 (4,032)— 
Investment income162 — 126 288 
Total revenues28,699 4,818 (3,906)29,611 
Operating expenses:
Benefits25,251 — (127)25,124 
Operating costs2,364 4,483 (3,805)3,042 
Depreciation and amortization186 53 (30)209 
Total operating expenses27,801 4,536 (3,962)28,375 
Income from operations898 282 56 1,236 
Interest expense— 1 158 159 
Other expense, net— — 63 63 
Income (loss) before income taxes and equity in net earnings 898 281 (165)1,014 
Equity in net losses(2)(22)— (24)
Segment earnings (loss)$896 $259 $(165)$990 
Net loss attributable to noncontrolling interests2 — — 2 
Segment earnings (loss) attributable to Humana$898 $259 $(165)$992 
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended March 31, 2023(in millions)
External revenues
Premiums:
Individual Medicare Advantage$19,809 $— $— $19,809 
Group Medicare Advantage1,765 — — 1,765 
Medicare stand-alone PDP616 — — 616 
Total Medicare22,190 — — 22,190 
Commercial fully-insured1,018 — — 1,018 
Specialty benefits254 — — 254 
Medicare Supplement179 — — 179 
State-based contracts and other1,909 — — 1,909 
Total premiums25,550 — — 25,550 
Services revenue:
Home solutions— 314 — 314 
Primary care— 201 — 201 
Commercial ASO71 — — 71 
Military services and other171 — — 171 
Pharmacy solutions— 242 — 242 
Total services revenue242 757 — 999 
Total external revenues 25,792 757 — 26,549 
Intersegment revenues
Services14 1,133 (1,147)— 
Products— 2,615 (2,615)— 
Total intersegment revenues14 3,748 (3,762)— 
Investment income 97 — 96 193 
Total revenues25,903 4,505 (3,666)26,742 
Operating expenses:
Benefits21,993 — (135)21,858 
Operating costs2,418 4,126 (3,565)2,979 
Depreciation and amortization165 49 (28)186 
Total operating expenses24,576 4,175 (3,728)25,023 
Income from operations1,327 330 62 1,719 
Interest expense— — 113 113 
Other income, net— — (8)(8)
Income (loss) before income taxes and equity in net earnings 1,327 330 (43)1,614 
Equity in net losses(3)(14)— (17)
Segment earnings (loss)$1,324 $316 $(43)$1,597 
Net loss attributable to noncontrolling interests1 — — 1 
Segment earnings (loss) attributable to Humana$1,325 $316 $(43)$1,598 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net income attributable to Humana $ 741 $ 1,239
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.
The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
Employer Group Commercial Medical Products Business Exit
In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.
Revenue Recognition
Revenue Recognition
Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are
recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Accounting Pronouncements Effective in Future Periods
Accounting Pronouncements Effective in Future Periods
In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENT SECURITIES (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment Securities Classified as Current and Long-Term
Investment securities classified as current and long-term were as follows at March 31, 2024 and December 31, 2023, respectively:
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
 (in millions)
March 31, 2024
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,928 $— $(84)$2,844 
Mortgage-backed securities3,925 — (486)3,439 
Tax-exempt municipal securities850 — (24)826 
Mortgage-backed securities:
Residential462 — (68)394 
Commercial1,420 1 (113)1,308 
Asset-backed securities1,552 2 (37)1,517 
Corporate debt securities7,348 24 (623)6,749 
Total debt securities$18,485 $27 $(1,435)17,077 
December 31, 2023
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,717 $1 $(51)$2,667 
Mortgage-backed securities3,946 1 (425)3,522 
Tax-exempt municipal securities879 1 (22)858 
Mortgage-backed securities:
Residential465 1 (66)400 
Commercial1,471 — (126)1,345 
Asset-backed securities1,813 2 (44)1,771 
Corporate debt securities7,011 28 (594)6,445 
Total debt securities$18,302 $34 $(1,328)17,008 
Schedule of Gross Unrealized Losses and Fair Value of Securities
Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at March 31, 2024 and December 31, 2023, respectively:
 Less than 12 months12 months or moreTotal
 Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
 (in millions)
March 31, 2024
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$2,301 $(43)$447 $(41)$2,748 $(84)
Mortgage-backed securities862 (15)2,513 (471)3,375 (486)
Tax-exempt municipal securities261 (1)508 (23)769 (24)
Mortgage-backed securities:
Residential9 — 365 (68)374 (68)
Commercial— — 1,242 (113)1,242 (113)
Asset-backed securities447 (2)787 (35)1,234 (37)
Corporate debt securities824 (7)4,702 (616)5,526 (623)
Total debt securities$4,704 $(68)$10,564 $(1,367)$15,268 $(1,435)
December 31, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$1,899 $(12)$431 $(39)$2,330 $(51)
Mortgage-backed securities958 (12)2,269 (413)3,227 (425)
Tax-exempt municipal securities160 (1)523 (21)683 (22)
Mortgage-backed securities:
Residential— — 373 (66)373 (66)
Commercial18 — 1,303 (126)1,321 (126)
Asset-backed securities120 (1)1,364 (43)1,484 (44)
Corporate debt securities466 (2)4,783 (592)5,249 (594)
Total debt securities$3,621 $(28)$11,046 $(1,300)$14,667 $(1,328)
Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income
The detail of gains (losses) related to investment securities and included within investment income was as follows for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
 20242023
 (in millions)
Gross gains on investment securities$2 $— 
Gross losses on investment securities(1)(61)
Gross gains on equity securities— 1 
Gross losses on equity securities— — 
Net recognized gains (losses) on investment securities$1 $(60)
Schedule of Gain (Loss) on Equity Securities
The gains and losses related to equity securities for the three months ended March 31, 2024 and 2023 was as follows:
Three Months Ended March 31,
20242023
(in millions)
Net gains (losses) recognized on equity securities during the period$— $1 
Less: Net gains (losses) recognized on equity securities sold during the period— 1 
Unrealized gains (losses) recognized on equity securities still held at the end of the period$— $— 
Schedule of Contractual Maturity of Debt Securities Available for Sale
The contractual maturities of debt securities available for sale at March 31, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.
Amortized
Cost		Fair
Value
 (in millions)
Due within one year$1,235 $1,229 
Due after one year through five years5,402 5,199 
Due after five years through ten years3,259 2,954 
Due after ten years1,230 1,037 
Mortgage and asset-backed securities7,359 6,658 
Total debt securities$18,485 $17,077 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Measured at Fair Value on Recurring Basis
The following table summarizes our fair value measurements at March 31, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:
 Fair Value Measurements Using
 Fair
Value		Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)
 (in millions)
March 31, 2024
Cash equivalents$5,594 $5,594 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,844 — 2,844 — 
Mortgage-backed securities3,439 — 3,439 — 
Tax-exempt municipal securities826 — 826 — 
Mortgage-backed securities:
Residential394 — 391 3 
Commercial1,308 — 1,308 — 
Asset-backed securities1,517 — 1,479 38 
Corporate debt securities6,749 — 6,564 185 
Total debt securities17,077 — 16,851 226 
Total invested assets$22,671 $5,594 $16,851 $226 
December 31, 2023
Cash equivalents$4,582 $4,582 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,667 — 2,667 — 
Mortgage-backed securities3,522 — 3,522 — 
Tax-exempt municipal securities858 — 858 — 
Mortgage-backed securities:
Residential400 — 396 4 
Commercial1,345 — 1,345 — 
Asset-backed securities1,771 — 1,733 38 
Corporate debt securities6,445 — 6,269 176 
Total debt securities17,008 — 16,790 218 
Total invested assets$21,590 $4,582 $16,790 $218 
Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation During the three months ended
March 31, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    
For the three months ended March 31, 2024For the three months ended March 31, 2023
Private Placements
(in millions)
Beginning balance at January 1$218 $101 
Total gains or losses:
Realized in earnings— — 
Unrealized in other comprehensive income(2)1 
Purchases11 1 
Sales— — 
Settlements(1)— 
Transfer out— (4)
Balance at March 31$226 $99 
Schedule of Notional Amounts of Outstanding Derivative Positions The following table summarizes the notional amounts at March 31, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:
March 31, 2024December 31, 2023
(in millions)
$750 million, 5.875% due March 1, 2033
$650 $650 
$850 million, 5.950% due March 15, 2034
800 400 
$500 million, 3.950% due August 15, 2049
450 450 
$750 million, 5.500% due March 15, 2053
700 300 
$1,000 million, 5.750% due April 15, 2054
400 — 
Schedule of Assumptions Used For Inputs In Fair Value Measurement The table below presents the assumptions used for each reporting period.
March 31, 2024December 31, 2023
Annualized volatility
17.0% - 18.8%
16.1% - 17.8%
Credit spread
1.0% - 1.3%
0.9% - 1.1%
Revenue exit multiple
1.5x - 2.5x
1.5x - 2.5x
Weighted average cost of capital
11.0% - 12.5%
11.0% - 12.5%
Long term growth rate3.0 %3.0 %
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
MEDICARE PART D (Tables)
 3 Months Ended
Mar. 31, 2024
Insurance [Abstract]  
Schedule of Balance Sheet Amounts Associated With Medicare Part D The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at March 31, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
 March 31, 2024December 31, 2023
Risk
Corridor
Settlement		CMS
Subsidies/
Discounts		Risk
Corridor
Settlement		CMS
Subsidies/
Discounts
 (in millions)
Other current assets$100 $592 $224 $514 
Trade accounts payable and accrued expenses(108)(2,472)(232)(1,825)
Net current liability(8)(1,880)(8)(1,311)
Other long-term assets293 — 17 — 
Other long-term liabilities(81)— (77)— 
Net long-term asset (liability)212 — (60)— 
Total net asset (liability)$204 $(1,880)$(68)$(1,311)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments
Changes in the carrying amount of goodwill for our reportable segments for the three months ended March 31, 2024 were as follows:
InsuranceCenterWellTotal
 (in millions)
Balance at January 1, 2024$2,663 $6,887 $9,550 
Acquisitions— 13 13 
Balance at March 31, 2024$2,663 $6,900 $9,563 
Schedule of Other Intangible Assets, Indefinite-Lived
The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at March 31, 2024 and December 31, 2023:
 March 31, 2024December 31, 2023
Weighted
Average
Life		CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
 ($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,092 $— $1,092 $1,092 $— $1,092 
Medicare licensesIndefinite288 — 288 288 — 288 
Customer contracts/
    relationships		9.4 years956 728 228 956 718 238 
Trade names and
    technology		6.7 years139 111 28 139 109 30 
Provider contracts11.9 years67 63 4 67 62 5 
Noncompetes and
    other		8.4 years85 46 39 84 44 40 
Total other intangible
    assets		9.2 years$2,627 $948 $1,679 $2,626 $933 $1,693 
Schedule of Other Intangible Assets, Amortizable
The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at March 31, 2024 and December 31, 2023:
 March 31, 2024December 31, 2023
Weighted
Average
Life		CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
 ($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,092 $— $1,092 $1,092 $— $1,092 
Medicare licensesIndefinite288 — 288 288 — 288 
Customer contracts/
    relationships		9.4 years956 728 228 956 718 238 
Trade names and
    technology		6.7 years139 111 28 139 109 30 
Provider contracts11.9 years67 63 4 67 62 5 
Noncompetes and
    other		8.4 years85 46 39 84 44 40 
Total other intangible
    assets		9.2 years$2,627 $948 $1,679 $2,626 $933 $1,693 
Schedule of Estimated Amortization Expense The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at March 31, 2024:
 (in millions)
For the years ending December 31,
2024$44 
202558 
202643 
202733 
202829 
202927 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BENEFITS PAYABLE (Tables)
 3 Months Ended
Mar. 31, 2024
Insurance [Abstract]  
Schedule of Activity in Benefits Payable
On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the three months ended March 31, 2024 and 2023:
For the three months ended March 31,
20242023
(in millions)
Balances, beginning of period$10,241 $9,264 
Incurred related to:
Current year25,659 22,380 
Prior years(535)(522)
Total incurred25,124 21,858 
Paid related to:
Current year(16,061)(14,203)
Prior years(7,575)(6,901)
Total paid(23,636)(21,104)
Balances, end of period$11,729 $10,018 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER COMMON SHARE COMPUTATION (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Details Supporting Computation of Earnings Per Share
Detail supporting the computation of basic and diluted earnings per common share was as follows for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders$741 $1,239 
Weighted average outstanding shares of common stock
    used to compute basic earnings per common share		120,978 125,005 
Dilutive effect of:
Employee stock options6 34 
Restricted stock284 525 
Shares used to compute diluted earnings per common share121,268 125,564 
Basic earnings per common share$6.13 $9.91 
Diluted earnings per common share$6.11 $9.87 
Number of antidilutive stock options and restricted stock
    excluded from computation		1,165 538 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Details of Dividend Payments
The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:
Record
Date		Payment
Date		Amount
per Share		Total
Amount
(in millions)
2024 payments
12/29/20231/26/2024$0.8850 $108 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Carrying Value of Debt Outstanding
The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at March 31, 2024 and December 31, 2023:
March 31, 2024December 31, 2023
(in millions)
Short-term debt:
Commercial paper$250 $871 
Senior notes:
$600 million, 3.850% due October 1, 2024
572 572 
Total senior notes572 572 
Total short-term debt$822 $1,443 
Long-term debt:
Senior notes:
$600 million, 4.500% due April 1, 2025
$599 $598 
$500 million, 5.700% due March 13, 2026
498 498 
$750 million, 1.350% due February 3, 2027
688 688 
$600 million, 3.950% due March 15, 2027
537 537 
$500 million, 5.750% due March 1, 2028
495 495 
$500 million, 5.750% due December 1, 2028
495 495 
$750 million, 3.700% due March 23, 2029
590 590 
$500 million, 3.125% due August 15, 2029
433 433 
$500 million, 4.875% due April 1, 2030
496 496 
$1,250 million, 5.375% due April 15, 2031
1,238 — 
$750 million, 2.150% due February 3, 2032
744 743 
$750 million, 5.875% due March 1, 2033
735 750 
$850 million, 5.950% due March 15, 2034
826 840 
$250 million, 8.150% due June 15, 2038
261 261 
$400 million, 4.625% due December 1, 2042
396 396 
$750 million, 4.950% due October 1, 2044
740 740 
$400 million, 4.800% due March 15, 2047
396 396 
$500 million, 3.950% due August 15, 2049
514 529 
$750 million, 5.500% due March 15, 2053
720 728 
$1,000 million, 5.750% due April 15, 2054
989 — 
Total senior notes12,390 10,213 
Total long-term debt$12,390 $10,213 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Results
Our segment results were as follows for the three months ended March 31, 2024 and 2023:
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended March 31, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$22,448 $— $— $22,448 
Group Medicare Advantage1,989 — — 1,989 
Medicare stand-alone PDP821 — — 821 
Total Medicare25,258 — — 25,258 
Commercial fully-insured256 — — 256 
Specialty benefits239 — — 239 
Medicare Supplement197 — — 197 
State-based contracts and other2,311 — — 2,311 
Total premiums28,261 — — 28,261 
Services revenue:
Home solutions— 335 — 335 
Primary care— 241 — 241 
Commercial ASO24 — — 24 
Military services and other251 — — 251 
Pharmacy solutions— 211 — 211 
Total services revenue275 787 — 1,062 
Total external revenues 28,536 787 — 29,323 
Intersegment revenues
Services1 1,414 (1,415)— 
Products— 2,617 (2,617)— 
Total intersegment revenues1 4,031 (4,032)— 
Investment income162 — 126 288 
Total revenues28,699 4,818 (3,906)29,611 
Operating expenses:
Benefits25,251 — (127)25,124 
Operating costs2,364 4,483 (3,805)3,042 
Depreciation and amortization186 53 (30)209 
Total operating expenses27,801 4,536 (3,962)28,375 
Income from operations898 282 56 1,236 
Interest expense— 1 158 159 
Other expense, net— — 63 63 
Income (loss) before income taxes and equity in net earnings 898 281 (165)1,014 
Equity in net losses(2)(22)— (24)
Segment earnings (loss)$896 $259 $(165)$990 
Net loss attributable to noncontrolling interests2 — — 2 
Segment earnings (loss) attributable to Humana$898 $259 $(165)$992 
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended March 31, 2023(in millions)
External revenues
Premiums:
Individual Medicare Advantage$19,809 $— $— $19,809 
Group Medicare Advantage1,765 — — 1,765 
Medicare stand-alone PDP616 — — 616 
Total Medicare22,190 — — 22,190 
Commercial fully-insured1,018 — — 1,018 
Specialty benefits254 — — 254 
Medicare Supplement179 — — 179 
State-based contracts and other1,909 — — 1,909 
Total premiums25,550 — — 25,550 
Services revenue:
Home solutions— 314 — 314 
Primary care— 201 — 201 
Commercial ASO71 — — 71 
Military services and other171 — — 171 
Pharmacy solutions— 242 — 242 
Total services revenue242 757 — 999 
Total external revenues 25,792 757 — 26,549 
Intersegment revenues
Services14 1,133 (1,147)— 
Products— 2,615 (2,615)— 
Total intersegment revenues14 3,748 (3,762)— 
Investment income 97 — 96 193 
Total revenues25,903 4,505 (3,666)26,742 
Operating expenses:
Benefits21,993 — (135)21,858 
Operating costs2,418 4,126 (3,565)2,979 
Depreciation and amortization165 49 (28)186 
Total operating expenses24,576 4,175 (3,728)25,023 
Income from operations1,327 330 62 1,719 
Interest expense— — 113 113 
Other income, net— — (8)(8)
Income (loss) before income taxes and equity in net earnings 1,327 330 (43)1,614 
Equity in net losses(3)(14)— (17)
Segment earnings (loss)$1,324 $316 $(43)$1,597 
Net loss attributable to noncontrolling interests1 — — 1 
Segment earnings (loss) attributable to Humana$1,325 $316 $(43)$1,598 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Services  
Receivables and Other [Line Items]  
Accounts receivable $ 390
Value Creation Initiatives  
Receivables and Other [Line Items]  
Restructuring and impairment charge $ 29
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost $ 18,485 $ 18,302
Gross Unrealized Gains 27 34
Gross Unrealized Losses (1,435) (1,328)
Fair Value 17,077 17,008
U.S. Treasury and agency obligations    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 2,928 2,717
Gross Unrealized Gains 0 1
Gross Unrealized Losses (84) (51)
Fair Value 2,844 2,667
Mortgage-backed securities    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 3,925 3,946
Gross Unrealized Gains 0 1
Gross Unrealized Losses (486) (425)
Fair Value 3,439 3,522
Tax-exempt municipal securities    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 850 879
Gross Unrealized Gains 0 1
Gross Unrealized Losses (24) (22)
Fair Value 826 858
Residential    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 462 465
Gross Unrealized Gains 0 1
Gross Unrealized Losses (68) (66)
Fair Value 394 400
Commercial    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 1,420 1,471
Gross Unrealized Gains 1 0
Gross Unrealized Losses (113) (126)
Fair Value 1,308 1,345
Asset-backed securities    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 1,552 1,813
Gross Unrealized Gains 2 2
Gross Unrealized Losses (37) (44)
Fair Value 1,517 1,771
Corporate debt securities    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 7,348 7,011
Gross Unrealized Gains 24 28
Gross Unrealized Losses (623) (594)
Fair Value $ 6,749 $ 6,445
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENT SECURITIES - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
position
Dec. 31, 2023
USD ($)
Financing Receivable, Credit Quality Indicator [Line Items]    
Book value $ 18,485 $ 18,302
Fair value $ 17,077 17,008
Maximum individual state general bond obligation as a percentage of total debt securities (percent) 1.00%  
Securities in unrealized loss positions, number of positions | position 1,685  
Securities, number of positions | position 2,100  
S&P AA- rating    
Financing Receivable, Credit Quality Indicator [Line Items]    
Percentage of debt securities considered to be of investment-grade (percent) 97.00%  
Dispositions | Gentiva Hospice    
Financing Receivable, Credit Quality Indicator [Line Items]    
Book value $ 379 379
Fair value $ 397 $ 398
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Fair Value    
Less than 12 months $ 4,704 $ 3,621
12 months or more 10,564 11,046
Total 15,268 14,667
Gross Unrealized Losses    
Less than 12 months (68) (28)
12 months or more (1,367) (1,300)
Total (1,435) (1,328)
U.S. Treasury and agency obligations    
Fair Value    
Less than 12 months 2,301 1,899
12 months or more 447 431
Total 2,748 2,330
Gross Unrealized Losses    
Less than 12 months (43) (12)
12 months or more (41) (39)
Total (84) (51)
Mortgage-backed securities    
Fair Value    
Less than 12 months 862 958
12 months or more 2,513 2,269
Total 3,375 3,227
Gross Unrealized Losses    
Less than 12 months (15) (12)
12 months or more (471) (413)
Total (486) (425)
Tax-exempt municipal securities    
Fair Value    
Less than 12 months 261 160
12 months or more 508 523
Total 769 683
Gross Unrealized Losses    
Less than 12 months (1) (1)
12 months or more (23) (21)
Total (24) (22)
Residential    
Fair Value    
Less than 12 months 9 0
12 months or more 365 373
Total 374 373
Gross Unrealized Losses    
Less than 12 months 0 0
12 months or more (68) (66)
Total (68) (66)
Commercial    
Fair Value    
Less than 12 months 0 18
12 months or more 1,242 1,303
Total 1,242 1,321
Gross Unrealized Losses    
Less than 12 months 0 0
12 months or more (113) (126)
Total (113) (126)
Asset-backed securities    
Fair Value    
Less than 12 months 447 120
12 months or more 787 1,364
Total 1,234 1,484
Gross Unrealized Losses    
Less than 12 months (2) (1)
12 months or more (35) (43)
Total (37) (44)
Corporate debt securities    
Fair Value    
Less than 12 months 824 466
12 months or more 4,702 4,783
Total 5,526 5,249
Gross Unrealized Losses    
Less than 12 months (7) (2)
12 months or more (616) (592)
Total $ (623) $ (594)
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]    
Gross gains on investment securities $ 2 $ 0
Gross losses on investment securities (1) (61)
Gross gains on equity securities 0 1
Gross losses on equity securities 0 0
Net recognized gains (losses) on investment securities $ 1 $ (60)
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]    
Net gains (losses) recognized on equity securities during the period $ 0 $ 1
Less: Net gains (losses) recognized on equity securities sold during the period 0 1
Unrealized gains (losses) recognized on equity securities still held at the end of the period $ 0 $ 0
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Amortized Cost    
Due within one year $ 1,235  
Due after one year through five years 5,402  
Due after five years through ten years 3,259  
Due after ten years 1,230  
Mortgage and asset-backed securities 7,359  
Amortized Cost 18,485 $ 18,302
Fair Value    
Due within one year 1,229  
Due after one year through five years 5,199  
Due after five years through ten years 2,954  
Due after ten years 1,037  
Mortgage and asset-backed securities 6,658  
Fair Value $ 17,077 $ 17,008
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities $ 17,077 $ 17,008
U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 2,844 2,667
Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 3,439 3,522
Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 826 858
Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 394 400
Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,308 1,345
Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,517 1,771
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 6,749 6,445
Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 5,594 4,582
Total debt securities 17,077 17,008
Total invested assets 22,671 21,590
Recurring Basis | U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 2,844 2,667
Recurring Basis | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 3,439 3,522
Recurring Basis | Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 826 858
Recurring Basis | Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 394 400
Recurring Basis | Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,308 1,345
Recurring Basis | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,517 1,771
Recurring Basis | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 6,749 6,445
Recurring Basis | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 5,594 4,582
Total debt securities 0 0
Total invested assets 5,594 4,582
Recurring Basis | Quoted Prices in Active Markets (Level 1) | U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Total debt securities 16,851 16,790
Total invested assets 16,851 16,790
Recurring Basis | Other Observable Inputs (Level 2) | U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 2,844 2,667
Recurring Basis | Other Observable Inputs (Level 2) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 3,439 3,522
Recurring Basis | Other Observable Inputs (Level 2) | Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 826 858
Recurring Basis | Other Observable Inputs (Level 2) | Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 391 396
Recurring Basis | Other Observable Inputs (Level 2) | Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,308 1,345
Recurring Basis | Other Observable Inputs (Level 2) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,479 1,733
Recurring Basis | Other Observable Inputs (Level 2) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 6,564 6,269
Recurring Basis | Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Total debt securities 226 218
Total invested assets 226 218
Recurring Basis | Unobservable Inputs (Level 3) | U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Unobservable Inputs (Level 3) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Unobservable Inputs (Level 3) | Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Unobservable Inputs (Level 3) | Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 3 4
Recurring Basis | Unobservable Inputs (Level 3) | Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Unobservable Inputs (Level 3) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 38 38
Recurring Basis | Unobservable Inputs (Level 3) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities $ 185 $ 176
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Swap asset $ 20 $ 68
Interest rate swaps    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cumulative, aggregate adjustment 17  
Put option    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of financial liability 731 595
Call option    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of financial asset 22 18
Term Loan And Commercial Paper    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Short-term debt 300 900
Carrying Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt outstanding 13,000 10,800
Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt outstanding 12,600 10,600
Recurring Basis    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Assets, fair value disclosure 22,671 21,590
Unobservable Inputs (Level 3) | Recurring Basis    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Assets, fair value disclosure $ 226 $ 218
Investments | Fair Value Risk | Unobservable Inputs (Level 3)    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Concentration risk (percent) 1.00% 1.00%
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance at January 1 $ 218 $ 101
Total gains or losses:    
Realized in earnings 0 0
Unrealized in other comprehensive income (2) 1
Purchases 11 1
Sales 0 0
Settlements (1) 0
Transfer out 0 (4)
Balance at March 31 $ 226 $ 99
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE - Put and Call Options Measured at Fair Value (Details) - Options - Level 3 fair value measurement
Mar. 31, 2024
Dec. 31, 2023
Annualized volatility | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.170 0.161
Annualized volatility | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.188 0.178
Credit spread | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.010 0.009
Credit spread | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.013 0.011
Revenue exit multiple | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 1.5 1.5
Revenue exit multiple | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 2.5 2.5
Weighted average cost of capital | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.110 0.110
Weighted average cost of capital | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.125 0.125
Long term growth rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.030 0.030
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE - Fair Value of Swap Agreements (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Interest Rate Swap Maturing 2033 | Interest rate swaps    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative, notional amount $ 650,000,000 $ 650,000,000
Interest Rate Swap Maturing 2053 | Interest rate swaps    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative, notional amount 700,000,000 300,000,000
Interest Rate Swap Maturing 2049 | Interest rate swaps    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative, notional amount 450,000,000 450,000,000
Interest Rate Swap Maturing 2034 | Interest rate swaps    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative, notional amount 800,000,000 400,000,000
Interest Rate Swap Maturing 2054 | Interest rate swaps    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative, notional amount 400,000,000 $ 0
$750 million, 5.875% due March 1, 2033 | Senior Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Aggregate principal $ 750,000,000  
Stated interest rate (percent) 5.875%  
$750 million, 5.500% due March 15, 2053 | Senior Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Aggregate principal $ 750,000,000  
Stated interest rate (percent) 5.50%  
$500 million, 3.950% due August 15, 2049 | Senior Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Aggregate principal $ 500,000,000  
Stated interest rate (percent) 3.95%  
$850 million, 5.950% due March 15, 2034 | Senior Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Aggregate principal $ 850,000,000  
Stated interest rate (percent) 5.95%  
$1,000 million, $5.750% due April 15, 2054 | Senior Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Aggregate principal $ 1,000,000,000  
Stated interest rate (percent) 5.75%  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
MEDICARE PART D (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Other current assets $ 6,264 $ 6,631
Trade accounts payable and accrued expenses (6,504) (6,569)
Other long-term assets 3,643 3,377
Other long-term liabilities (1,826) (1,662)
Risk Corridor Settlement    
Segment Reporting Information [Line Items]    
Other current assets 100 224
Trade accounts payable and accrued expenses (108) (232)
Net current liability (8) (8)
Other long-term assets 293 17
Other long-term liabilities (81) (77)
Net long-term asset (liability) 212 (60)
Total net asset (liability) 204 (68)
CMS Subsidies/ Discounts    
Segment Reporting Information [Line Items]    
Other current assets 592 514
Trade accounts payable and accrued expenses (2,472) (1,825)
Net current liability (1,880) (1,311)
Other long-term assets 0 0
Other long-term liabilities 0 0
Net long-term asset (liability) 0 0
Total net asset (liability) $ (1,880) $ (1,311)
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Goodwill  
Goodwill, beginning balance $ 9,550
Acquisitions 13
Goodwill, ending balance 9,563
Insurance  
Goodwill  
Goodwill, beginning balance 2,663
Acquisitions 0
Goodwill, ending balance 2,663
CenterWell  
Goodwill  
Goodwill, beginning balance 6,887
Acquisitions 13
Goodwill, ending balance $ 6,900
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Other intangible assets:    
Weighted average life (in years) 9 years 2 months 12 days  
Total other intangible assets, cost $ 2,627 $ 2,626
Amortizable intangible assets, accumulated amortization 948 933
Total other intangible assets, net 1,679 1,693
Certificates of need    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 1,092 1,092
Medicare licenses    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets $ 288 288
Customer contracts/ relationships    
Other intangible assets:    
Weighted average life (in years) 9 years 4 months 24 days  
Amortizable intangible assets, cost $ 956 956
Amortizable intangible assets, accumulated amortization 728 718
Amortizable intangible assets, net $ 228 238
Trade names and technology    
Other intangible assets:    
Weighted average life (in years) 6 years 8 months 12 days  
Amortizable intangible assets, cost $ 139 139
Amortizable intangible assets, accumulated amortization 111 109
Amortizable intangible assets, net $ 28 30
Provider contracts    
Other intangible assets:    
Weighted average life (in years) 11 years 10 months 24 days  
Amortizable intangible assets, cost $ 67 67
Amortizable intangible assets, accumulated amortization 63 62
Amortizable intangible assets, net $ 4 5
Noncompetes and other    
Other intangible assets:    
Weighted average life (in years) 8 years 4 months 24 days  
Amortizable intangible assets, cost $ 85 84
Amortizable intangible assets, accumulated amortization 46 44
Amortizable intangible assets, net $ 39 $ 40
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization $ 16 $ 18
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details)
$ in Millions
Mar. 31, 2024
USD ($)
For the years ending December 31,  
2024 $ 44
2025 58
2026 43
2027 33
2028 29
2029 $ 27
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BENEFITS PAYABLE - Activity in Benefits Payable (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]    
Balances, beginning of period $ 10,241 $ 9,264
Incurred related to:    
Current year 25,659 22,380
Prior years (535) (522)
Total incurred 25,124 21,858
Paid related to:    
Current year (16,061) (14,203)
Prior years (7,575) (6,901)
Total paid (23,636) (21,104)
Balances, end of period 11,729 $ 10,018
Total IBNR included in benefits payable $ 7,300  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER COMMON SHARE COMPUTATION (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Net income available for common stockholders $ 741 $ 1,239
Weighted average outstanding shares of common stock used to compute basic earnings per common share (in shares) 120,978 125,005
Shares used to compute diluted earnings per common share (in shares) 121,268 125,564
Basic earnings per common share (in dollars per share) $ 6.13 $ 9.91
Diluted earnings per common share (in dollars per share) $ 6.11 $ 9.87
Number of antidilutive stock options and restricted stock excluded from computation (in shares) 1,165 538
Employee stock options    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Dilutive effect of employee stock options and restricted stock (in shares) 6 34
Restricted stock    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Dilutive effect of employee stock options and restricted stock (in shares) 284 525
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY - Dividends (Details)
$ / shares in Units, $ in Millions
Jan. 26, 2024
USD ($)
$ / shares
Equity [Abstract]  
Amount per Share (in dollars per share) | $ / shares $ 0.8850
Total Amount | $ $ 108
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 1 Months Ended 3 Months Ended
Apr. 30, 2024
Feb. 29, 2024
Mar. 31, 2024
Mar. 31, 2023
Apr. 23, 2024
Feb. 16, 2024
Equity, Class of Treasury Stock [Line Items]            
Dividends declared (in dollars per share)   $ 0.885        
Stock repurchases     $ 723 $ 94    
Common shares acquired in connection with employee stock plans (in shares)     40 50    
Common shares acquired in connection with employee stock plans, amount     $ 15 $ 27    
Subsequent Event            
Equity, Class of Treasury Stock [Line Items]            
Dividends declared (in dollars per share) $ 0.885          
Remaining authorized amount         $ 2,960  
2023 And 2024 Share Repurchase Authorization            
Equity, Class of Treasury Stock [Line Items]            
Stock repurchases (in shares)     1,800      
Stock repurchases     $ 702      
Stock repurchase average price (in dollars per share)     $ 388.78      
2023 Share Repurchase Authorization            
Equity, Class of Treasury Stock [Line Items]            
Remaining authorized amount           $ 824
Stock repurchases (in shares)       100    
Stock repurchases       $ 67    
Stock repurchase average price (in dollars per share)       $ 495.68    
2024 Share Repurchase Authorization            
Equity, Class of Treasury Stock [Line Items]            
Share repurchase authorization           $ 3,000
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES (Details)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Effective income tax rate (percent) 25.30% 22.50%
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Debt Outstanding (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Total short-term debt $ 822,000,000 $ 1,443,000,000
Total long-term debt 12,390,000,000 10,213,000,000
Senior Notes    
Debt Instrument [Line Items]    
Total senior notes 572,000,000 572,000,000
Total long-term debt 12,390,000,000 10,213,000,000
Senior Notes | $600 million, 3.850% due October 1, 2024    
Debt Instrument [Line Items]    
Aggregate principal $ 600,000,000  
Stated interest rate (percent) 3.85%  
Total senior notes $ 572,000,000 572,000,000
Senior Notes | $600 million, 4.500% due April 1, 2025    
Debt Instrument [Line Items]    
Aggregate principal $ 600,000,000  
Stated interest rate (percent) 4.50%  
Total long-term debt $ 599,000,000 598,000,000
Senior Notes | $500 million, 5.700% due March 13, 2026    
Debt Instrument [Line Items]    
Aggregate principal $ 500,000,000  
Stated interest rate (percent) 5.70%  
Total long-term debt $ 498,000,000 498,000,000
Senior Notes | $750 million, 1.350% due February 3, 2027    
Debt Instrument [Line Items]    
Aggregate principal $ 750,000,000  
Stated interest rate (percent) 1.35%  
Total long-term debt $ 688,000,000 688,000,000
Senior Notes | $600 million, 3.950% due March 15, 2027    
Debt Instrument [Line Items]    
Aggregate principal $ 600,000,000  
Stated interest rate (percent) 3.95%  
Total long-term debt $ 537,000,000 537,000,000
Senior Notes | $500 million, 5.750% due March 1, 2028    
Debt Instrument [Line Items]    
Aggregate principal $ 500,000,000  
Stated interest rate (percent) 5.75%  
Total long-term debt $ 495,000,000 495,000,000
Senior Notes | $500 million, 5.750% due December 1, 2028    
Debt Instrument [Line Items]    
Aggregate principal $ 500,000,000  
Stated interest rate (percent) 5.75%  
Total long-term debt $ 495,000,000 495,000,000
Senior Notes | $750 million, 3.700% due March 23, 2029    
Debt Instrument [Line Items]    
Aggregate principal $ 750,000,000  
Stated interest rate (percent) 3.70%  
Total long-term debt $ 590,000,000 590,000,000
Senior Notes | $500 million, 3.125% due August 15, 2029    
Debt Instrument [Line Items]    
Aggregate principal $ 500,000,000  
Stated interest rate (percent) 3.125%  
Total long-term debt $ 433,000,000 433,000,000
Senior Notes | $500 million, 4.875% due April 1, 2030    
Debt Instrument [Line Items]    
Aggregate principal $ 500,000,000  
Stated interest rate (percent) 4.875%  
Total long-term debt $ 496,000,000 496,000,000
Senior Notes | $1,250 million, $5.375% due April 15, 2031    
Debt Instrument [Line Items]    
Aggregate principal $ 1,250,000,000  
Stated interest rate (percent) 5.375%  
Total long-term debt $ 1,238,000,000 0
Senior Notes | $750 million, 2.150% due February 3, 2032    
Debt Instrument [Line Items]    
Aggregate principal $ 750,000,000  
Stated interest rate (percent) 2.15%  
Total long-term debt $ 744,000,000 743,000,000
Senior Notes | $750 million, 5.875% due March 1, 2033    
Debt Instrument [Line Items]    
Aggregate principal $ 750,000,000  
Stated interest rate (percent) 5.875%  
Total long-term debt $ 735,000,000 750,000,000
Senior Notes | $850 million, 5.950% due March 15, 2034    
Debt Instrument [Line Items]    
Aggregate principal $ 850,000,000  
Stated interest rate (percent) 5.95%  
Total long-term debt $ 826,000,000 840,000,000
Senior Notes | $250 million, 8.150% due June 15, 2038    
Debt Instrument [Line Items]    
Aggregate principal $ 250,000,000  
Stated interest rate (percent) 8.15%  
Total long-term debt $ 261,000,000 261,000,000
Senior Notes | $400 million, 4.625% due December 1, 2042    
Debt Instrument [Line Items]    
Aggregate principal $ 400,000,000  
Stated interest rate (percent) 4.625%  
Total long-term debt $ 396,000,000 396,000,000
Senior Notes | $750 million, 4.950% due October 1, 2044    
Debt Instrument [Line Items]    
Aggregate principal $ 750,000,000  
Stated interest rate (percent) 4.95%  
Total long-term debt $ 740,000,000 740,000,000
Senior Notes | $400 million, 4.800% due March 15, 2047    
Debt Instrument [Line Items]    
Aggregate principal $ 400,000,000  
Stated interest rate (percent) 4.80%  
Total long-term debt $ 396,000,000 396,000,000
Senior Notes | $500 million, 3.950% due August 15, 2049    
Debt Instrument [Line Items]    
Aggregate principal $ 500,000,000  
Stated interest rate (percent) 3.95%  
Total long-term debt $ 514,000,000 529,000,000
Senior Notes | $750 million, 5.500% due March 15, 2053    
Debt Instrument [Line Items]    
Aggregate principal $ 750,000,000  
Stated interest rate (percent) 5.50%  
Total long-term debt $ 720,000,000 728,000,000
Senior Notes | $1,000 million, $5.750% due April 15, 2054    
Debt Instrument [Line Items]    
Aggregate principal $ 1,000,000,000  
Stated interest rate (percent) 5.75%  
Total long-term debt $ 989,000,000 0
Commercial paper    
Debt Instrument [Line Items]    
Short-term debt $ 250,000,000 $ 871,000,000
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Senior Notes (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Debt Instrument [Line Items]    
Proceeds from issuance of senior notes, net $ 2,232,000,000 $ 1,215,000,000
Interest rate swaps    
Debt Instrument [Line Items]    
Cumulative, aggregate adjustment 17,000,000  
5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 | Senior Notes    
Debt Instrument [Line Items]    
Proceeds from issuance of senior notes, net 2,200,000,000  
$1,250 million, $5.375% due April 15, 2031 | Senior Notes    
Debt Instrument [Line Items]    
Aggregate principal $ 1,250,000,000  
Stated interest rate (percent) 5.375%  
$1,000 million, $5.750% due April 15, 2054 | Senior Notes    
Debt Instrument [Line Items]    
Aggregate principal $ 1,000,000,000  
Stated interest rate (percent) 5.75%  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Revolving Credit Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Mar. 31, 2024
Term Loan        
Line of Credit Facility [Line Items]        
Actual debt to capitalization percentage       45.10%
Revolving credit facility        
Line of Credit Facility [Line Items]        
Debt to capitalization percentage, maximum       60.00%
Outstanding borrowings       $ 0
Uncommitted incremental loan facility       $ 750,000,000
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023        
Line of Credit Facility [Line Items]        
Debt instrument term (in years) 5 years     5 years
Maximum borrowing capacity $ 2,500,000,000      
Facility fee (percent)       0.11%
Remaining borrowing capacity       $ 2,482,000,000
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | Minimum        
Line of Credit Facility [Line Items]        
Facility fee (percent)       0.08%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | Maximum        
Line of Credit Facility [Line Items]        
Facility fee (percent)       0.20%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | SOFR        
Line of Credit Facility [Line Items]        
Basis points spread on variable rate (percent)       1.14%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | SOFR | Minimum        
Line of Credit Facility [Line Items]        
Basis points spread on variable rate (percent)       0.92%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | SOFR | Maximum        
Line of Credit Facility [Line Items]        
Basis points spread on variable rate (percent)       1.30%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2021        
Line of Credit Facility [Line Items]        
Debt instrument term (in years)     5 years  
Maximum borrowing capacity     $ 2,500,000,000  
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023        
Line of Credit Facility [Line Items]        
Debt instrument term (in years) 364 days     364 days
Maximum borrowing capacity $ 1,500,000,000      
Facility fee (percent)       0.15%
Remaining borrowing capacity       $ 1,500,000,000
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | Minimum        
Line of Credit Facility [Line Items]        
Facility fee (percent)       0.06%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | Maximum        
Line of Credit Facility [Line Items]        
Facility fee (percent)       0.15%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | SOFR        
Line of Credit Facility [Line Items]        
Basis points spread on variable rate (percent)       1.16%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | SOFR | Minimum        
Line of Credit Facility [Line Items]        
Basis points spread on variable rate (percent)       0.94%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023 | SOFR | Maximum        
Line of Credit Facility [Line Items]        
Basis points spread on variable rate (percent)       1.35%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2022        
Line of Credit Facility [Line Items]        
Debt instrument term (in years)   364 days    
Maximum borrowing capacity   $ 1,500,000,000    
Letter of credit        
Line of Credit Facility [Line Items]        
Outstanding borrowings       $ 18,000,000
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Commercial Paper and Other Short-term Borrowings (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Commercial paper    
Short-term Debt [Line Items]    
Maximum amount outstanding during period $ 2,700,000,000  
Short-term debt outstanding $ 250,000,000 $ 871,000,000
Weighted average annual interest rate (percent) 5.46%  
FHLB borrowings    
Short-term Debt [Line Items]    
Short-term debt outstanding $ 0  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)
 1 Months Ended 3 Months Ended
Dec. 31, 2022
state
beneficiary
option_period
Mar. 31, 2024
beneficiary
state
T2017 East Region    
Loss Contingencies [Line Items]    
Number of states comprising TRICARE beneficiaries | state   32
Number of TRICARE beneficiaries | beneficiary   6,000,000
T-5, Effective 2024    
Loss Contingencies [Line Items]    
Number of TRICARE managed care support contract beneficiaries | beneficiary 4,600,000  
Number of states comprising of TRICARE managed care support contract beneficiaries | state 24  
Contract base term 1 year  
Annual option periods | option_period 8  
Contract term with exercises 9 years  
Medicare    
Loss Contingencies [Line Items]    
Percentage of premiums and services revenue   86.00%
Medicaid    
Loss Contingencies [Line Items]    
Percentage of premiums and services revenue   7.00%
Military services | T2017 East Region    
Loss Contingencies [Line Items]    
Percentage of premiums and services revenue   1.00%
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT INFORMATION - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
segment
Mar. 31, 2023
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | segment 2  
Member co-share amounts and government subsidies $ 3,700 $ 4,000
Depreciation and amortization classified as benefit expense $ 32 $ 33
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT INFORMATION - Segment Results (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Premiums $ 28,261 $ 25,550
Services revenue 1,062 999
Total revenues 29,611 26,742
Investment income 288 193
Benefits 25,124 21,858
Operating costs 3,042 2,979
Depreciation and amortization 209 186
Total operating expenses 28,375 25,023
Income from operations 1,236 1,719
Interest expense 159 113
Other expense (income), net 63 (8)
Income (loss) before income taxes and equity in net losses 1,014 1,614
Equity in net losses (24) (17)
Segment earnings (loss) 990 1,597
Net loss (income) attributable to noncontrolling interests 2 1
Segment earnings (loss) attributable to Humana 992 1,598
Products    
Segment Reporting Information [Line Items]    
Premiums 28,261 25,550
Products | Total Medicare    
Segment Reporting Information [Line Items]    
Premiums 25,258 22,190
Products | Individual Medicare Advantage    
Segment Reporting Information [Line Items]    
Premiums 22,448 19,809
Products | Group Medicare Advantage    
Segment Reporting Information [Line Items]    
Premiums 1,989 1,765
Products | Medicare stand-alone PDP    
Segment Reporting Information [Line Items]    
Premiums 821 616
Products | Commercial fully-insured    
Segment Reporting Information [Line Items]    
Premiums 256 1,018
Products | Specialty benefits    
Segment Reporting Information [Line Items]    
Premiums 239 254
Products | Medicare Supplement    
Segment Reporting Information [Line Items]    
Premiums 197 179
Products | State-based contracts and other    
Segment Reporting Information [Line Items]    
Premiums 2,311 1,909
Services    
Segment Reporting Information [Line Items]    
Services revenue 1,062 999
Services | Home solutions    
Segment Reporting Information [Line Items]    
Services revenue 335 314
Services | Primary care    
Segment Reporting Information [Line Items]    
Services revenue 241 201
Services | Commercial ASO    
Segment Reporting Information [Line Items]    
Services revenue 24 71
Services | Military services and other    
Segment Reporting Information [Line Items]    
Services revenue 251 171
Services | Pharmacy solutions    
Segment Reporting Information [Line Items]    
Services revenue 211 242
Total external revenues    
Segment Reporting Information [Line Items]    
Total revenues 29,323 26,549
Operating segments | Insurance    
Segment Reporting Information [Line Items]    
Total revenues 28,699 25,903
Investment income 162 97
Benefits 25,251 21,993
Operating costs 2,364 2,418
Depreciation and amortization 186 165
Total operating expenses 27,801 24,576
Income from operations 898 1,327
Interest expense 0 0
Other expense (income), net 0 0
Income (loss) before income taxes and equity in net losses 898 1,327
Equity in net losses (2) (3)
Segment earnings (loss) 896 1,324
Net loss (income) attributable to noncontrolling interests 2 1
Segment earnings (loss) attributable to Humana 898 1,325
Operating segments | Insurance | Products    
Segment Reporting Information [Line Items]    
Premiums 28,261 25,550
Operating segments | Insurance | Products | Total Medicare    
Segment Reporting Information [Line Items]    
Premiums 25,258 22,190
Operating segments | Insurance | Products | Individual Medicare Advantage    
Segment Reporting Information [Line Items]    
Premiums 22,448 19,809
Operating segments | Insurance | Products | Group Medicare Advantage    
Segment Reporting Information [Line Items]    
Premiums 1,989 1,765
Operating segments | Insurance | Products | Medicare stand-alone PDP    
Segment Reporting Information [Line Items]    
Premiums 821 616
Operating segments | Insurance | Products | Commercial fully-insured    
Segment Reporting Information [Line Items]    
Premiums 256 1,018
Operating segments | Insurance | Products | Specialty benefits    
Segment Reporting Information [Line Items]    
Premiums 239 254
Operating segments | Insurance | Products | Medicare Supplement    
Segment Reporting Information [Line Items]    
Premiums 197 179
Operating segments | Insurance | Products | State-based contracts and other    
Segment Reporting Information [Line Items]    
Premiums 2,311 1,909
Operating segments | Insurance | Services    
Segment Reporting Information [Line Items]    
Services revenue 275 242
Operating segments | Insurance | Services | Home solutions    
Segment Reporting Information [Line Items]    
Services revenue 0 0
Operating segments | Insurance | Services | Primary care    
Segment Reporting Information [Line Items]    
Services revenue 0 0
Operating segments | Insurance | Services | Commercial ASO    
Segment Reporting Information [Line Items]    
Services revenue 24 71
Operating segments | Insurance | Services | Military services and other    
Segment Reporting Information [Line Items]    
Services revenue 251 171
Operating segments | Insurance | Services | Pharmacy solutions    
Segment Reporting Information [Line Items]    
Services revenue 0 0
Operating segments | Insurance | Total external revenues    
Segment Reporting Information [Line Items]    
Total revenues 28,536 25,792
Operating segments | CenterWell    
Segment Reporting Information [Line Items]    
Total revenues 4,818 4,505
Investment income 0 0
Benefits 0 0
Operating costs 4,483 4,126
Depreciation and amortization 53 49
Total operating expenses 4,536 4,175
Income from operations 282 330
Interest expense 1 0
Other expense (income), net 0 0
Income (loss) before income taxes and equity in net losses 281 330
Equity in net losses (22) (14)
Segment earnings (loss) 259 316
Net loss (income) attributable to noncontrolling interests 0 0
Segment earnings (loss) attributable to Humana 259 316
Operating segments | CenterWell | Products    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Products | Total Medicare    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Products | Individual Medicare Advantage    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Products | Group Medicare Advantage    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Products | Medicare stand-alone PDP    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Products | Commercial fully-insured    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Products | Specialty benefits    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Products | Medicare Supplement    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Products | State-based contracts and other    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating segments | CenterWell | Services    
Segment Reporting Information [Line Items]    
Services revenue 787 757
Operating segments | CenterWell | Services | Home solutions    
Segment Reporting Information [Line Items]    
Services revenue 335 314
Operating segments | CenterWell | Services | Primary care    
Segment Reporting Information [Line Items]    
Services revenue 241 201
Operating segments | CenterWell | Services | Commercial ASO    
Segment Reporting Information [Line Items]    
Services revenue 0 0
Operating segments | CenterWell | Services | Military services and other    
Segment Reporting Information [Line Items]    
Services revenue 0 0
Operating segments | CenterWell | Services | Pharmacy solutions    
Segment Reporting Information [Line Items]    
Services revenue 211 242
Operating segments | CenterWell | Total external revenues    
Segment Reporting Information [Line Items]    
Total revenues 787 757
Eliminations/ Corporate    
Segment Reporting Information [Line Items]    
Total revenues (3,906) (3,666)
Investment income 126 96
Benefits (127) (135)
Operating costs (3,805) (3,565)
Depreciation and amortization (30) (28)
Total operating expenses (3,962) (3,728)
Income from operations 56 62
Interest expense 158 113
Other expense (income), net 63 (8)
Income (loss) before income taxes and equity in net losses (165) (43)
Equity in net losses 0 0
Segment earnings (loss) (165) (43)
Net loss (income) attributable to noncontrolling interests 0 0
Segment earnings (loss) attributable to Humana (165) (43)
Eliminations/ Corporate | Insurance    
Segment Reporting Information [Line Items]    
Total revenues 1 14
Eliminations/ Corporate | Insurance | Products    
Segment Reporting Information [Line Items]    
Total revenues 0 0
Eliminations/ Corporate | Insurance | Services    
Segment Reporting Information [Line Items]    
Total revenues 1 14
Eliminations/ Corporate | CenterWell    
Segment Reporting Information [Line Items]    
Total revenues 4,031 3,748
Eliminations/ Corporate | CenterWell | Products    
Segment Reporting Information [Line Items]    
Total revenues 2,617 2,615
Eliminations/ Corporate | CenterWell | Services    
Segment Reporting Information [Line Items]    
Total revenues 1,414 1,133
Intersegment Eliminations    
Segment Reporting Information [Line Items]    
Total revenues (4,032) (3,762)
Intersegment Eliminations | Products    
Segment Reporting Information [Line Items]    
Total revenues (2,617) (2,615)
Intersegment Eliminations | Services    
Segment Reporting Information [Line Items]    
Total revenues $ (1,415) $ (1,147)
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�=' MH\'HF/YFV3%\-EXH$J1%(Z.4^:7Q9#2!A9#O.#A*QW$R3@DI'<99,CA^[N0D M'IVPFW%\FJ1[1Q4C'F6#>#P8TQ[Y29/A8? DU_.PT_@D.VWB3]()?&9] Q0Z M+ZFQ(1]_D4U.7ZZ$+-U3;,N:ZL)X+AYC*:(8Z-!\=GL7@PS'5,VIVDF_H*M'^'#2&\"R*8$8*DOK M5M*Z<,[D,JC.;%Y$0O38(7%HR#SM/"6+X2B^1D@'6_IHP MP@*4%,1#>HGA%G#PK5/Z0.SI"LL7S'N%10]N<2WXF[07I),U:/\VH:8ZZ/82 M<$.H=;1$+OD#=ZVK@+=WHM Q.Z$I=Y*NB5#/PCA:B:VQ0?H"M_31KK@;'/?@ M$W6)IO&QDXK;J*1V07DG8MQGI/-TDL LYF:MY3\81*!S->6$RFU)7I[5'#>> M/=M.O\>#RJ/T=-;.4YL0MN#(O];2-NBU"TB4[KJL0I,*'VFZ =093(&VU;W8 MHJ6C^,#91+HH^SZXIH*S08-&4*X$>-*@;?6'6H2B;]>#DCZD-4A #D/&BIJX M:M\+#4T4A61JH4LTW")(;H51-F M=5]7E0KO?"-X[(@8@:,(79G')6HV/_S2>^W+V#\85DJTZS"2.9*/JK.96[K5 M;NJ[;(:=I^/-R$C-@PJ82WI%IDGO9!2!;<:PYL6;*HP^2^-ID J/&YIE8J&SY)+GI_OTH.?%ENS88#C"L-_+A0XJD)@>IGG2! M:."E%)6>>H4Q]=CW=5I@R71?UEC122Y5R0PMU=[7M4*6.:52^%$0#/V2\6LTFLC&"5[A6H)NR9.K; H4\3+W0.VUL^+XP=L.?36JVQRV:3_5:T8J6YK$!A/O7FX7@QL/).X&^.!WTV!^O)3LHGN[C+IEY@":' U%@$1L,S MWJ 0%HAH_'/$]#J35O%\?D+_R_E.ONR8QALI/O/,%%-OY$&&.6N$V/=&G(L;YEA MLXF2!U!6FM#LQ+GJM(DQ %T> "7MSY'3N\^"V_F:IXM=>P1@7;@BF$+_.=-HK2Y.MK M_K9P@]?A;.F,=PZ.3/<^[GV6M'/R1 MD0VF-/"*"DH((JM[@"\IUN:_O"@N5-_Z/51-N:-#_Z:D1CT@N"!&YM@*F] >8Y]3N2'\.RK(7\1B%I561M M[T7#$.(!;)!2G:?6:GL:C0:01$E;"AH:32=&'F\4?^$"PXB\&;:,DN$ %N[R MWY9_!\-^&--PW;\.6_X7\9U\Z.1'5[#J;H-5AFT:YM^?$0F!.JD'_*O% MM6]$NS"R=GUY)PUU>3&PO=V]R:W-H965T)TPS#L RW1%AM*5$G*CO?K]_ H MRTZ;I"VP+[8D\AX^=WSNCCQ<:G-KGG4B3OK#]=RGCO_H7=\6/&YF CWJ;HR>.NU*)DL1&FE+ID1LZ/.27QPNNOG MTX0_I%C:K6?F/9EJ?>M?+K.C3M\3$DJDSB-P_"W$F5#* X'&EP:STR[I#;>? MU^AOR7?X,N56G&GUI\QL(O?/UW>_'78@A'\>\C% [#X,X;/CP%8\%4<=R-\*LQ"=X^?/XE'_S1,$ M=UN"NT^A__ ^_#C*\V?C)-Y[TV"Q<[F0F2@SRVYRP69:(1UE.6>.3Y5@E=%^ MV$+0CDMEF9ZQK+%@%5\A#9WM,G&7JCKS9NV@0&077&&<&9\!%MB&U>5"6"R1)8HA82WK\(Z:_8L3GK)/JI5,F!Q+QGU M:'2']:/Q>-C'0]P?L\N2O153 P8KLNXRAV@%@IE(%3<@R+\BAECM$ JKX)'- M,82YTG^8LV0]S(\^G,?^?R/Q2 M(ZX_P(73BU\O5=H*_S*M+>1F;8 I!4O&:YKGQ(:'.KM1C+>:U:X&AAC+ MTIR7'8)MVI1:- M-M+-;^K&=E;&9TP1Q:G=\/^D=44&,6R$2? M+A! "CM(VZ_B^W'C;I=- :4\F]8[+Q*CZWG.*L5+G]!6SDNL FSPK[ #2^ER M=EU#$'%_.GP=-ZGHP24N[D($V4E*&QGO#Z! !)]C:U'ENS[LX 1V M"^Z$6KTNQ5P[R?T>HPF$92Z1X53L M[F1!@6,[8^1B4[9@[<]2 *[+&NIX%?SGD/KR.PJCRFNVA([EZLH':&? I@W\ M5U(.DJ2Z;GT ,-Q\VP!E?IN1665SDB)" E+2*R&:;""Q^09122KQH7YLPCFD M<.YU&_^7WHN9%YWV4WT,J2 ]YAI*3&@=?B8$CG6+<.(@+39U=O7[2VB ?.7X74.M"UQBY M]?2^V9_R;O"-=_TH_FGO1GO?=6YW?QB-'G?N:9\BJK)!R]ZS1S6[Q/;O)-'^ MJ%5HD$[3]@9;G?#')(C@\!2'$D.1Z6\2Z[[D*0KQ;(*6_80< MUSJ +X"J0JE1JXCA7H&V%AH6#B^R#)>L4 7F*#E^"9^MVTWZ!1VYW*J[R:#? MM$,M'U'[R'V 0D69]AMG)DRJK!O95HG>O!G_OZ)#BP)2DX>]+Z"VOWT50I@YW\DW'8VT\.=$7&>2TA:B1E,^]'>L!-.H>L7IRNZ^TRUPTV* M'G-<787Q$S ^TPA=\^(7:"_#Q_\!4$L#!!0 ( .E]F%AA(?D&;@, %P' M 9 >&PO=V]R:W-H965TN1O3PV"CMYE'M?7L>QRZOL1%N;%K4=%(:VPA/IJUBUUH410 U*DZ3 MY&W<"*FCQ2SLW=C%S'1>28TW%ES7-,+N+E&9[3R:1(>-+[*J/6_$BUDK*ERC M_Z>]L63% TLA&]1.&@T6RWET,3F_G+)_<(E*,1&E\=^>,QI",O!X?6#_&&JG6C;"X=*H.UGX>AZ=15!@*3KE MOYCM7[BOYY3YQ\2*4&M"4G-0\E+6W="H)YQ>K3\O/UU=P>_'U:CV+ M/3'R?ISOT9<].GT!G<&UT;YV<*4++'[$QY3)D$YZ2.)N]?R7\(K#DQBX3B#0/YR2M)!:R5)@U0[*#HZ,2 @KX6N!G0C M'\&4]#"L1>U#+* _+77E8(-^BZC!=!96FB8M=([@L&K8EW/FDR49:.](!Z!& MH7P-/$29HSNXCH":P]&4\.3*B7;642XU/7&RGTHHJ #G9?Y4A*=T Y;U$NDR MKTAYBD*R!(W" =5(?3[TYJ>AE.+!6+&A%LB&KIFGYF]V 6@Q-Y4.3-P# =KH M$\*2,T)%^CL&$JHAFE#$WZMV+Z"5L 7UZ2@J.AY@2251JS\9RB#E%0<3';%0 M[*71SBA9"#8^2DTME<2\]K3!O7),ISJ^(S2B&V$]K%8C6-$IG(T@>A;"HUAW M;:N"3=\"8.V*F($GQ#>+2VE@DIS\/7[N6<5'BD=MKH*N.\A-IWTO?L/N\.FX MZ!7SR;W_[M#5KJ1VH+ D:#)^=QJ![;6\-[QI@WYNC" 9 >&PO=V]R M:W-H965T,9.FFEZ M[243)]:C M72GEQ*=U7MCG@Y5SFZ>7ES9=J;6THW*C"CQ9E&8M'7Z:Y:7=&"4SWK3.+\/Q M>'*YEKH87#_C>V_-];.R2W-_J_)R]WP0#)H;[_1RY>C&Y?6S MC5RJ.^4^;-X:_+ILJ61ZK0JKRT(8M7@^N F>WL:TGA?\6ZN=[7P7I,F\+#_2 MC]?9\\&8!%*Y2AU1D/BW52]4GA,AB/%[37/0LJ2-W>\-]5>L.W292ZM>E/FO M.G.KYX/90&1J(:O=>MWA6=V1>*7LG K*WXH,I7U]U]"@E:,L!'C-GR0 MX"_2C$04#$4X#N,'Z$6M6A'3B\ZII>9.O-0VS4M;&27^' M8B>MP-^BS)&J^.H$W)*N6K\($!0O5:K6 M-Z2&(AK-DO$CD4'Q-ZDKB63JBC]GXB+I;DE&TV:+-V(0\9Z)B+&6KHMI MTED?C*)&X5=J;BK J/ [IF(RF_%U:**KI,\AJ=@6N8)XQ7WT.T2@(D]JJU1* V&AP)>(HXJN_(1[-ILF1&Z(Q M9)GP=1$,PZ2G0W2P@1E$ 7:&T4Q\^\TL#,+O#_0(1\%I5T2AF,8QKNA@1[(7 MK&-:R#^-$D$K+V;]Y2<]%\4(T(F8Q5C?4V.V%^BGJE#-\ID()P%?%W'?3)/& MKGW/Q:&(8"6Z^O+'>X%ZV<;*CODZ9#$;G] @GNX9)&=BM>?J&+$1(*7A\D.+ M)J<8)#!I"($0@_#U^$R\=GV=Q.)J=M5Z^@1H!.$P0FP&XV$81/6"O <.A!E^ MT46SK$:+?S&%UT43\, G@*UB_ 467R"KQ=Q+2#A=QV-56)6B=F5]04Z$*<$R MB(S[1%C1SR22Q"/QIC)<*3:F3)7*4 ^PK4JQ%:V?<*@U%8J]V1D-E>T_1(;J M6E:%L\P_!89#'T)X@+C.2$'4W8MP%#9BC<2OH&%!D(AU63&'I2J4@573TFQ* M(YT2FPK?K*+*M-(PG"[2O,H4;S=J(^_1'')E4Y^T=50$=4&>4%FA+';Y]71_ M7AJ497RS7@G41\,B]\H.Q%D:N68Y5W*K!,@KLITN7$D?^&'=$Y;-[N1&R*51 MBH2PZ-K<"GW9;U!DH0M452*K"XCE*L=6 8FT++;*..;>)Z<^;7RC N_91 M[["J=95+FAV@R!(>7Y+#/$_6%%S/RMR7F!NL#<+LD\8\02:_"*8-.!WW6R.! MP0.<,DT1Q/'DIS _$"VEX> F;W21AA)W 5-#+C8P@*@642(;R$XO$(]EKC-) M/UZUX7KG<,.'50QI(!D2! M).1&D 8I@..3?X[$.[4M\RW)_P(IIIVXV2<3H))+&.UAI.PE(OPGL8ZD(Y[D M+U8D>7*OI!D2YB0M%.X!T+0,4\^PS5[Q'= DERD](S/]=4)[.5L%@LZ?B93 '+&8P+C@X9_J.;9QR/Q@;&4@_^ M.B6]Q[ERX[CR[BA#BAJ)"4249D"0A,,;!9Q$AB'8M\P*\*4M9:<\5H&?^=P\ M>K:A 0?$YW"@W:WCW5FAAF6]Y=&]5.C"V M5X%U]3H- 6+&P"U G""(J5-@^VY*3>E6M6[TD?]0U% L!\'D/(DF(,_3&'*Q MHBY$;521U9IS3?$K#6N*D@,(IZ=<[ZY"\$3N!-'X:^7W].*&7O(URG"S('-; M4G5F:"J*"L"X0(KFVMV+A5(U5N=H2G@.=WCRAVP\!;[=Q7U?'8@V_')??9%V M7^FCF3=I^/_QT*1VT%?ZY\U>Z$Z_AE;,2<";/V*C:D5I:S0?$N+I5J'$U55- M=EJZYDFG_JXERGE5#P'4Y.>EB)-1\(C8K]'N5&?@W9U"U8[=) M[ MV*?<'+8NC/5;GB,__.F(2?&WAH?Y!*!S!#GLM&Y' M>^LAT&#BXM2A-M#/8[(=QFN@="M35LN52#%M$LK-3?F1AR_,:H9/=JF#H0X$ MV;*NIWCJ3WB$W$=B(R[)BH#P4:NR(8_?NNF_GS3W/6YS8T-^8O+O#V=]BL;Z MX-GZ,=L/<00-AB=AE=;#W+P^+WCX>,#S:% 8]H%#-U@I6;$>@-2*4[BSE!E& MU+J1ALE0J=?^M8:?+@[.M6EZ V!,FXRN?;^M##D_:EY^M/\F2<]_[P5KEG+.U\TJ"3UGJ 01P M""E^H],-JN]U:J]14"CNTS+/8142J(/#]D1M[I3F;D1UN)+ G;(].O6:Z[+S MSA%QL.0WJ]17(>?\Z\?V;OOR]L:_L]PO]V]^(1YZ2(OBO\#6\6B:#(3Q;U/] M#U=N^ WFO'3HF_CK"F.-,K0 SQ&UL[5QK MG1_&#MVZS'?C!PZ??[LS&7MGAI]UEAY\> MIETJU]BV=[XM.KO^[NC\].MGC_F\//!79V_Z[-\%;[+R_@-_N*B^.SHA0;:V MY< =#/ZZML]M77,CD/%+V/,H'GM[HR5%1 MV;49Z^&MO_G1AOM\SOU*7_?R9W&CSWY^=E248S_X)BP&!8UK]6_S,? A6_#D MY)X%9V'!F="M!PF5+\Q@GG[;^9NBX]/8C?^0J\IJ$.=:"N5JZ/"MP[KAZ?,W MKUY=O'OU\O6[JT7QPT_G;\]?OWOY\JHX?_VB>/[F];N+US^\?/W\XN75MP\' M',=%#\NP]3/=^NR>K1\5KWP[;/OB95O9:K[^(SWZ+Z[^Z9Q S1LZ O35L5SD.O:C6U+9_OBA>O+VO=C M9XO_.%_U0P<%^L]#7-!#'A\^A$;U=;\SI?WN"%;3V^[:'CW]_>].OSCYYA-7 M>)RN\/A3N_]CXOM?VKKXP5_;KB4?A85D5%^\&;OBE:U<:<# 7>>K$9\NBINM M*[>PQ=*/[6"K FZE,#M\_]'!Q&Q]6SSYXM\*ORX\U@]^,#46V\:-C<%15F@8UP1N=P1NGA57J>CY,B5I=$(0^0X?GG9^2%$Z; !,,6);G!QB1TF,]B9 MVQXD@@4W6]P%C.3%_]#'.VW=#IR'2!&-8<3VXPX;@[[2@Z'+XJ=@VJZ/]^R@ M1QF#SR,CL3>C/3R$0(?14-E 0&5I=?"55;%R5?)HKBWKL1)Z.E_2((4^Z'[0 MFIZ$ (#P!B'DY$?P*=L/X@25VN":KIV($T*D@4R^YS@*00=,(/0P0 0J2M,0P==@$^J&E;8$_RV M*'EINP&@#PQI_*8S.["A*+>&I@C+P%5*]=AWM%"NJE1FJOA3KA_K(3 M7*O(ELJ'&U+AR3E<;*=>?04J*\!=LB>8C'B5@_8KQLWSIE,JP+)%I)*N94;G M@H?"_94CG)25I3.&'8OWPK+L/-JA>H8DKDQU<]-=C]U ,X@.1>3F1:%V9H"< M(#Y'3P;,8R<'FE$1K"%8\!2V$,GL,;8[#@%9C/7[[Z\89:D.S;)X;S.[[1C: M?9M?7$V&M$15FJ3GU"):$ 10CQMY,1=1';@C?VMM8!UE"-(<+E8;UZC,>T:A M$';%^R+TD[U!*C8Q"6&LMVT5)6]4>+ &I\SB@7-Y3"((K.^@6;#K(%CQ\$F5 MD^,XK"["(U/W/K%G$"PP\0%T5;XX,RZ'>$*PQ72(_-D1\L1XSYVI&\EKE.4(!T" M!2DYAH;"KL'(0:4ECEL?DDL@ Q/;S6VR57+ZC(WBL>XR3R06-//->@TMC'CB MHA5W"P'^H!K(+WY4.7*%((3B*F!)T=T??[PZ?G/Q _37=O0(A0$O!W%8UQ"A M'WNYE&F!KW[_NR=GIU]^N0SQ7511)X[:\D ]2#@> IV^I'.?3/LSDBK^: MVE7JE\[E22'S[?F+OX:5R_R'(*(]P8DAX::T]68G;N):MYV4;%_64=_T:'(K M>@RZ=L'> T,&'&<]TF]$!"<0W87^O%L[B@% 6$^!%/[GQRI_#BR-!%D-8$OS@QKN@-X4W$,_(94X?I MR"!L)A6#ZS[EGHL[[CE$T9BC"+I5M9:#Y,Z5E_CNX[U+OVG=K]B$!Y^=?"-7 M$XN>"28!@I%<@IAS9:#;B#B%6Z,%2;GGZ3?&.OKSK))+[ -&FV*3,(<]YEJA?E#?< M(MUA9-?W(2X%XR[4K,!Q.37^]" >"^L+"PT5=]W;A&TAQ-J!@P0-Y Q"WVV0 MZ$3U=D)(72!H9>.6*:Y73()X@PE2BKR.:_?!1M.%@D:KG;PU:.G'W0X>M)BX M)NXET;#/&46WF7'D?"*(4QU9V8UK6^J>1(3+O]'Z3I^+EE53LGQ2'!EIL M1G@0&CZT+E#*;6 S1,0AEJ:-)+[59FS++%%;\!M$&0)8KGBR*K;^!,72JM0@!H]R M46*%SX"?VXWMHP8>OF(>Z8.&1K?+1?-KDH!TKJ@ E\6 T0L"/[SSY$:KJ/XL M+5!9_!CD4J:3S>Q<"?:Y0ZHT U^9\@._2LKVIBW^:-J1)O;H1.HTCY1INW%5 MNUXU9NV8O@C3HKO])(-@ZK)"OGV+90\4MN]]2K>X=EVSIURIB($S(GOM MVE',L)]MYY WMS&[R&-35*($&P68* J9\>Z@H3Z1S'4K E:'A@J "U(&RJ> M:6&B9Y_DRH-@UFM,Y8$0@%J G!S E$9&'+O(R!9I=W=9KHKF6K#&5-$;D?B0 M 4B,UY*0 MWD=&_E:H EZP35"POL^;Q66#(^>5Y MH/F!\I14Z?4:]FC(T]INB&AA(!NC4-FUL^HB3:4Q'Q2T:34"ZS<\E8[=])X\ MI")3T"K5B%'$S'P7X2$6--90^]8CSI1(-+9NT(*D6&E))YI*F;?J\,LM=%"8 MJ6$G[MS9H?/:BB'^SU0XJY'43/3[R&8)GK6YB3X[J7)>EF$*R=IG%6+0MO/C M)AC+V:,BEMZK_3U@*DZMDVHAH72;PXIV9O4*IV]SOY/6B:%K^,O,7("_5J'D MJ1E']C1P/X73BNF>HYWY924A"T<9ZE-T:X=!BW>9Y[[KJC_E?D)*&(JBP?O$ M\DH/$=$*B&S[@SYQ_U(U0\"!@"%UUO8V>?C.;@B=8&[UO]E/EO428LN]:*4;?S7N15D,9$?^H\3&[E"HMPQZ()Y4QP][?<#7VK#OU MT9"E\Q%CX()P%'SUP8I8CU[H-9F.A+R-G-W/1ZG($&P;JJZI/W%/IJTMBDAC M8VYCU8+,C-X'WJ+-' IUE>G%5#V:SM=BM*!]H2:HH-@2=D?$<7(E"-[!"XUB MXKZ+)YG-!NH!)BP8!:+$E\4YD7.Y761Y7T!%>]3_LW7E#8L+NT%JF\5IQ#4! M>$?6HEY5PHW7ECJ8HQ& MGRAS\+-_-V!#AT/A,3M#CC)=\"R?2#?%[$Q)]PX-O[(EW+51"SQT+H.9HV,# MMX9%\=I+M;&=OIAN\STSF/=\ -]>*\#JK94899+;,I,K/A2AY^'T\ER]T#9F M7NOP'*>08CF#2)Q$E-AC]!FC[>^\J+2D -1F$'<$JH MF^+M*D#08*=+'I:R) Y[6[,&2KA6BP,2#O$V]"#6G MO7YT+&MJT@+O.=SIF$N[E K.2)6X\??P]_1?W,SGZG=O+YZ?OWU9O -2^;)X M:6"5;Y%#^:DCKTCE_N\ECB,6@K1'9S&K$X0RN]P71>/JF@OCD=J,@]XR5XY\ M5R[!A2I9 MFD 1?_'N^/-%TJIQ5PEPBNMS1L:[VK5MX:-"$#WG,%"* V#$4L1P_/EO:0T\ M@&J-&O-[N"V8_4 .+9\O%R%<7$NC34LV4234 Y[0A88&S=+Y*ER-1 MB9 5T%$K0Q9!C<0G\= ;QUD&'%R;74@R&&.E,AW-1[1L;BI(:3?@1QS7B.<0 M.2#7D"=\+TZ#K+1$3(;?D.^ZOM:L MV7=99E!H"I!'0:2+8YF2XD,-AQ$RR;; ,8)59(DV* '&0EB?[ZSX<76;+U\! M8\>.")&EI">A4WE@>FBV>QQ(:7U[?.#9'/KG),4DJ+.A3)UOF;6KTGA+Z&?? M0]+DS;7&*3@@8;#;B*/")C$F=2J[V%21#&2A$+UDA4'EJK%J&E'P$0VQLK9Q M@68B(D*$E*$*DNAW; 6R6)GO>)]$_RFH7JPT0QQ_EL*+%&YL)<,_,F,46/)V MTHI7TESOF9#LJ#<0!T='=*+05IJ@/ <.KBY<0\R=IO\!'0US (L@ZFV&$L1ML]*YLI*[L C0B_*KAO*,=6?&2M(H M3>C#=LL#A4_7)SFNQ5XGO7$'ZP*T2\*8J4V5),3&=9$UKJ=YC] BECX,O7D[ MBA;FBS.OJ',K<[X#$5:^TRN47DTUCB]HJ#Y@&HO +?4%S%# Q*Z:>IB'#4J2 M3G;-Q&X1I2@2Q,R3Y?TFG(.TKP2E?;%00XPUBY"]&\!T5PRFT3P>&39YBR_F MI@YRSALXKM( (U%IE_B&N+BX*OTP%-?+60%AD8&QG8V>\CV'_83]#]A MC['\@,#R9S^Z'CZ)78'@E=3N14^9U'+JQ-+O3ZD)?9CFY1)!Q5KNJRX=+I0' MQR<=@A0I%#GO%6N?(;LOB\L7E_+P0EIJV>1MQXU][0KMY, M 814(MBD:LPF 'VP%,;'T"Y ;&OJ]6$//4VI?&]JV.US[=">1^3$^M[ B-H2S1^!-4ROJSXI&CT2EOEP4O9\*(N+*)/XSP=YI("+ K1&@J &,"^JHW5U@"L># ?)-T)MB2A(VMBR#17P]IXG-MB+8-M41V, MR H4DHHE98J3"+V.3*K?CQB;(_VC="*NW<9WP8P)\ZN\I,9Y'.JVTK(L7HR< M[@V%NQL96NK8Q8V*#\\%9+X3E\3R?AOPR5VU3V[E_\N"_^=EP7A]QUBH]&%2++V?FBEHJB=ZK&- MHT58TGN=P:KD*HHZA7E9^0U[\+6CXO3D^"]:5PG-!U/O8;V-"1/?,U639/O/ M2KT:S %\RA):"",!H4"3LKPC0BBI4XRKGPFCI8FK2* +G0?77G/,8C/%@%EM MB7WAP.IL(+C4]QRF7&X$^&=M-'A@W5HWX,^IN7EP2>Q1Y+OHDYU4*SHV8-RO MFC(=N.$$MQ*QBQFEJ7PCF#"&J302N-\C6?MRE-@!X&/I=8JU*>V0&CQ3UI6- MP6KHB# Q$;?(6L\P1#<(%R9W."&GE')+VWX/[2Z$6CLX'4.?=I<2N2+VF%9) M?>V:&%6F5UC*&I"L_:HZUTCA99_(W=9 *;$DR(5JMGUM%YZ!P6"UM3+:UAKX/Q M)06!_8[FGJ+/DNT81?&,">E=[(YCT?I M_0S95 #!8?MR?-UEQPR*OHPM>3'/.T:KW^>9(M*-W3C,^SSQ,TF[H3RN69'? M.HLN83"?FU#/@5NE910D]Q&,.*<8/JN+9BW=YO3F3:)Q%&X%1A(]RFL-HU3V M>4= A/2U + M856RG''5^2"E3!_UW0]U]1N .M,*THAYKLA_WNKR_6P63)?& M+)&7X=@,+I-&8^((@8"YH&UZ G;X;-QI$S"]\,&YKZ%_,'O190^K"OA%("]O MM[Y.6:OHE@E1W#'27_,&4P1,$2/ #M:^M#MN8*OR#@[.K-7\UUEY@Y6/HO*2 MD9K\38PH&M^ERXEUSQW06K*3H/J3L2RD8\[=8UJ2S'XE(S0#M6C*:;7O1(BF M\K1W\Z.)M(5B:A59 &\'"<\&7F=T!C9G:Z3^JW+GAZD,F#*>_/2D,?-!B0SH M+Y(NT0=G9I$F)P+6F9#"@;=#[YF:^$ODZ.2:7'Q?4'=AYBIFY"!GY)M;+>6K(X3D[T^J7F=/D>HVX1ZO*^CG":REL7%ONBFN<"T MU2(:4BQO:+U[BGB](CFOAGL,\ MC0F%A-Q-[=EKYJM#"W4QXPF^(RS""?K>85#*S)^K^>=!@=%EYO%DF"FZJ.G0N>I!GN:KG(F0';[4: H*.R/> M%-H]V\CKRE/4@KO1_"W(G&2'D$N2M38BG% MZ&3HUJU<&.'4XH>R7AN*XP#C"2,X4B&7V@EE&L%C.?M%"ZRICGUXBT4B81P+ MT[;A 0GIFVJ*\)RT(4'42@A4L'KGKI:%64EUJS2/%M[.B>[0BWK0-X496>QW M.[T_L"Q>^_13*EK&R7UM?W;:%Q-F\P-<*.@=.Z-R7!]+23)#8]K;13RT,1RW M#25Z%N%FN;V-N"H-:(?7D2-D469!9":T#]1;;VTH$H\M/ QL;1 VP5W1Q6EW M5=%;;&JEL0ZZX0"5[$=DK]TJ=DEBHK"6Z)T[SZ^+S]P#.3KJ<*\H(LAVES?/ M.NH6[70@>M:@+D-_J>YCO\%^V) ZHB_@!).([VW(]^'$:>_0R2"*L5H 8)^A MY\/7#V;,E,%@0DSAPMC&\2TG3^O#G$B@Y\QZUVMI:_/M9X75?-;E#T,#3OJ(D/9Q).W=>WDI@E!P'&GGH\(6?8B,_UH:PH9IUCF7PX12X3:VB M"V.K\XK0_IA:9/Z>\HHE!(^:3<$%M:7%M#("UM+^PZ=A9CBBMY_':A,+&+&" MO[@_F4YM>YP84^KXMATTKK,Q8,?BDX]IRCV%*WK?^?""*5-1#(;=55$/X$[X M<@:.JK4,)%J0.9[D6M2C\44)(O5,0CF*_SLO7J;B:+*^>OI%#=D96K>( OL7 M=-D7*?HH# R[RI:P- 4_AWYSSL/LER U%K;'7_4D-VT'_7U(Z=/TVZ3.]977.^D/@]_)KU1:^6'PC?QS:^&^.SZ M[UG]C3_P@/0[MI[^%U!+ P04 " #I?9A87#1U==H- !?)P &0 'AL M+W=O8^0"0DH2$)%: LN[_^G@5 D+(HI[UV)HDH$%CLR[/[+!"] MW2K]U:R$J-EC653FW=&JKM=OSLY,MA(E-Z=J+2J\62A=\AI?]?+,K+7@N5U4 M%F?)8# ^*[FLCMZ_M6.W^OU;M:D+68E;SB_G5]J_'M+$C)92DJ(U7%M%B\.SJ/WWP8TGP[X=]2;$WGF9$E MK_-W1@!02A;UZMW1](CE8L$W1?U9;7\6WIX1RR_;.OF)K,CEFU,K4J_&!J4 MLG*?_-'[H;-@.CBP(/$+$JNWV\AJ^2.O^?NW6FV9IMF01@_65+L:RLF*@G)7 M:[R56%>_O[O\Z?KRTSV[^O3QYO/U^?W5S:>W9S4$T^NSS OYX(0D!X2D[%I5 M][Z,R@4M$H:K3XD+PJ\YOJ4I7'$DD$R?$%>&JQ,K;STD)5B"2#5 M[+-8*UW+:LG^?+&K'DFWATA$8S0#^+H_???Q>/! M#R_H.@RZ#E^2_F"U4]K0<\KP8MZQ=8%KSR> MA;;B>/X;]$-0YAL#[8T1AF5V"R=UBXU.YH*"952Q(=F&H0HQ!94[4HV5IK"G M#AM =VZ0G";3<@YQV$H%';*VK(N=8+9FN=2HA<43>Y#<6=\*X%FF-C;H+ZSAJ1HQ21M[0U^Q=92MKRJ@(0!/LDMMCDLI!+27BZA_Y&DB,CTN*7JY-/ ME_<1(UPB/&OKX5QOE@XC:ZV6FI?6*QFW^P+54&\-,#4<9T@.389_P9L@\ M8F0L$\W6N2CAK5ISMSO)_$55RY-[H4MVMUD3YMD=L@,A-!TG;EHI#5FR 1M(WWY ]/HB$$811E.M" M/6$C%Q0X$1C.)"Q9;(KBZ402"+!):PXB 5:O[LG M;'9*DD8Y%.=(\@>+W:B37P8N*T1IWS?[ME[K(*V'ZR#9I6%;^_HU6Z\XDCE[:O1X8I15SG4KRHFV MA+7;.=']2''XPD0HG[$UUW6%LK:2:Y\+7R[.;2;F HA4:Q;6PN-X#3HB"W0Y5].'7$W'J,L&/K7RZ+$V1"+EKT!-"]CKH+ M[T*JWP:84;RUJ"&D62VATV\*ND(CQR7.>@2K*\MB@]UZ"%Q8"*![D)GIR<=O M.L'CM1T07%@^ZY4XZ@T=CNM[20#P!O&AV'6!<;\9BMR#K7:^P: M!A4S =50>HE92[DI,8LC5PVU8D0;P,4:'.DZ-H#TQ&>#?:3^G3HZ:9I<.Q@2 MM(K44E(^,\!U"9[M=C-J#O9U-F_!&1UL[S5,W7':1R%0!O6)G]"H0D[I* (O62CD;+.FHR9U%Q&KA(N2 MIPWJ*ZA)VY*1KEQZ[?LLET3Q8%C+OLH9FE.1@$2OS"G[(ECC2=]I@7E],P&^ MD+DU%#-PPG3 6H%+,WZUGLW5F\YRQ2J%\P5J M$CE@33W7G%J(IVZWX[,@4R=F93OATC;"=O+U8L1;5GLNT+8YWV-!C?)(B:F,Z)P4X>H'.F10FVJK MN#L7D<_62,G, T!P[--M:VBNX24L^PCUFN#Q8N<^*10 M+)*FI^" *@7BHEL8/N+$7=E3PAT=1%QQ#GY'Z&^1H.SJ"N=XO&73B!WU+B$O MW;6-/<)+-TE')('4) >2426+!R?_.G7'.9ZY,C07]5:(JN_ZH ,E?]JQQ8\7 MSH/A*&0/,TT!UQ1'W3EM[_7=78A^N^OV;*@+*NT^(X15T)LKAL M^4OG%B@A45"$N-2.,-V* @?BR@9)5IUJ#I>=XJQJ4\WJUAH:O*86M; W#@%2 M;8D%)=G;V@APAZ\).1L*.4X7):4YC%XA#IG-79_=211I'$JAI%.FJMBP8 M+C]*2TWA^B1XWD>OT8VVI>U=S^4+'>("#)(4Z:XA]F)'9-!LE3>IU=YVM93P MC&MDA;ZJ;@Y]))HD&7=]8.^GO'7=(A@.2TU94UT5&Z2->V=!84=!)L9K?#@$EC0?D&\L9;H-9GZ:CG>?;;I,4 MA [CG>>..\_O;C"TK\:PY[ZK8^>H1W.,A5N&?463CF.2X [SS$Z63$9L,IUT MT#48)WZRV ,^O#5*QSL+DEF4HF>XZKTQ"&Z-(7@8([/H8_0ZK+YM&H,V=N-X MPH[M1SO-Z=-_*Q&S831(8W9,'TF[YFJOD,>P+-B9C&'-U$ON&CB>S2!Q&D_9 M<1K-!N/79.(8'KS9HZHW[$- .R5.Z_'C.('Z&(P1V7:AHU3@X_GH[9B)8,('HP\[KW,&@R@5#R"P6+K!C#+S M1;#]M;UC M@O:(.9U-,2-AR.4X2K#LZCFE!<^Q&!4B'LU\9^W?NS/T_,L7Z&TR M'NV7?3MZD-[&\3X!T=AS>DNB&*'<"XL;/DAOA*Y]4G2C?10WZJGD&.NEN$D/ ME6/L6Q0'NA_T-@&A +04-XI&HQZCW?"?I[AXN//<3W&#>.?Y&<5-]OD*0R]1 M7-RSA,9>HKAALO-\B.+P:C)J&6LVFQTFN%$TF>U.3\;1:#C[)L$-$9,X38GA MXN'D&PPW<@PW^I,,-P0]3(:6D";C%RFNTT>ANL6S=(_@1D!.2M0P&)&\\9@( M;@SQR3<(#I"#N);@4FB/P2G(8)_@ADB8840DBSU&5,R2: :T?X/@D/EP]7$R M?6W)[C#!0?_)F':86"LFM *F#9+T$,'%:%,F:-D&#%T BDP\.TQQ 7]Q:O\Z MHG,N[N>Y8^Q/?_\6T[4J'@]3HKKQ0:K#Z^-XV*$ZZI8.4QU)'N(SC8GRK'0: M' $N?YWM>O+TK[,=:33JTVC*^GY6<];YT1/JS-+^M(NNW7'<=;]_"J/AUV/G M[D=3[73WTS.0X1+U'D?H!98.3B>C(Z;=S[G&ULK511;],P$/XKIS AD*!IDVR#D49: M6]!X**HV#9[=Y-I8<^Q@.\WV[SD[:>A&-R'$2^,[W_?=?5??I:W2=Z9$M'!? M"6FF06EM?1&&)B^Q8F:D:I1TLU&Z8I9,O0U-K9$5'E2),!J/S\**<1EDJ?>M M=):JQ@HN<:7!-%7%],,,A6JGP238.Z[YMK3.$69IS;9X@_:V7FFRPH&EX!5* MPY4$C9MI<#FYF"$V'(:? B@P UKA+U6[17V>DX=7ZZ$ M\;_0=K&G20!Y8ZRJ>C!54''9?=E]WX<# /$"Y#W -B+[2KS,M: M,,NR5*L6M(LF-G?PO?%H4L.E^Q=OK*9;3CB;K=@#[ RL4/L7(7.$!3>Y4*;1 M"._A]F8!;T[>P@EP"4LN!/7>I*&EU(X@S/LTLRY-]$R:&)9*VM+ 9UE@\1@? M4LE#W=&^[EGT(N&2Z1'$DW<0C:/D2#WSOX?'+Y03#VV,/5_\+VT\UJZ.+CE. MYT;WPM0LQVE LVE0[S#(7K^:G(T_'=/ZG\@>*4\&YCH70#=;Y2R>\,E T]@M02P,$% @ Z7V86";: M+PY$ @ B@8 !D !X;"]W;W)K&ULG95=;YLP M%$#_BL6D/;6%0#ZV#)"2;M/RT"E*N^W9P1>P:FQFF]#^^]F&L&Q*J)278)M[ MC\]UY$O<"OFL2@"-7BK&5>*56M=+WU=9"156=Z(&;M[D0E98FZDL?%5+P,0E M5

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 406 300 1 false 115 0 false 9 false false R1.htm 0000001 - Document - Cover Sheet http://www.humana.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS Sheet http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTS BASIS OF PRESENTATION AND SIGNIFICANT EVENTS Notes 8 false false R9.htm 0000009 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://www.humana.com/role/RECENTLYISSUEDACCOUNTINGPRONOUNCEMENTS RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Notes 9 false false R10.htm 0000010 - Disclosure - ACQUISITIONS Sheet http://www.humana.com/role/ACQUISITIONS ACQUISITIONS Notes 10 false false R11.htm 0000011 - Disclosure - INVESTMENT SECURITIES Sheet http://www.humana.com/role/INVESTMENTSECURITIES INVESTMENT SECURITIES Notes 11 false false R12.htm 0000012 - Disclosure - FAIR VALUE Sheet http://www.humana.com/role/FAIRVALUE FAIR VALUE Notes 12 false false R13.htm 0000013 - Disclosure - MEDICARE PART D Sheet http://www.humana.com/role/MEDICAREPARTD MEDICARE PART D Notes 13 false false R14.htm 0000014 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 14 false false R15.htm 0000015 - Disclosure - BENEFITS PAYABLE Sheet http://www.humana.com/role/BENEFITSPAYABLE BENEFITS PAYABLE Notes 15 false false R16.htm 0000016 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION Sheet http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION EARNINGS PER COMMON SHARE COMPUTATION Notes 16 false false R17.htm 0000017 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.humana.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 17 false false R18.htm 0000018 - Disclosure - INCOME TAXES Sheet http://www.humana.com/role/INCOMETAXES INCOME TAXES Notes 18 false false R19.htm 0000019 - Disclosure - DEBT Sheet http://www.humana.com/role/DEBT DEBT Notes 19 false false R20.htm 0000020 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES Sheet http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES COMMITMENTS, GUARANTEES AND CONTINGENCIES Notes 20 false false R21.htm 0000021 - Disclosure - SEGMENT INFORMATION Sheet http://www.humana.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies) Sheet http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies) Policies 24 false false R25.htm 9954472 - Disclosure - INVESTMENT SECURITIES (Tables) Sheet http://www.humana.com/role/INVESTMENTSECURITIESTables INVESTMENT SECURITIES (Tables) Tables http://www.humana.com/role/INVESTMENTSECURITIES 25 false false R26.htm 9954473 - Disclosure - FAIR VALUE (Tables) Sheet http://www.humana.com/role/FAIRVALUETables FAIR VALUE (Tables) Tables http://www.humana.com/role/FAIRVALUE 26 false false R27.htm 9954474 - Disclosure - MEDICARE PART D (Tables) Sheet http://www.humana.com/role/MEDICAREPARTDTables MEDICARE PART D (Tables) Tables http://www.humana.com/role/MEDICAREPARTD 27 false false R28.htm 9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 28 false false R29.htm 9954476 - Disclosure - BENEFITS PAYABLE (Tables) Sheet http://www.humana.com/role/BENEFITSPAYABLETables BENEFITS PAYABLE (Tables) Tables http://www.humana.com/role/BENEFITSPAYABLE 29 false false R30.htm 9954477 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables) Sheet http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables EARNINGS PER COMMON SHARE COMPUTATION (Tables) Tables http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION 30 false false R31.htm 9954478 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.humana.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.humana.com/role/STOCKHOLDERSEQUITY 31 false false R32.htm 9954479 - Disclosure - DEBT (Tables) Sheet http://www.humana.com/role/DEBTTables DEBT (Tables) Tables http://www.humana.com/role/DEBT 32 false false R33.htm 9954480 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.humana.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.humana.com/role/SEGMENTINFORMATION 33 false false R34.htm 9954481 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) Sheet http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) Details http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies 34 false false R35.htm 9954482 - Disclosure - INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) Details 35 false false R36.htm 9954483 - Disclosure - INVESTMENT SECURITIES - Narrative (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails INVESTMENT SECURITIES - Narrative (Details) Details 36 false false R37.htm 9954484 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) Details 37 false false R38.htm 9954485 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) Details 38 false false R39.htm 9954486 - Disclosure - INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) Details 39 false false R40.htm 9954487 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) Details 40 false false R41.htm 9954488 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) Sheet http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) Details 41 false false R42.htm 9954489 - Disclosure - FAIR VALUE - Narrative (Details) Sheet http://www.humana.com/role/FAIRVALUENarrativeDetails FAIR VALUE - Narrative (Details) Details 42 false false R43.htm 9954490 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) Sheet http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) Details 43 false false R44.htm 9954491 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details) Sheet http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails FAIR VALUE - Put and Call Options Measured at Fair Value (Details) Details 44 false false R45.htm 9954492 - Disclosure - FAIR VALUE - Fair Value of Swap Agreements (Details) Sheet http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails FAIR VALUE - Fair Value of Swap Agreements (Details) Details 45 false false R46.htm 9954493 - Disclosure - MEDICARE PART D (Details) Sheet http://www.humana.com/role/MEDICAREPARTDDetails MEDICARE PART D (Details) Details http://www.humana.com/role/MEDICAREPARTDTables 46 false false R47.htm 9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details) Details 47 false false R48.htm 9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) Details 48 false false R49.htm 9954496 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details 49 false false R50.htm 9954497 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details) Details 50 false false R51.htm 9954498 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details) Sheet http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails BENEFITS PAYABLE - Activity in Benefits Payable (Details) Details 51 false false R52.htm 9954499 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details) Sheet http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails EARNINGS PER COMMON SHARE COMPUTATION (Details) Details http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables 52 false false R53.htm 9954500 - Disclosure - STOCKHOLDERS' EQUITY - Dividends (Details) Sheet http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails STOCKHOLDERS' EQUITY - Dividends (Details) Details 53 false false R54.htm 9954501 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) Sheet http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY - Narrative (Details) Details 54 false false R55.htm 9954502 - Disclosure - INCOME TAXES (Details) Sheet http://www.humana.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.humana.com/role/INCOMETAXES 55 false false R56.htm 9954503 - Disclosure - DEBT - Debt Outstanding (Details) Sheet http://www.humana.com/role/DEBTDebtOutstandingDetails DEBT - Debt Outstanding (Details) Details 56 false false R57.htm 9954504 - Disclosure - DEBT - Senior Notes (Details) Notes http://www.humana.com/role/DEBTSeniorNotesDetails DEBT - Senior Notes (Details) Details 57 false false R58.htm 9954505 - Disclosure - DEBT - Revolving Credit Agreements (Details) Sheet http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails DEBT - Revolving Credit Agreements (Details) Details 58 false false R59.htm 9954506 - Disclosure - DEBT - Commercial Paper and Other Short-term Borrowings (Details) Sheet http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails DEBT - Commercial Paper and Other Short-term Borrowings (Details) Details 59 false false R60.htm 9954507 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details) Sheet http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details) Details http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES 60 false false R61.htm 9954508 - Disclosure - SEGMENT INFORMATION - Narrative (Details) Sheet http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails SEGMENT INFORMATION - Narrative (Details) Details 61 false false R62.htm 9954509 - Disclosure - SEGMENT INFORMATION - Segment Results (Details) Sheet http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails SEGMENT INFORMATION - Segment Results (Details) Details 62 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept PolicyholderBenefitsAndClaimsIncurredHealthCare in us-gaap/2023 used in 10 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. hum-20240331.htm 4 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: hum:TRICAREManagedCareSupportContractBaseTerm, us-gaap:CommonStockParOrStatedValuePerShare - hum-20240331.htm 4 hum-20240331.htm hum-20240331.xsd hum-20240331_cal.xml hum-20240331_def.xml hum-20240331_lab.xml hum-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hum-20240331.htm": { "nsprefix": "hum", "nsuri": "http://www.humana.com/20240331", "dts": { "inline": { "local": [ "hum-20240331.htm" ] }, "schema": { "local": [ "hum-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "hum-20240331_cal.xml" ] }, "definitionLink": { "local": [ "hum-20240331_def.xml" ] }, "labelLink": { "local": [ "hum-20240331_lab.xml" ] }, "presentationLink": { "local": [ "hum-20240331_pre.xml" ] } }, "keyStandard": 268, "keyCustom": 32, "axisStandard": 29, "axisCustom": 1, "memberStandard": 50, "memberCustom": 65, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2023": 5, "http://www.humana.com/20240331": 1, "http://fasb.org/us-gaap/2023": 4 }, "contextCount": 406, "entityCount": 1, "segmentCount": 115, "elementCount": 646, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1139, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.humana.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R5": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R6": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R8": { "role": "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTS", "longName": "0000008 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.humana.com/role/RECENTLYISSUEDACCOUNTINGPRONOUNCEMENTS", "longName": "0000009 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS", "shortName": "RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.humana.com/role/ACQUISITIONS", "longName": "0000010 - Disclosure - ACQUISITIONS", "shortName": "ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.humana.com/role/INVESTMENTSECURITIES", "longName": "0000011 - Disclosure - INVESTMENT SECURITIES", "shortName": "INVESTMENT SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.humana.com/role/FAIRVALUE", "longName": "0000012 - Disclosure - FAIR VALUE", "shortName": "FAIR VALUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.humana.com/role/MEDICAREPARTD", "longName": "0000013 - Disclosure - MEDICARE PART D", "shortName": "MEDICARE PART D", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "hum:MedicarePartDDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hum:MedicarePartDDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "longName": "0000014 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.humana.com/role/BENEFITSPAYABLE", "longName": "0000015 - Disclosure - BENEFITS PAYABLE", "shortName": "BENEFITS PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InsuranceDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InsuranceDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION", "longName": "0000016 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION", "shortName": "EARNINGS PER COMMON SHARE COMPUTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.humana.com/role/STOCKHOLDERSEQUITY", "longName": "0000017 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.humana.com/role/INCOMETAXES", "longName": "0000018 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.humana.com/role/DEBT", "longName": "0000019 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES", "longName": "0000020 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES", "shortName": "COMMITMENTS, GUARANTEES AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.humana.com/role/SEGMENTINFORMATION", "longName": "0000021 - Disclosure - SEGMENT INFORMATION", "shortName": "SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies", "longName": "9954471 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESTables", "longName": "9954472 - Disclosure - INVESTMENT SECURITIES (Tables)", "shortName": "INVESTMENT SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.humana.com/role/FAIRVALUETables", "longName": "9954473 - Disclosure - FAIR VALUE (Tables)", "shortName": "FAIR VALUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.humana.com/role/MEDICAREPARTDTables", "longName": "9954474 - Disclosure - MEDICARE PART D (Tables)", "shortName": "MEDICARE PART D (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "longName": "9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.humana.com/role/BENEFITSPAYABLETables", "longName": "9954476 - Disclosure - BENEFITS PAYABLE (Tables)", "shortName": "BENEFITS PAYABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables", "longName": "9954477 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables)", "shortName": "EARNINGS PER COMMON SHARE COMPUTATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954478 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.humana.com/role/DEBTTables", "longName": "9954479 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.humana.com/role/SEGMENTINFORMATIONTables", "longName": "9954480 - Disclosure - SEGMENT INFORMATION (Tables)", "shortName": "SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "longName": "9954481 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-49", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-49", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails", "longName": "9954482 - Disclosure - INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details)", "shortName": "INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R36": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails", "longName": "9954483 - Disclosure - INVESTMENT SECURITIES - Narrative (Details)", "shortName": "INVESTMENT SECURITIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hum:MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R37": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "longName": "9954484 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)", "shortName": "INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails", "longName": "9954485 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details)", "shortName": "INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "hum:DebtAndEquitySecuritiesRealizedGain", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hum:DebtAndEquitySecuritiesRealizedGain", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails", "longName": "9954486 - Disclosure - INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details)", "shortName": "INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails", "longName": "9954487 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)", "shortName": "INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "longName": "9954488 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)", "shortName": "FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R42": { "role": "http://www.humana.com/role/FAIRVALUENarrativeDetails", "longName": "9954489 - Disclosure - FAIR VALUE - Narrative (Details)", "shortName": "FAIR VALUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:InterestRateFairValueHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:InterestRateFairValueHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details", "longName": "9954490 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)", "shortName": "FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails", "longName": "9954491 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details)", "shortName": "FAIR VALUE - Put and Call Options Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-159", "name": "us-gaap:DerivativeAssetLiabilityNetMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:DerivativeAssetLiabilityNetMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "longName": "9954492 - Disclosure - FAIR VALUE - Fair Value of Swap Agreements (Details)", "shortName": "FAIR VALUE - Fair Value of Swap Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-135", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-135", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.humana.com/role/MEDICAREPARTDDetails", "longName": "9954493 - Disclosure - MEDICARE PART D (Details)", "shortName": "MEDICARE PART D (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R47": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "longName": "9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfGoodwillTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfGoodwillTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R48": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails", "longName": "9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "longName": "9954496 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails", "longName": "9954497 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails", "longName": "9954498 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details)", "shortName": "BENEFITS PAYABLE - Activity in Benefits Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-33", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R52": { "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "longName": "9954499 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details)", "shortName": "EARNINGS PER COMMON SHARE COMPUTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R53": { "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails", "longName": "9954500 - Disclosure - STOCKHOLDERS' EQUITY - Dividends (Details)", "shortName": "STOCKHOLDERS' EQUITY - Dividends (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-203", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-203", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "longName": "9954501 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-204", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-204", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.humana.com/role/INCOMETAXESDetails", "longName": "9954502 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.humana.com/role/DEBTDebtOutstandingDetails", "longName": "9954503 - Disclosure - DEBT - Debt Outstanding (Details)", "shortName": "DEBT - Debt Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:DebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-215", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R57": { "role": "http://www.humana.com/role/DEBTSeniorNotesDetails", "longName": "9954504 - Disclosure - DEBT - Senior Notes (Details)", "shortName": "DEBT - Senior Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-252", "name": "us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } }, "R58": { "role": "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "longName": "9954505 - Disclosure - DEBT - Revolving Credit Agreements (Details)", "shortName": "DEBT - Revolving Credit Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-274", "name": "hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-274", "name": "hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "longName": "9954506 - Disclosure - DEBT - Commercial Paper and Other Short-term Borrowings (Details)", "shortName": "DEBT - Commercial Paper and Other Short-term Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-278", "name": "us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-278", "name": "us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails", "longName": "9954507 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-283", "name": "hum:NumberOfStatesComprisingTRICAREBeneficiaries", "unitRef": "state", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-283", "name": "hum:NumberOfStatesComprisingTRICAREBeneficiaries", "unitRef": "state", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails", "longName": "9954508 - Disclosure - SEGMENT INFORMATION - Narrative (Details)", "shortName": "SEGMENT INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails", "longName": "9954509 - Disclosure - SEGMENT INFORMATION - Segment Results (Details)", "shortName": "SEGMENT INFORMATION - Segment Results (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetInvestmentIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240331.htm", "unique": true } } }, "tag": { "hum_A135PercentSeniorNotesDueFebruary2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A135PercentSeniorNotesDueFebruary2027Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750\u00a0million, 1.350% due February 3, 2027", "label": "1.35 Percent Senior Notes Due February 2027 [Member]", "documentation": "1.35 Percent Senior Notes Due February 2027" } } }, "auth_ref": [] }, "hum_A2023And2024ShareRepurchaseAuthorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A2023And2024ShareRepurchaseAuthorizationMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 And 2024 Share Repurchase Authorization", "label": "2023 And 2024 Share Repurchase Authorization [Member]", "documentation": "2023 And 2024 Share Repurchase Authorization" } } }, "auth_ref": [] }, "hum_A2023ShareRepurchaseAuthorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A2023ShareRepurchaseAuthorizationMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Share Repurchase Authorization", "label": "2023 Share Repurchase Authorization [Member]", "documentation": "2023 Share Repurchase Authorization" } } }, "auth_ref": [] }, "hum_A2024ShareRepurchaseAuthorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A2024ShareRepurchaseAuthorizationMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Share Repurchase Authorization", "label": "2024 Share Repurchase Authorization [Member]", "documentation": "2024 Share Repurchase Authorization" } } }, "auth_ref": [] }, "hum_A215PercentSeniorNotesDueFebruary2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A215PercentSeniorNotesDueFebruary2032Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750\u00a0million, 2.150% due February 3, 2032", "label": "2.15 Percent Senior Notes Due February 2032 [Member]", "documentation": "2.15 Percent Senior Notes Due February 2032" } } }, "auth_ref": [] }, "hum_A3.85PercentSeniorNotesDueOctober2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A3.85PercentSeniorNotesDueOctober2024Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$600 million, 3.850% due October 1, 2024", "label": "3.85 Percent Senior Notes Due October 2024 [Member]", "documentation": "3.85 Percent Senior Notes Due October 2024 [Member]" } } }, "auth_ref": [] }, "hum_A3.95PercentSeniorNotesDueMarch2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A3.95PercentSeniorNotesDueMarch2027Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$600\u00a0million, 3.950% due March 15, 2027", "label": "3.95 Percent Senior Notes Due March 2027 [Member]", "documentation": "3.95 Percent Senior Notes Due March 2027 [Member]" } } }, "auth_ref": [] }, "hum_A3125PercentSeniorNotesDueAugust2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A3125PercentSeniorNotesDueAugust2029Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500\u00a0million, 3.125% due August 15, 2029", "label": "3.125 Percent Senior Notes Due August 2029 [Member]", "documentation": "A 3.125 Percent Senior Notes Due August 2029 [Member]" } } }, "auth_ref": [] }, "hum_A3700PercentSeniorNotesDueMarch2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A3700PercentSeniorNotesDueMarch2029Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750 million, 3.700% due March 23, 2029", "label": "3.700 Percent Senior Notes Due March 2029 [Member]", "documentation": "3.700 Percent Senior Notes Due March 2029" } } }, "auth_ref": [] }, "hum_A395PercentSeniorNotesDueAugust2049Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A395PercentSeniorNotesDueAugust2049Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million, 3.950% due August 15, 2049", "label": "3.95 Percent Senior Notes Due August 2049 [Member]", "documentation": "3.95 Percent Senior Notes Due August 2049 [Member]" } } }, "auth_ref": [] }, "hum_A4.625PercentSeniorNotesDueDecember2042Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A4.625PercentSeniorNotesDueDecember2042Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$400\u00a0million, 4.625% due December\u00a01, 2042", "label": "4.625 Percent Senior Notes Due December 2042 [Member]", "documentation": "4.625 Percent Senior Notes Due December 2042 [Member]" } } }, "auth_ref": [] }, "hum_A4.80PercentSeniorNotesDueMarch2047Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A4.80PercentSeniorNotesDueMarch2047Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$400\u00a0million, 4.800% due March 15, 2047", "label": "4.80 Percent Senior Notes Due March 2047 [Member]", "documentation": "4.80 Percent Senior Notes Due March 2047 [Member]" } } }, "auth_ref": [] }, "hum_A4.95PercentSeniorNotesDueOctober2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A4.95PercentSeniorNotesDueOctober2044Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750\u00a0million, 4.950% due October 1, 2044", "label": "4.95 Percent Senior Notes Due October 2044 [Member]", "documentation": "4.95 Percent Senior Notes Due October 2044 [Member]" } } }, "auth_ref": [] }, "hum_A450PercentSeniorNotesDueApril2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A450PercentSeniorNotesDueApril2025Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$600\u00a0million, 4.500% due April 1, 2025", "label": "4.50 Percent Senior Notes Due April 2025 [Member]", "documentation": "A 4.50 Percent Senior Notes Due April 2025 [Member]" } } }, "auth_ref": [] }, "hum_A4875PercentSeniorNotesDueApril2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A4875PercentSeniorNotesDueApril2030Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500\u00a0million, 4.875% due April 1, 2030", "label": "4.875 Percent Senior Notes Due April 2030 [Member]", "documentation": "A 4.875 Percent Senior Notes Due April 2030 [Member]" } } }, "auth_ref": [] }, "hum_A5.375PercentSeniorNotesDueApril2031And5.750PercentSeniorNotesDueApril2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A5.375PercentSeniorNotesDueApril2031And5.750PercentSeniorNotesDueApril2054Member", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054", "label": "5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 [Member]", "documentation": "5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054" } } }, "auth_ref": [] }, "hum_A5.375PercentSeniorNotesDueApril2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A5.375PercentSeniorNotesDueApril2031Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$1,250 million, $5.375% due April 15, 2031", "label": "5.375 Percent Senior Notes Due April 2031 [Member]", "documentation": "5.375 Percent Senior Notes Due April 2031" } } }, "auth_ref": [] }, "hum_A5.750PercentSeniorNotesDueApril2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A5.750PercentSeniorNotesDueApril2054Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$1,000 million, $5.750% due April 15, 2054", "label": "5.750 Percent Senior Notes Due April 2054 [Member]", "documentation": "5.750 Percent Senior Notes Due April 2054" } } }, "auth_ref": [] }, "hum_A5.750PercentSeniorNotesDueDecember2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A5.750PercentSeniorNotesDueDecember2028Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million, 5.750% due December 1, 2028", "label": "5.750 Percent Senior Notes Due December 2028 [Member]", "documentation": "5.750 Percent Senior Notes Due December 2028" } } }, "auth_ref": [] }, "hum_A5.950PercentSeniorNotesDueMarch2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A5.950PercentSeniorNotesDueMarch2034Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$850 million, 5.950% due March 15, 2034", "label": "5.950 Percent Senior Notes Due March 2034 [Member]", "documentation": "5.950 Percent Senior Notes Due March 2034" } } }, "auth_ref": [] }, "hum_A550PercentSeniorNotesDueMarch2053Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A550PercentSeniorNotesDueMarch2053Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750 million, 5.500% due March 15, 2053", "label": "5.50 Percent Senior Notes Due March 2053 [Member]", "documentation": "5.50 Percent Senior Notes Due March 2053" } } }, "auth_ref": [] }, "hum_A570PercentSeniorNotesDueMarch2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A570PercentSeniorNotesDueMarch2026Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million, 5.700% due March 13, 2026", "label": "5.70 Percent Senior Notes Due March 2026 [Member]", "documentation": "5.70 Percent Senior Notes Due March 2026" } } }, "auth_ref": [] }, "hum_A5750PercentSeniorNotesDueMarch2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A5750PercentSeniorNotesDueMarch2028Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million, 5.750% due March 1, 2028", "label": "5.750 Percent Senior Notes Due March 2028 [Member]", "documentation": "5.750 Percent Senior Notes Due March 2028" } } }, "auth_ref": [] }, "hum_A5875PercentSeniorNotesDueMarch2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A5875PercentSeniorNotesDueMarch2033Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750 million, 5.875% due March 1, 2033", "label": "5.875 Percent Senior Notes Due March 2033 [Member]", "documentation": "5.875 Percent Senior Notes Due March 2033" } } }, "auth_ref": [] }, "hum_A8.15PercentSeniorNotesDueJune2038Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "A8.15PercentSeniorNotesDueJune2038Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$250\u00a0million, 8.150% due June\u00a015, 2038", "label": "8.15 Percent Senior Notes Due June 2038 [Member]", "documentation": "8.15 Percent Senior Notes Due June 2038 [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables and Other [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetCurrentLiabilityAsset", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable and accrued expenses", "negatedLabel": "Trade accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r308", "r309" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r37", "r38", "r123", "r206", "r626", "r671", "r674" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r13", "r38", "r521", "r524", "r566", "r667", "r668", "r891", "r892", "r893", "r903", "r904", "r905" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r840" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r118" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Capital\u00a0In Excess\u00a0of Par Value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r491", "r492", "r493", "r684", "r903", "r904", "r905", "r955", "r973" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r846" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r846" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r846" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r846" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r9", "r68" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r78", "r79", "r463" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r811", "r822", "r832", "r857" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r814", "r825", "r835", "r860" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r846" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r853" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r818", "r826", "r836", "r853", "r861", "r865", "r873" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r871" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, net of allowances", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r207", "r310", "r353" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r63", "r68" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of antidilutive stock options and restricted stock excluded from computation (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r270" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed securities", "verboseLabel": "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r779", "r913", "r919", "r920" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r158", "r202", "r236", "r279", "r294", "r300", "r348", "r395", "r396", "r398", "r399", "r400", "r402", "r404", "r406", "r407", "r513", "r517", "r551", "r622", "r709", "r787", "r802", "r946", "r947", "r958" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r195", "r209", "r236", "r348", "r395", "r396", "r398", "r399", "r400", "r402", "r404", "r406", "r407", "r513", "r517", "r551", "r787", "r946", "r947", "r958" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total invested assets", "terseLabel": "Assets, fair value disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r96" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r319" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r320" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails", "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "terseLabel": "Book value", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r316", "r359", "r621" ] }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r361", "r769" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r916" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r325", "r616" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r915" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r324", "r615" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r917" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r326", "r617" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r914" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r323", "r614" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage and asset-backed securities", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping." } } }, "auth_ref": [ "r912", "r913" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage and asset-backed securities", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping." } } }, "auth_ref": [ "r322", "r613", "r912" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails", "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value", "terseLabel": "Fair value", "totalLabel": "Fair Value", "netLabel": "Total debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r317", "r359", "r608", "r909" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investment securities", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r198", "r313", "r359" ] }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Securities, Available-for-sale Amortized Cost to Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss) [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r868" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r864" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r864" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r867" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r866" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r865" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r865" ] }, "hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.humana.com/20240331", "localname": "BalanceSheetAccountAssociatedWithMedicarePartDTableTableTextBlock", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Balance Sheet Amounts Associated With Medicare Part D", "label": "Balance Sheet Account Associated With Medicare Part D Table [Table Text Block]", "documentation": "Balance Sheet Account Associated With Medicare Part D" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BenefitsLossesAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BenefitsLossesAndExpenses", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Benefits, Losses and Expenses", "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs." } } }, "auth_ref": [ "r171" ] }, "hum_BookOverdraftLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "BookOverdraftLiability", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Book overdraft", "label": "Book Overdraft Liability", "documentation": "Book Overdraft Liability" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/ACQUISITIONS" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r150", "r511" ] }, "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CallOptionMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Call option", "label": "Call Option [Member]", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } } }, "auth_ref": [ "r745", "r746" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r99", "r100" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r47", "r197", "r760" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r47", "r133", "r233" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r133" ] }, "hum_CenterWellSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "CenterWellSegmentMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CenterWell", "label": "CenterWell Segment [Member]", "documentation": "CenterWell Segment" } } }, "auth_ref": [] }, "hum_CertificateOfNeedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "CertificateOfNeedMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of need", "label": "Certificate Of Need [Member]", "documentation": "Certificate Of Need" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r844" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Treasury Stock [Table]", "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r74", "r75", "r76", "r77" ] }, "hum_CmsSubsidiesOrDiscountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "CmsSubsidiesOrDiscountsMember", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CMS Subsidies/ Discounts", "label": "Cms Subsidies Or Discounts [Member]", "documentation": "CMS Subsidies Or Discounts [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r845" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r845" ] }, "hum_CommercialASOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "CommercialASOMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial ASO", "label": "Commercial ASO [Member]", "documentation": "Commercial ASO" } } }, "auth_ref": [] }, "hum_CommercialFullyInsuredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "CommercialFullyInsuredMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial fully-insured", "label": "Commercial Fully-Insured [Member]", "documentation": "Commercial Fully-Insured" } } }, "auth_ref": [] }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialMortgageBackedSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial", "label": "Commercial Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by commercial real estate mortgage loans." } } }, "auth_ref": [ "r913", "r919", "r920", "r950" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r145", "r794", "r795", "r796", "r799" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 13)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r32", "r107", "r623", "r696" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsContingenciesAndGuaranteesTextBlock", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS, GUARANTEES AND CONTINGENCIES", "label": "Commitments Contingencies and Guarantees [Text Block]", "documentation": "The entire disclosure for commitments, contingencies, and guarantees." } } }, "auth_ref": [ "r142", "r143", "r941" ] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount per Share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r149" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r149" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r790", "r791", "r792", "r794", "r795", "r796", "r799", "r903", "r904", "r955", "r971", "r973" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r117" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r117", "r697" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r117" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r117", "r697", "r715", "r973", "r974" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,593 shares issued at March\u00a031, 2024 and 198,690,082 shares issued at December 31, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r117", "r625", "r787" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r850" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r849" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r851" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r848" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Humana", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r39", "r216", "r218", "r224", "r609", "r639" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r55", "r56", "r101", "r102", "r307", "r754" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r55", "r56", "r101", "r102", "r307", "r676", "r754" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r55", "r56", "r101", "r102", "r307", "r754", "r880" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r55", "r56", "r101", "r102", "r307" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r55", "r56", "r101", "r102", "r307", "r754" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r238", "r281", "r292", "r293", "r294", "r295", "r296", "r298", "r302", "r395", "r396", "r397", "r398", "r400", "r401", "r403", "r405", "r406", "r946", "r947" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r238", "r281", "r292", "r293", "r294", "r295", "r296", "r298", "r302", "r395", "r396", "r397", "r398", "r400", "r401", "r403", "r405", "r406", "r946", "r947" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unearned revenues", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r450", "r451", "r454" ] }, "us-gaap_ContractualRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualRightsMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provider contracts", "label": "Contractual Rights [Member]", "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements)." } } }, "auth_ref": [ "r82" ] }, "hum_CorporateAndEliminationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "CorporateAndEliminationsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eliminations/ Corporate", "label": "Corporate And Eliminations [Member]", "documentation": "Corporate And Eliminations [Member]" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "verboseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r779", "r781", "r970" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "srt_CreditRatingStandardPoorsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CreditRatingStandardPoorsAxis", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Rating, Standard & Poor's [Axis]", "label": "Credit Rating, Standard & Poor's [Axis]" } } }, "auth_ref": [ "r767", "r908", "r928", "r954" ] }, "us-gaap_CreditSpreadOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditSpreadOptionMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit spread", "label": "Credit Spread Option [Member]", "documentation": "An option on the yield spread on a bond." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerContractsMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer contracts/ relationships", "label": "Customer Contracts [Member]", "documentation": "Entity's established relationships with its customers through contracts." } } }, "auth_ref": [ "r81" ] }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndEquitySecuritiesGainLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 }, "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) loss on investment securities, net", "totalLabel": "Net recognized gains (losses) on investment securities", "label": "Debt and Equity Securities, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r127", "r128" ] }, "hum_DebtAndEquitySecuritiesRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "DebtAndEquitySecuritiesRealizedGain", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross gains on investment securities", "label": "Debt And Equity Securities, Realized Gain", "documentation": "Debt And Equity Securities, Realized Gain" } } }, "auth_ref": [] }, "hum_DebtAndEquitySecuritiesRealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "DebtAndEquitySecuritiesRealizedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross losses on investment securities", "label": "Debt And Equity Securities, Realized Loss", "documentation": "Debt And Equity Securities, Realized Loss" } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.humana.com/role/DEBTDebtOutstandingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "totalLabel": "Total short-term debt", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r204" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r144", "r234", "r408", "r414", "r415", "r416", "r417", "r418", "r419", "r424", "r431", "r432", "r434" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r21", "r114", "r115", "r159", "r160", "r238", "r409", "r410", "r411", "r412", "r413", "r415", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r563", "r771", "r772", "r773", "r774", "r775", "r901" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis points spread on variable rate (percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240331", "localname": "DebtInstrumentCovenantDebtToCapitalizationPercentageActual", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual debt to capitalization percentage", "label": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual", "documentation": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual" } } }, "auth_ref": [] }, "hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240331", "localname": "DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt to capitalization percentage, maximum", "label": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum", "documentation": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r104", "r106", "r409", "r563", "r772", "r773" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt outstanding", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r422", "r550", "r772", "r773" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate (percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r29", "r410" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r238", "r409", "r410", "r411", "r412", "r413", "r415", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r433", "r563", "r771", "r772", "r773", "r774", "r775", "r901" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r30", "r238", "r409", "r410", "r411", "r412", "r413", "r415", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r563", "r771", "r772", "r773", "r774", "r775", "r901" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r72", "r73", "r103", "r104", "r106", "r108", "r147", "r148", "r238", "r409", "r410", "r411", "r412", "r413", "r415", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r433", "r563", "r771", "r772", "r773", "r774", "r775", "r901" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument term (in years)", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "12 months or more", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r179", "r365", "r769" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "12 months or more", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r179", "r365" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r179", "r365", "r769" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r179", "r365" ] }, "hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240331", "localname": "DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities, number of positions", "label": "Debt, Securities, Available-For-Sale, Securities, Number Of Positions", "documentation": "Debt Securities, Available-for-sale, Securities, Number Of Positions" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r176", "r362", "r769" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r177", "r363" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r361", "r769" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities in unrealized loss positions, number of positions", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r178", "r364" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r69" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r9", "r69" ] }, "hum_DepreciationAndAmortizationClassifiedAsBenefitExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "DepreciationAndAmortizationClassifiedAsBenefitExpense", "crdr": "debit", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization classified as benefit expense", "label": "Depreciation And Amortization Classified As Benefit Expense", "documentation": "Depreciation and amortization expense that has been reclassified to be included with benefit expenses. The reclassification is the result of depreciation and amortization expense associated primarily from the delivery of pharmacy services by our wholly-owned pharmacy business included in our Healthcare Services segment." } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetLiabilityNetMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetLiabilityNetMeasurementInput", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs", "label": "Derivative Asset (Liability) Net, Measurement Input", "documentation": "Value of input used to measure net derivative asset (liability)." } } }, "auth_ref": [ "r541" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r686", "r688", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r710", "r711", "r712", "r713", "r724", "r725", "r726", "r727", "r730", "r731", "r732", "r733", "r746", "r748", "r749", "r750", "r790", "r792" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r90", "r91", "r92", "r93", "r686", "r688", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r710", "r711", "r712", "r713", "r724", "r725", "r726", "r727", "r730", "r731", "r732", "r733", "r746", "r748", "r749", "r750", "r761", "r790", "r792" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r952", "r953" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r193" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dispositions", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r10", "r17" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r782", "r783" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Amount", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r5", "r149" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends and dividend equivalents", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r149" ] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsDeclaredTableTextBlock", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Details of Dividend Payments", "label": "Dividends Declared [Table Text Block]", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r806" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r839" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r225", "r248", "r249", "r250", "r251", "r252", "r259", "r261", "r267", "r268", "r269", "r273", "r531", "r532", "r610", "r640", "r763" ] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r261", "r265", "r267" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r225", "r248", "r249", "r250", "r251", "r252", "r261", "r267", "r268", "r269", "r273", "r531", "r532", "r610", "r640", "r763" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE COMPUTATION", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r258", "r270", "r271", "r272" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.humana.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate (percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r497" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r804" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r804" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r804" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r878" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r804" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r804" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r804" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r804" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Class of Treasury Stock [Line Items]", "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r189", "r219", "r220", "r221", "r239", "r240", "r241", "r245", "r253", "r255", "r274", "r349", "r352", "r449", "r491", "r492", "r493", "r501", "r502", "r520", "r521", "r522", "r523", "r524", "r526", "r530", "r555", "r556", "r557", "r558", "r559", "r560", "r566", "r667", "r668", "r669", "r684", "r736" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r289", "r347", "r889", "r926" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net gains (losses) recognized on equity securities during the period", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r643", "r925" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiRealizedGain", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross gains on equity securities", "label": "Equity Securities, FV-NI, Realized Gain", "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r925" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net gains (losses) recognized on equity securities sold during the period", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r641", "r925" ] }, "us-gaap_EquitySecuritiesFvNiRealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiRealizedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross losses on equity securities", "label": "Equity Securities, FV-NI, Realized Loss", "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r925" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) recognized on equity securities still held at the end of the period", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r642", "r925" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r847" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r811", "r822", "r832", "r857" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r808", "r819", "r829", "r854" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r422", "r550", "r772", "r773" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r853" ] }, "srt_ExternalCreditRatingStandardPoorsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ExternalCreditRatingStandardPoorsMember", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "External Credit Rating, Standard & Poor's [Domain]", "label": "External Credit Rating, Standard & Poor's [Domain]" } } }, "auth_ref": [] }, "hum_ExternalRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "ExternalRevenuesMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total external revenues", "label": "External Revenues [Member]", "documentation": "External Revenues" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r537", "r538", "r545" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r537", "r538", "r545" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions Used For Inputs In Fair Value Measurement", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r96", "r156" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r16", "r98" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r96", "r99", "r100" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r422", "r456", "r457", "r458", "r459", "r460", "r461", "r538", "r572", "r573", "r574", "r772", "r773", "r779", "r780", "r781" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r20", "r96", "r422", "r772", "r773" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r537", "r538", "r540", "r541", "r546" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r422", "r772", "r773" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUE" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r536" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted\u00a0Prices in Active Markets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r422", "r456", "r461", "r538", "r572", "r779", "r780", "r781" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r422", "r456", "r461", "r538", "r573", "r772", "r773", "r779", "r780", "r781" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable Inputs (Level 3)", "verboseLabel": "Level 3 fair value measurement", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r422", "r456", "r457", "r458", "r459", "r460", "r461", "r538", "r574", "r772", "r773", "r779", "r780", "r781" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.humana.com/20240331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Total gains or losses:", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) [Abstract]", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Realized in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r542" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized in other comprehensive income", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r543" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r97" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r97" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r97" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transfer out", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r544" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance at January\u00a01", "periodEndLabel": "Balance at March 31", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r422", "r456", "r457", "r458", "r459", "r460", "r461", "r572", "r573", "r574", "r772", "r773", "r779", "r780", "r781" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring Basis", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r536", "r546" ] }, "us-gaap_FairValueOfAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfAssetsAcquired", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of assets acquired, net of cash and cash equivalents acquired", "label": "Fair Value of Assets Acquired", "documentation": "The fair value of assets acquired in noncash investing or financing activities." } } }, "auth_ref": [ "r49", "r50", "r51" ] }, "hum_FairValueRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "FairValueRiskMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Risk", "label": "Fair Value Risk [Member]", "documentation": "Fair Value Risk" } } }, "auth_ref": [] }, "us-gaap_FederalHomeLoanBankAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalHomeLoanBankAdvancesMember", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FHLB borrowings", "label": "Federal Home Loan Bank Advances [Member]", "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans." } } }, "auth_ref": [ "r165" ] }, "hum_FinancialAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "FinancialAssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial asset", "label": "Financial Assets, Fair Value Disclosure", "documentation": "Financial Assets, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r354", "r355", "r356", "r357", "r358", "r360", "r366", "r367", "r433", "r447", "r527", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r636", "r769", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r921", "r922", "r923", "r924" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial liability", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableRecordedInvestmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableRecordedInvestmentLineItems", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Credit Quality Indicator [Line Items]", "label": "Financing Receivable, Credit Quality Indicator [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r768", "r928" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable intangible assets, accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r200", "r383" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r139" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r139" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r139" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r139" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r139" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r380", "r382", "r383", "r385", "r602", "r606" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "For the years ending December 31,", "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable intangible assets, cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r138", "r606" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r602" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r64", "r67" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 }, "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortizable intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r138", "r602" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r815", "r826", "r836", "r861" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r815", "r826", "r836", "r861" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r815", "r826", "r836", "r861" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r815", "r826", "r836", "r861" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r815", "r826", "r836", "r861" ] }, "us-gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestmentsTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gain (Loss) on Equity Securities", "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": [ "r894", "r895" ] }, "hum_GentivaHospiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "GentivaHospiceMember", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gentiva Hospice", "label": "Gentiva Hospice [Member]", "documentation": "Gentiva Hospice" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r199", "r368", "r607", "r770", "r787", "r930", "r937" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r371", "r770" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r137" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r770" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "hum_GovernmentAndHealthPlanMemberSubsidiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "GovernmentAndHealthPlanMemberSubsidiesAmount", "crdr": "debit", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Member co-share amounts and government subsidies", "label": "Government And Health Plan Member Subsidies Amount", "documentation": "Amount of member co-share amounts and government subsidies that are excluded from benefits expense because the health plans do not bear responsibility." } } }, "auth_ref": [] }, "hum_GroupMedicareAdvantageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "GroupMedicareAdvantageMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Group Medicare Advantage", "label": "Group Medicare Advantage [Member]", "documentation": "Group Medicare Advantage" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative, aggregate adjustment", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r519" ] }, "hum_HomeSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "HomeSolutionsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Home solutions", "label": "Home Solutions [Member]", "documentation": "Home Solutions" } } }, "auth_ref": [] }, "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss (income) attributable to noncontrolling interests", "label": "Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Noncontrolling Interest", "documentation": "Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Noncontrolling Interest" } } }, "auth_ref": [] }, "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent", "crdr": "credit", "calculation": { "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Segment earnings (loss) attributable to Humana", "label": "Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Parent", "documentation": "Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Parent" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Segment earnings (loss)", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r124", "r167", "r279", "r293", "r299", "r302", "r611", "r632", "r765" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes and equity in net losses", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r279", "r293", "r299", "r302", "r644", "r765" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in net losses", "negatedTerseLabel": "Equity in net losses", "verboseLabel": "Equity in net losses", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r9", "r125", "r166", "r286", "r347", "r631" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r782", "r783" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r237", "r495", "r498", "r499", "r500", "r506", "r508", "r509", "r510", "r681" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r180", "r184", "r254", "r255", "r287", "r496", "r507", "r645" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax payments, net", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r48" ] }, "us-gaap_IncreaseDecreaseInBookOverdrafts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInBookOverdrafts", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in book overdraft", "label": "Increase (Decrease) in Book Overdrafts", "documentation": "The increase (decrease) in cash during the period due to the net increase or decrease in book overdrafts." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unearned revenues", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r600", "r899" ] }, "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Benefits payable", "label": "Increase (Decrease) in Health Care Insurance Liabilities", "documentation": "The increase (decrease) in health care insurance liability balances during the period." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Receivables", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of employee stock options and restricted stock (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r262", "r263", "r264", "r269", "r464" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r381", "r384" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r140" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r65", "r140" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r818", "r826", "r836", "r853", "r861", "r865", "r873" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r871" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r807", "r877" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r807", "r877" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r807", "r877" ] }, "us-gaap_InsuranceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InsuranceAbstract", "lang": { "en-us": { "role": { "terseLabel": "Insurance [Abstract]", "label": "Insurance [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InsuranceDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InsuranceDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLE" ], "lang": { "en-us": { "role": { "terseLabel": "BENEFITS PAYABLE", "label": "Insurance Disclosure [Text Block]", "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items." } } }, "auth_ref": [ "r619", "r620", "r663", "r664" ] }, "hum_InsuranceSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "InsuranceSegmentMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance", "label": "Insurance Segment [Member]", "documentation": "Insurance Segment" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other intangible assets, cost", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r199" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r62", "r66" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets:", "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r105", "r169", "r222", "r283", "r562", "r720", "r800", "r972" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r228", "r231", "r232" ] }, "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateFairValueHedgeAssetAtFairValue", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swap asset", "label": "Interest Rate Fair Value Hedge Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments." } } }, "auth_ref": [ "r91" ] }, "hum_InterestRateSwapMaturing2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "InterestRateSwapMaturing2033Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2033", "label": "Interest Rate Swap Maturing 2033 [Member]", "documentation": "Interest Rate Swap Maturing 2033" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "InterestRateSwapMaturing2034Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2034", "label": "Interest Rate Swap Maturing 2034 [Member]", "documentation": "Interest Rate Swap Maturing 2034" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2049Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "InterestRateSwapMaturing2049Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2049", "label": "Interest Rate Swap Maturing 2049 [Member]", "documentation": "Interest Rate Swap Maturing 2049" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2053Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "InterestRateSwapMaturing2053Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2053", "label": "Interest Rate Swap Maturing 2053 [Member]", "documentation": "Interest Rate Swap Maturing 2053" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "InterestRateSwapMaturing2054Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2054", "label": "Interest Rate Swap Maturing 2054 [Member]", "documentation": "Interest Rate Swap Maturing 2054" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r758", "r797", "r798" ] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntersegmentEliminationMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intersegment Eliminations", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r281", "r292", "r293", "r294", "r295", "r296", "r298", "r302" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r130" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contractual Maturity of Debt Securities Available for Sale", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTMENT SECURITIES", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r157", "r170", "r175", "r188", "r311", "r314", "r547", "r548" ] }, "us-gaap_InvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments [Member]", "documentation": "Assets held for their financial return, rather than for the entity's operations." } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r27", "r236", "r348", "r395", "r396", "r398", "r399", "r400", "r402", "r404", "r406", "r407", "r514", "r517", "r518", "r551", "r695", "r764", "r802", "r946", "r958", "r959" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r122", "r162", "r629", "r787", "r902", "r927", "r957" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Fair value of liabilities assumed", "label": "Liabilities Assumed", "documentation": "The fair value of liabilities assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r49", "r50", "r51" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r28", "r196", "r236", "r348", "r395", "r396", "r398", "r399", "r400", "r402", "r404", "r406", "r407", "r514", "r517", "r518", "r551", "r787", "r946", "r958", "r959" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Benefits payable", "periodStartLabel": "Balances, beginning of period", "periodEndLabel": "Balances, end of period", "label": "Liability for Claims and Claims Adjustment Expense", "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date." } } }, "auth_ref": [ "r109", "r174" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paid related to:", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "crdr": "credit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current year", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs." } } }, "auth_ref": [ "r19" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "crdr": "credit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Prior years", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs." } } }, "auth_ref": [ "r19" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount", "crdr": "credit", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total IBNR included in benefits payable", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount", "documentation": "Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement." } } }, "auth_ref": [ "r110" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "crdr": "debit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total incurred", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process." } } }, "auth_ref": [ "r173" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incurred related to:", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare licenses", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r83", "r494", "r951" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility fee (percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r901" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r24", "r901" ] }, "hum_LineOfCreditFacilityUncommittedIncrementalCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "LineOfCreditFacilityUncommittedIncrementalCapacity", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncommitted incremental loan facility", "label": "Line Of Credit Facility, Uncommitted Incremental Capacity", "documentation": "Line Of Credit Facility, Uncommitted Incremental Capacity" } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding borrowings", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r114", "r159" ] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/DEBTDebtOutstandingDetails": { "parentTag": "us-gaap_DebtCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total senior notes", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r203" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r205" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r30" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r70" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r389", "r390", "r391", "r394", "r942", "r943" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r389", "r390", "r391", "r394", "r942", "r943" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r307", "r778", "r949", "r968", "r969" ] }, "hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum individual state general bond obligation as a percentage of total debt securities (percent)", "label": "Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities", "documentation": "Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r462", "r599", "r666", "r687", "r688", "r741", "r742", "r743", "r744", "r751", "r755", "r756", "r766", "r776", "r784", "r789", "r948", "r960", "r961", "r962", "r963", "r964", "r965" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r845" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r845" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average cost of capital", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r956" ] }, "us-gaap_MeasurementInputLongTermRevenueGrowthRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputLongTermRevenueGrowthRateMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term growth rate", "label": "Measurement Input, Long-Term Revenue Growth Rate [Member]", "documentation": "Measurement input using compounded annualized rate of long-term growth in revenue." } } }, "auth_ref": [ "r956" ] }, "us-gaap_MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputOptionVolatilityMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annualized volatility", "label": "Measurement Input, Option Volatility [Member]", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth_ref": [ "r956" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r539" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "hum_MedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MedicaidMember", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicaid", "label": "Medicaid [Member]", "documentation": "Medicaid [Member]" } } }, "auth_ref": [] }, "hum_MedicareAdvantageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MedicareAdvantageMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Individual Medicare Advantage", "label": "Medicare Advantage [Member]", "documentation": "Medicare Advantage [Member]" } } }, "auth_ref": [] }, "hum_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MedicareMember", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Medicare", "terseLabel": "Total Medicare", "label": "Medicare [Member]", "documentation": "Medicare [Member]" } } }, "auth_ref": [] }, "hum_MedicarePartDDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MedicarePartDDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/MEDICAREPARTD" ], "lang": { "en-us": { "role": { "terseLabel": "MEDICARE PART D", "label": "Medicare Part D Disclosure [Text Block]", "documentation": "Balance sheet amounts associated with Medicare Part D." } } }, "auth_ref": [] }, "hum_MedicareStandAlonePrescriptionDrugPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MedicareStandAlonePrescriptionDrugPlanMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare stand-alone PDP", "label": "Medicare Stand Alone Prescription Drug Plan [Member]", "documentation": "Medicare Stand Alone Prescription Drug Plan [Member]" } } }, "auth_ref": [] }, "hum_MedicareSupplementProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MedicareSupplementProductMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare Supplement", "label": "Medicare Supplement Product [Member]", "documentation": "Medicare Supplement Product" } } }, "auth_ref": [] }, "hum_MilitaryAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MilitaryAndOtherMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Military services and other", "label": "Military And Other [Member]", "documentation": "Military And Other" } } }, "auth_ref": [] }, "hum_MilitaryServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "MilitaryServiceMember", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Military services", "label": "Military Service [Member]", "documentation": "Military Service [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r462", "r599", "r666", "r687", "r688", "r741", "r742", "r743", "r744", "r751", "r755", "r756", "r766", "r776", "r784", "r789", "r948", "r960", "r961", "r962", "r963", "r964", "r965" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r36", "r161", "r236", "r348", "r395", "r398", "r399", "r400", "r406", "r407", "r551", "r628", "r699" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r86", "r149", "r153" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r864" ] }, "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Mortgage-backed securities", "label": "Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]", "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac)." } } }, "auth_ref": [ "r913", "r919", "r920", "r950" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r872" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r307", "r778", "r949", "r968", "r969" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r846" ] }, "hum_NetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NetAssetLiability", "crdr": "debit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net asset (liability)", "label": "Net Asset (Liability)", "documentation": "Net Asset (Liability)" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r230" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r230" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r133", "r134", "r135" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "hum_NetCurrentLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NetCurrentLiabilityAsset", "crdr": "debit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetAssetLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net current liability", "label": "Net Current (Liability) Asset", "documentation": "Net current (liability) asset" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Humana", "terseLabel": "Net income attributable to Humana", "verboseLabel": "Net income available for common stockholders", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r126", "r135", "r168", "r194", "r214", "r217", "r221", "r236", "r244", "r248", "r249", "r250", "r251", "r254", "r255", "r266", "r279", "r293", "r299", "r302", "r348", "r395", "r396", "r398", "r399", "r400", "r402", "r404", "r406", "r407", "r532", "r551", "r635", "r717", "r734", "r735", "r765", "r800", "r946" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net loss attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r88", "r154", "r214", "r217", "r254", "r255", "r634", "r893" ] }, "us-gaap_NetInvestmentIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentIncome", "crdr": "credit", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Investment income", "label": "Net Investment Income", "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": [ "r181", "r637", "r638", "r721", "r800" ] }, "hum_NetNoncurrentAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NetNoncurrentAssetLiability", "crdr": "debit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetAssetLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net long-term asset (liability)", "label": "Net Noncurrent Asset (Liability)", "documentation": "Net Noncurrent Asset (Liability)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.humana.com/role/RECENTLYISSUEDACCOUNTINGPRONOUNCEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r182", "r183", "r187", "r191", "r242", "r243", "r246", "r247", "r256", "r257", "r350", "r351", "r503", "r504", "r505", "r525", "r529", "r533", "r534", "r535", "r552", "r553", "r554", "r564", "r565", "r567", "r603", "r604", "r605", "r670", "r671", "r672", "r673", "r674" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Pronouncements Effective in Future Periods", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r845" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r815", "r826", "r836", "r853", "r861" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r843" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r842" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r853" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r872" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Details of businesses acquired in purchase transactions:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Noncontrolling interests acquired", "label": "Noncash or Part Noncash Acquisition, Noncontrolling Interest Acquired", "documentation": "Noncash or Part Noncash Acquisition, Noncontrolling Interest Acquired" } } }, "auth_ref": [] }, "hum_NoncompetesAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NoncompetesAndOtherMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncompetes and other", "label": "Noncompetes And Other [Member]", "documentation": "Noncompetes and Other [Member]" } } }, "auth_ref": [] }, "hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsFromNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsFromNoncontrollingInterestHolders", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution from noncontrolling interest holders, net", "label": "Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions From Noncontrolling Interest Holders", "documentation": "Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions From Noncontrolling Interest Holders" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r84", "r449", "r903", "r904", "r905", "r973" ] }, "us-gaap_NontaxableMunicipalNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NontaxableMunicipalNotesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax-exempt municipal securities", "label": "Nontaxable Municipal Notes [Member]", "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments that are not taxable." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r907" ] }, "hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states comprising of TRICARE managed care support contract beneficiaries", "label": "Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries", "documentation": "Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries" } } }, "auth_ref": [] }, "hum_NumberOfStatesComprisingTRICAREBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NumberOfStatesComprisingTRICAREBeneficiaries", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states comprising TRICARE beneficiaries", "label": "Number Of States Comprising TRICARE Beneficiaries", "documentation": "Number Of States Comprising TRICARE Beneficiaries" } } }, "auth_ref": [] }, "hum_NumberOfTRICAREBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NumberOfTRICAREBeneficiaries", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of TRICARE beneficiaries", "label": "Number Of TRICARE Beneficiaries", "documentation": "Number Of TRICARE Beneficiaries" } } }, "auth_ref": [] }, "hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240331", "localname": "NumberOfTRICAREManagedCareSupportContractBeneficiaries", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of TRICARE managed care support contract beneficiaries", "label": "Number Of TRICARE Managed Care Support Contract Beneficiaries", "documentation": "Number Of TRICARE Managed Care Support Contract Beneficiaries" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r279", "r293", "r299", "r302", "r765" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r296", "r302" ] }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityEquityAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Indexed to Issuer's Equity [Axis]", "label": "Option Indexed to Issuer's Equity [Axis]", "documentation": "Information by type of options indexed to an issuer's equity." } } }, "auth_ref": [ "r71", "r94", "r95", "r155" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OptionOnSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionOnSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Option on Securities [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION AND SIGNIFICANT EVENTS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r111", "r151", "r677", "r678" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetCurrentLiabilityAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r208", "r787" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetNoncurrentAssetLiability", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r201" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive (loss) income, net of tax", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r6", "r12", "r152", "r215", "r218" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustment for net realized (gains) losses", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r4", "r123", "r213", "r346" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total reclassification adjustment, net of tax", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r4", "r123", "r213", "r346" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of income taxes", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in gross unrealized investment (losses) gains", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r210", "r212", "r346" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total change in unrealized investment (losses) gains, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r210", "r212", "r346" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Effect of income taxes", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r3", "r211" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetNoncurrentAssetLiability", "weight": -1.0, "order": 2.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "negatedTerseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense (income), net", "negatedLabel": "Other expense (income), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r131" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r845" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r813", "r824", "r834", "r859" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total Stockholders' Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r841" ] }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLossesAndLossAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total paid", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process." } } }, "auth_ref": [ "r7", "r19" ] }, "hum_PaymentsForProceedsFromContractDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "PaymentsForProceedsFromContractDeposits", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Receipts from contract deposits, net", "label": "Payments For Proceeds From Contract Deposits", "documentation": "Payments For Proceeds From Contract Deposits" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Common stock repurchases", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r44" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt issue costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r46" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r44" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investment securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r41", "r226", "r312" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions, net of cash and cash equivalents acquired", "verboseLabel": "Cash paid for acquired businesses, net of cash and cash equivalents acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r42" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment, net", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r132" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r844" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r844" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r843" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r853" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r846" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r842" ] }, "hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240331", "localname": "PercentageOfTotalDebtSecuritiesInvestmentGradeQuality", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of debt securities considered to be of investment-grade (percent)", "label": "Percentage Of Total Debt Securities, Investment Grade Quality", "documentation": "Percentage Of Total Debt Securities, Investment Grade Quality" } } }, "auth_ref": [] }, "hum_PercentageOfTotalPremiumAndServicesRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240331", "localname": "PercentageOfTotalPremiumAndServicesRevenues", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of premiums and services revenue", "label": "Percentage Of Total Premium And Services Revenues", "documentation": "Percentage Of Total Premium And Services Revenues" } } }, "auth_ref": [] }, "hum_PharmacySolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "PharmacySolutionsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharmacy solutions", "label": "Pharmacy Solutions [Member]", "documentation": "Pharmacy Solutions" } } }, "auth_ref": [] }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyholderBenefitsAndClaimsIncurredHealthCare", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefits", "label": "Policyholder Benefits and Claims Incurred, Net, Health", "documentation": "Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts." } } }, "auth_ref": [ "r967" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r549" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r116", "r436" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r116", "r697" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r116", "r436" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $1 par; 10,000,000 shares authorized; none issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r116", "r624", "r787" ] }, "us-gaap_PremiumsEarnedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PremiumsEarnedNet", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premiums", "label": "Premiums Earned, Net", "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned." } } }, "auth_ref": [ "r185", "r186", "r661", "r675" ] }, "hum_PrimaryCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "PrimaryCareMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Primary care", "label": "Primary Care [Member]", "documentation": "Primary Care" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of senior notes, net", "label": "Proceeds from Issuance of Senior Long-Term Debt", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of investment securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r226", "r227", "r910" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r879", "r896" ] }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfCommercialPaper", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of commercial paper, net", "label": "Proceeds from (Repayments of) Commercial Paper", "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper." } } }, "auth_ref": [ "r897", "r898", "r900" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of investment securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r40", "r226", "r312", "r345" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r777" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r304", "r601", "r657", "r658", "r659", "r660", "r661", "r662", "r759", "r777", "r788", "r881", "r944", "r945", "r949", "r968" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r304", "r601", "r657", "r658", "r659", "r660", "r661", "r662", "r759", "r777", "r788", "r881", "r944", "r945", "r949", "r968" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r194", "r214", "r217", "r229", "r236", "r244", "r254", "r255", "r279", "r293", "r299", "r302", "r348", "r395", "r396", "r398", "r399", "r400", "r402", "r404", "r406", "r407", "r512", "r515", "r516", "r532", "r551", "r611", "r633", "r683", "r717", "r734", "r735", "r765", "r785", "r786", "r801", "r893", "r946" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r618", "r630", "r787" ] }, "us-gaap_PutOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PutOptionMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Put option", "label": "Put Option [Member]", "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option." } } }, "auth_ref": [ "r745", "r746", "r747" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r841" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r841" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r455", "r462", "r487", "r488", "r489", "r575", "r599", "r666", "r687", "r688", "r741", "r742", "r743", "r744", "r751", "r755", "r756", "r766", "r776", "r784", "r789", "r792", "r940", "r948", "r961", "r962", "r963", "r964", "r965" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r455", "r462", "r487", "r488", "r489", "r575", "r599", "r666", "r687", "r688", "r741", "r742", "r743", "r744", "r751", "r755", "r756", "r766", "r776", "r784", "r789", "r792", "r940", "r948", "r961", "r962", "r963", "r964", "r965" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, net of allowances of $85 in 2024 and $88 in 2023", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r787" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r808", "r819", "r829", "r854" ] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of senior notes", "label": "Repayments of Senior Debt", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": [ "r45" ] }, "us-gaap_RepaymentsOfUnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfUnsecuredDebt", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of term loan", "label": "Repayments of Unsecured Debt", "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResidentialMortgageBackedSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Residential", "label": "Residential Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by residential real estate mortgage loans." } } }, "auth_ref": [ "r911", "r913", "r918", "r919", "r920", "r950" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r809", "r820", "r830", "r855" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r810", "r821", "r831", "r856" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r817", "r828", "r838", "r863" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r53" ] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and impairment charge", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r119", "r149", "r627", "r670", "r674", "r680", "r698", "r787" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r189", "r239", "r240", "r241", "r245", "r253", "r255", "r349", "r352", "r491", "r492", "r493", "r501", "r502", "r520", "r522", "r523", "r526", "r530", "r667", "r669", "r684", "r973" ] }, "hum_RevenueExitMultipleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "RevenueExitMultipleMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue exit multiple", "label": "Revenue Exit Multiple [Member]", "documentation": "Revenue Exit Multiple" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services", "verboseLabel": "Services revenue", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r280", "r281", "r292", "r297", "r298", "r304", "r306", "r307", "r452", "r453", "r601" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": [ "r777" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r718", "r757", "r762" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r223", "r236", "r280", "r281", "r292", "r297", "r298", "r304", "r306", "r307", "r348", "r395", "r396", "r398", "r399", "r400", "r402", "r404", "r406", "r407", "r551", "r611", "r946" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "hum_RevolvingCreditAgreementJune2021FiveYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "RevolvingCreditAgreementJune2021FiveYearMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5-year unsecured revolving credit agreement June 2021", "label": "Revolving Credit Agreement June 2021 Five Year [Member]", "documentation": "Revolving Credit Agreement June 2021 Five Year" } } }, "auth_ref": [] }, "hum_RevolvingCreditAgreementJune2022OneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "RevolvingCreditAgreementJune2022OneYearMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "364-day unsecured revolving credit agreement June 2022", "label": "Revolving Credit Agreement June 2022 One Year [Member]", "documentation": "Revolving Credit Agreement June 2022 One Year" } } }, "auth_ref": [] }, "hum_RevolvingCreditAgreementJune2023FiveYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "RevolvingCreditAgreementJune2023FiveYearMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5-year unsecured revolving credit agreement June 2023", "label": "Revolving Credit Agreement June 2023 Five Year [Member]", "documentation": "Revolving Credit Agreement June 2023 Five Year" } } }, "auth_ref": [] }, "hum_RevolvingCreditAgreementJune2023OneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "RevolvingCreditAgreementJune2023OneYearMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "364-day unsecured revolving credit agreement June 2023", "label": "Revolving Credit Agreement June 2023 One Year [Member]", "documentation": "Revolving Credit Agreement June 2023 One Year" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "hum_RiskCorridorSettlementsMedicarePartDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "RiskCorridorSettlementsMedicarePartDMember", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk Corridor Settlement", "label": "Risk Corridor Settlements Medicare Part D [Member]", "documentation": "Risk Corridor Settlements - Medicare Part D [Member]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r872" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Securities Classified as Current and Long-Term", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.humana.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Value of Debt Outstanding", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Details Supporting Computation of Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r906" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share." } } }, "auth_ref": [ "r52", "r54", "r261", "r265", "r267" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Revenue from External Customers by Products and Services [Table]", "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Credit Quality Indicator [Table]", "label": "Financing Receivable, Credit Quality Indicator [Table]", "documentation": "Disclosure of information about credit quality indicator for financing receivable." } } }, "auth_ref": [ "r768", "r928" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r64", "r67", "r602" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Intangible Assets, Amortizable", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r64", "r67" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r770" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r770", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r18", "r140" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Intangible Assets, Indefinite-Lived", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r18", "r140" ] }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity in Benefits Payable", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims." } } }, "auth_ref": [ "r172" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r89" ] }, "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealizedGainLossTableTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income", "label": "Schedule of Realized Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales." } } }, "auth_ref": [ "r921" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r57", "r58", "r59", "r61" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Results", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r57", "r58", "r59", "r61" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-term Debt [Table]", "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r67" ] }, "hum_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r803" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r805" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r276", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r307", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r387", "r388", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r770", "r881", "r968" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r279", "r291", "r296", "r300", "r301", "r302", "r303", "r304", "r305", "r307" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating costs", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r129" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r777" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490" ] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.humana.com/20240331", "localname": "ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares acquired in connection with employee stock plans (in shares)", "label": "Share Repurchases Related To Employee Stock Based Compensation Awards Shares", "documentation": "Number of shares of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares." } } }, "auth_ref": [] }, "hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240331", "localname": "ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue", "crdr": "debit", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares acquired in connection with employee stock plans, amount", "label": "Share Repurchases Related To Employee Stock Based Compensation Awards Value", "documentation": "Cost of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.humana.com/role/DEBTDebtOutstandingDetails": { "parentTag": "us-gaap_DebtCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "verboseLabel": "Short-term debt outstanding", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r113", "r159", "r787", "r966" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt [Line Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtWeightedAverageInterestRate", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average annual interest rate (percent)", "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time", "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment securities", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r163", "r164", "r890" ] }, "us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShorttermDebtMaximumAmountOutstandingDuringPeriod", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount outstanding during period", "label": "Short-Term Debt, Maximum Amount Outstanding During Period", "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, the maximum amount borrowed at any time during the period." } } }, "auth_ref": [] }, "hum_SpecialtyBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "SpecialtyBenefitsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty benefits", "label": "Specialty Benefits [Member]", "documentation": "Specialty [Member]" } } }, "auth_ref": [] }, "srt_StandardPoorsAAMinusRatingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StandardPoorsAAMinusRatingMember", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S&P AA- rating", "label": "Standard & Poor's, AA- Rating [Member]" } } }, "auth_ref": [] }, "hum_StateBasedContractsAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "StateBasedContractsAndOtherMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State-based contracts and other", "label": "State-Based Contracts and Other [Member]", "documentation": "State-Based Contracts and Other" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r192", "r276", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r307", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r386", "r387", "r388", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r770", "r881", "r968" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r33", "r189", "r219", "r220", "r221", "r239", "r240", "r241", "r245", "r253", "r255", "r274", "r349", "r352", "r449", "r491", "r492", "r493", "r501", "r502", "r520", "r521", "r522", "r523", "r524", "r526", "r530", "r555", "r556", "r557", "r558", "r559", "r560", "r566", "r667", "r668", "r669", "r684", "r736" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r239", "r240", "r241", "r274", "r601", "r679", "r685", "r689", "r690", "r691", "r692", "r693", "r694", "r697", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r710", "r711", "r712", "r713", "r714", "r716", "r718", "r719", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r793" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r239", "r240", "r241", "r274", "r601", "r679", "r685", "r689", "r690", "r691", "r692", "r693", "r694", "r697", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r710", "r711", "r712", "r713", "r714", "r716", "r718", "r719", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r793" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r812", "r823", "r833", "r858" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit vesting (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r14", "r149" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit vesting", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r14", "r116", "r117", "r149" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r14", "r33", "r149" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share repurchase authorization", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining authorized amount", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r117", "r120", "r121", "r136", "r699", "r715", "r737", "r738", "r787", "r802", "r902", "r927", "r957", "r973" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r84", "r85", "r87", "r189", "r190", "r220", "r239", "r240", "r241", "r245", "r253", "r349", "r352", "r449", "r491", "r492", "r493", "r501", "r502", "r520", "r521", "r522", "r523", "r524", "r526", "r530", "r555", "r556", "r560", "r566", "r668", "r669", "r682", "r699", "r715", "r737", "r738", "r752", "r801", "r902", "r927", "r957", "r973" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r146", "r235", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r448", "r449", "r528", "r739", "r740", "r753" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r561", "r568" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r561", "r568" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r561", "r568" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow disclosures:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current year", "label": "Current Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs." } } }, "auth_ref": [ "r665" ] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior years", "label": "Prior Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs." } } }, "auth_ref": [ "r665" ] }, "hum_TRICARE2017EastRegionContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "TRICARE2017EastRegionContractMember", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "T2017 East Region", "label": "TRICARE 2017 East Region Contract [Member]", "documentation": "TRICARE 2017 East Region Contract" } } }, "auth_ref": [] }, "hum_TRICAREContractAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.humana.com/20240331", "localname": "TRICAREContractAxis", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TRICARE Contract [Axis]", "label": "TRICARE Contract [Axis]", "documentation": "TRICARE Contract" } } }, "auth_ref": [] }, "hum_TRICAREContractDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "TRICAREContractDomain", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TRICARE Contract [Domain]", "label": "TRICARE Contract [Domain]", "documentation": "TRICARE Contract [Domain]" } } }, "auth_ref": [] }, "hum_TRICAREManagedCareSupportContractBaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.humana.com/20240331", "localname": "TRICAREManagedCareSupportContractBaseTerm", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract base term", "label": "TRICARE Managed Care Support Contract, Base Term", "documentation": "TRICARE Managed Care Support Contract, Base Term" } } }, "auth_ref": [] }, "hum_TRICAREManagedCareSupportContractEffective2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "TRICAREManagedCareSupportContractEffective2024Member", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "T-5, Effective 2024", "label": "TRICARE Managed Care Support Contract, Effective 2024 [Member]", "documentation": "TRICARE Managed Care Support Contract, Effective 2024" } } }, "auth_ref": [] }, "hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240331", "localname": "TRICAREManagedCareSupportContractNumberOfOptionPeriods", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual option periods", "label": "TRICARE Managed Care Support Contract, Number Of Option Periods", "documentation": "TRICARE Managed Care Support Contract, Number Of Option Periods" } } }, "auth_ref": [] }, "hum_TRICAREManagedCareSupportContractTermWithOptionExercises": { "xbrltype": "durationItemType", "nsuri": "http://www.humana.com/20240331", "localname": "TRICAREManagedCareSupportContractTermWithOptionExercises", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract term with exercises", "label": "TRICARE Managed Care Support Contract, Term With Option Exercises", "documentation": "TRICARE Managed Care Support Contract, Term With Option Exercises" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r852" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of property and equipment", "label": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r112", "r141" ] }, "hum_TermLoanAndCommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "TermLoanAndCommercialPaperMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan And Commercial Paper", "label": "Term Loan And Commercial Paper [Member]", "documentation": "Term Loan And Commercial Paper" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r844" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r851" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade names and technology", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r80" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r871" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r873" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r433", "r447", "r527", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r636", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r921", "r922", "r923", "r924" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r874" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r875" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r873" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r873" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r876" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r874" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase average price (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r74" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r74" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r74" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost, 78,189,958 shares at March\u00a031, 2024 and 76,465,862 shares at December 31, 2023", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r35", "r74", "r77" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchases (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r14", "r117", "r149" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock repurchases", "terseLabel": "Stock repurchases", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r14", "r74", "r149" ] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryAndGovernmentMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury and agency obligations", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r612", "r779", "r970" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r870" ] }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gross Unrealized Losses and Fair Value of Securities", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "documentation": "Tabular disclosure of unrealized gains and losses on investments." } } }, "auth_ref": [] }, "hum_ValueCreationInitiativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240331", "localname": "ValueCreationInitiativesMember", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value Creation Initiatives", "label": "Value Creation Initiatives [Member]", "documentation": "Value Creation Initiatives" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Shares used to compute diluted earnings per common share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r260", "r269" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average outstanding shares of common stock used to compute basic earnings per common share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r259", "r269" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.W)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479583/944-40-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "460", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//460/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04.5,6,7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "220", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(1))", "SubTopic": "220", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(c))", "SubTopic": "220", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EE" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//944/tableOfContent" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-7" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(4)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(4)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-15" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-29" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4K" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 81 0000049071-24-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000049071-24-000023-xbrl.zip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�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�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end XML 83 hum-20240331_htm.xml IDEA: XBRL DOCUMENT 0000049071 2024-01-01 2024-03-31 0000049071 2024-03-31 0000049071 2023-12-31 0000049071 2023-01-01 2023-03-31 0000049071 us-gaap:CommonStockMember 2023-12-31 0000049071 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000049071 us-gaap:RetainedEarningsMember 2023-12-31 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000049071 us-gaap:TreasuryStockCommonMember 2023-12-31 0000049071 us-gaap:ParentMember 2023-12-31 0000049071 us-gaap:NoncontrollingInterestMember 2023-12-31 0000049071 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000049071 us-gaap:ParentMember 2024-01-01 2024-03-31 0000049071 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000049071 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000049071 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000049071 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000049071 us-gaap:CommonStockMember 2024-03-31 0000049071 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000049071 us-gaap:RetainedEarningsMember 2024-03-31 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000049071 us-gaap:TreasuryStockCommonMember 2024-03-31 0000049071 us-gaap:ParentMember 2024-03-31 0000049071 us-gaap:NoncontrollingInterestMember 2024-03-31 0000049071 us-gaap:CommonStockMember 2022-12-31 0000049071 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000049071 us-gaap:RetainedEarningsMember 2022-12-31 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000049071 us-gaap:TreasuryStockCommonMember 2022-12-31 0000049071 us-gaap:ParentMember 2022-12-31 0000049071 us-gaap:NoncontrollingInterestMember 2022-12-31 0000049071 2022-12-31 0000049071 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000049071 us-gaap:ParentMember 2023-01-01 2023-03-31 0000049071 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000049071 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000049071 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000049071 us-gaap:CommonStockMember 2023-03-31 0000049071 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000049071 us-gaap:RetainedEarningsMember 2023-03-31 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000049071 us-gaap:TreasuryStockCommonMember 2023-03-31 0000049071 us-gaap:ParentMember 2023-03-31 0000049071 us-gaap:NoncontrollingInterestMember 2023-03-31 0000049071 2023-03-31 0000049071 hum:ValueCreationInitiativesMember 2024-01-01 2024-03-31 0000049071 us-gaap:ServiceMember 2024-03-31 0000049071 us-gaap:USTreasuryAndGovernmentMember 2024-03-31 0000049071 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-03-31 0000049071 us-gaap:NontaxableMunicipalNotesMember 2024-03-31 0000049071 us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000049071 us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hum:GentivaHospiceMember 2024-03-31 0000049071 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hum:GentivaHospiceMember 2023-12-31 0000049071 srt:StandardPoorsAAMinusRatingMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:InvestmentsMember hum:FairValueRiskMember us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-03-31 0000049071 us-gaap:InvestmentsMember hum:FairValueRiskMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0000049071 us-gaap:InterestRateSwapMember 2024-03-31 0000049071 hum:A5875PercentSeniorNotesDueMarch2033Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2033Member us-gaap:InterestRateSwapMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2033Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A5.950PercentSeniorNotesDueMarch2034Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2034Member us-gaap:InterestRateSwapMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2034Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A395PercentSeniorNotesDueAugust2049Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2049Member us-gaap:InterestRateSwapMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2049Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A550PercentSeniorNotesDueMarch2053Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2053Member us-gaap:InterestRateSwapMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2053Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A5.750PercentSeniorNotesDueApril2054Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2054Member us-gaap:InterestRateSwapMember 2024-03-31 0000049071 hum:InterestRateSwapMaturing2054Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-03-31 0000049071 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000049071 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0000049071 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000049071 hum:TermLoanAndCommercialPaperMember 2024-03-31 0000049071 hum:TermLoanAndCommercialPaperMember 2023-12-31 0000049071 us-gaap:PutOptionMember 2024-03-31 0000049071 us-gaap:CallOptionMember 2024-03-31 0000049071 us-gaap:PutOptionMember 2023-12-31 0000049071 us-gaap:CallOptionMember 2023-12-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputOptionVolatilityMember 2024-03-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputOptionVolatilityMember 2024-03-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputOptionVolatilityMember 2023-12-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputOptionVolatilityMember 2023-12-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:CreditSpreadOptionMember 2024-03-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:CreditSpreadOptionMember 2024-03-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:CreditSpreadOptionMember 2023-12-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:CreditSpreadOptionMember 2023-12-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember hum:RevenueExitMultipleMember 2024-03-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember hum:RevenueExitMultipleMember 2024-03-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember hum:RevenueExitMultipleMember 2023-12-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember hum:RevenueExitMultipleMember 2023-12-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputDiscountRateMember 2023-12-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputDiscountRateMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputLongTermRevenueGrowthRateMember 2024-03-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputLongTermRevenueGrowthRateMember 2023-12-31 0000049071 hum:RiskCorridorSettlementsMedicarePartDMember 2024-03-31 0000049071 hum:CmsSubsidiesOrDiscountsMember 2024-03-31 0000049071 hum:RiskCorridorSettlementsMedicarePartDMember 2023-12-31 0000049071 hum:CmsSubsidiesOrDiscountsMember 2023-12-31 0000049071 hum:InsuranceSegmentMember 2023-12-31 0000049071 hum:CenterWellSegmentMember 2023-12-31 0000049071 hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:InsuranceSegmentMember 2024-03-31 0000049071 hum:CenterWellSegmentMember 2024-03-31 0000049071 hum:CertificateOfNeedMember 2024-03-31 0000049071 hum:CertificateOfNeedMember 2023-12-31 0000049071 us-gaap:LicensingAgreementsMember 2024-03-31 0000049071 us-gaap:LicensingAgreementsMember 2023-12-31 0000049071 us-gaap:CustomerContractsMember 2024-03-31 0000049071 us-gaap:CustomerContractsMember 2023-12-31 0000049071 us-gaap:TradeNamesMember 2024-03-31 0000049071 us-gaap:TradeNamesMember 2023-12-31 0000049071 us-gaap:ContractualRightsMember 2024-03-31 0000049071 us-gaap:ContractualRightsMember 2023-12-31 0000049071 hum:NoncompetesAndOtherMember 2024-03-31 0000049071 hum:NoncompetesAndOtherMember 2023-12-31 0000049071 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000049071 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000049071 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000049071 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000049071 2024-01-26 2024-01-26 0000049071 2024-02-01 2024-02-29 0000049071 us-gaap:SubsequentEventMember 2024-04-01 2024-04-30 0000049071 hum:A2023ShareRepurchaseAuthorizationMember 2024-02-16 0000049071 hum:A2024ShareRepurchaseAuthorizationMember 2024-02-16 0000049071 hum:A2023And2024ShareRepurchaseAuthorizationMember 2024-01-01 2024-03-31 0000049071 hum:A2023ShareRepurchaseAuthorizationMember 2023-01-01 2023-03-31 0000049071 us-gaap:SubsequentEventMember 2024-04-23 0000049071 us-gaap:CommercialPaperMember 2024-03-31 0000049071 us-gaap:CommercialPaperMember 2023-12-31 0000049071 hum:A3.85PercentSeniorNotesDueOctober2024Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A3.85PercentSeniorNotesDueOctober2024Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 us-gaap:SeniorNotesMember 2024-03-31 0000049071 us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A450PercentSeniorNotesDueApril2025Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A450PercentSeniorNotesDueApril2025Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A570PercentSeniorNotesDueMarch2026Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A570PercentSeniorNotesDueMarch2026Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A135PercentSeniorNotesDueFebruary2027Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A135PercentSeniorNotesDueFebruary2027Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A3.95PercentSeniorNotesDueMarch2027Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A3.95PercentSeniorNotesDueMarch2027Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5750PercentSeniorNotesDueMarch2028Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A5750PercentSeniorNotesDueMarch2028Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.750PercentSeniorNotesDueDecember2028Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A5.750PercentSeniorNotesDueDecember2028Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A3700PercentSeniorNotesDueMarch2029Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A3700PercentSeniorNotesDueMarch2029Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A3125PercentSeniorNotesDueAugust2029Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A3125PercentSeniorNotesDueAugust2029Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A4875PercentSeniorNotesDueApril2030Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A4875PercentSeniorNotesDueApril2030Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.375PercentSeniorNotesDueApril2031Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A5.375PercentSeniorNotesDueApril2031Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A215PercentSeniorNotesDueFebruary2032Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A215PercentSeniorNotesDueFebruary2032Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5875PercentSeniorNotesDueMarch2033Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.950PercentSeniorNotesDueMarch2034Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A8.15PercentSeniorNotesDueJune2038Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A8.15PercentSeniorNotesDueJune2038Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A4.625PercentSeniorNotesDueDecember2042Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A4.625PercentSeniorNotesDueDecember2042Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A4.95PercentSeniorNotesDueOctober2044Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A4.95PercentSeniorNotesDueOctober2044Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A4.80PercentSeniorNotesDueMarch2047Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A4.80PercentSeniorNotesDueMarch2047Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A395PercentSeniorNotesDueAugust2049Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A550PercentSeniorNotesDueMarch2053Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.750PercentSeniorNotesDueApril2054Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.375PercentSeniorNotesDueApril2031And5.750PercentSeniorNotesDueApril2054Member us-gaap:SeniorNotesMember 2024-01-01 2024-03-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2023-06-01 2023-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2023-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2021FiveYearMember 2021-06-01 2021-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2021FiveYearMember 2021-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember 2023-06-01 2023-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember 2023-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2022OneYearMember 2022-06-01 2022-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2022OneYearMember 2022-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember hum:SecuredOvernightFinancingRateSOFRMember 2024-01-01 2024-03-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-01-01 2024-03-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember hum:SecuredOvernightFinancingRateSOFRMember 2024-01-01 2024-03-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember 2024-01-01 2024-03-31 0000049071 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember hum:SecuredOvernightFinancingRateSOFRMember 2024-01-01 2024-03-31 0000049071 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember hum:SecuredOvernightFinancingRateSOFRMember 2024-01-01 2024-03-31 0000049071 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember hum:SecuredOvernightFinancingRateSOFRMember 2024-01-01 2024-03-31 0000049071 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember hum:SecuredOvernightFinancingRateSOFRMember 2024-01-01 2024-03-31 0000049071 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-01-01 2024-03-31 0000049071 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-01-01 2024-03-31 0000049071 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember 2024-01-01 2024-03-31 0000049071 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember 2024-01-01 2024-03-31 0000049071 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0000049071 us-gaap:LoansPayableMember 2024-03-31 0000049071 us-gaap:LetterOfCreditMember 2024-03-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-03-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember 2024-03-31 0000049071 us-gaap:CommercialPaperMember 2024-01-01 2024-03-31 0000049071 us-gaap:FederalHomeLoanBankAdvancesMember 2024-03-31 0000049071 hum:MedicareMember 2024-01-01 2024-03-31 0000049071 hum:MedicaidMember 2024-01-01 2024-03-31 0000049071 hum:MilitaryServiceMember hum:TRICARE2017EastRegionContractMember 2024-01-01 2024-03-31 0000049071 hum:TRICARE2017EastRegionContractMember 2024-03-31 0000049071 hum:TRICARE2017EastRegionContractMember 2024-01-01 2024-03-31 0000049071 hum:TRICAREManagedCareSupportContractEffective2024Member 2022-12-31 0000049071 hum:TRICAREManagedCareSupportContractEffective2024Member 2022-12-01 2022-12-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:MedicareAdvantageMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:GroupMedicareAdvantageMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:MedicareMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:CommercialFullyInsuredMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:SpecialtyBenefitsMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:MedicareSupplementProductMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:StateBasedContractsAndOtherMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:HomeSolutionsMember us-gaap:ServiceMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:PrimaryCareMember us-gaap:ServiceMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:CommercialASOMember us-gaap:ServiceMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:MilitaryAndOtherMember us-gaap:ServiceMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:PharmacySolutionsMember us-gaap:ServiceMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:ServiceMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:ExternalRevenuesMember 2024-01-01 2024-03-31 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ServiceMember 2024-01-01 2024-03-31 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember 2024-01-01 2024-03-31 0000049071 hum:CorporateAndEliminationsMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 hum:CorporateAndEliminationsMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:IntersegmentEliminationMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:InsuranceSegmentMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CenterWellSegmentMember 2024-01-01 2024-03-31 0000049071 hum:CorporateAndEliminationsMember 2024-01-01 2024-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:MedicareAdvantageMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:GroupMedicareAdvantageMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:MedicareMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:CommercialFullyInsuredMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:SpecialtyBenefitsMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:MedicareSupplementProductMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:StateBasedContractsAndOtherMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:HomeSolutionsMember us-gaap:ServiceMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:PrimaryCareMember us-gaap:ServiceMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:CommercialASOMember us-gaap:ServiceMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:MilitaryAndOtherMember us-gaap:ServiceMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:PharmacySolutionsMember us-gaap:ServiceMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:ServiceMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:ExternalRevenuesMember 2023-01-01 2023-03-31 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ServiceMember 2023-01-01 2023-03-31 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember 2023-01-01 2023-03-31 0000049071 hum:CorporateAndEliminationsMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 hum:CorporateAndEliminationsMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:InsuranceSegmentMember 2023-01-01 2023-03-31 0000049071 us-gaap:OperatingSegmentsMember hum:CenterWellSegmentMember 2023-01-01 2023-03-31 0000049071 hum:CorporateAndEliminationsMember 2023-01-01 2023-03-31 shares iso4217:USD iso4217:USD shares pure hum:position hum:state hum:beneficiary hum:option_period hum:segment 0000049071 --12-31 2024 Q1 false 0.1667 0.1667 http://fasb.org/us-gaap/2023#HealthCareMember http://fasb.org/us-gaap/2023#HealthCareMember P1Y 10-Q true 2024-03-31 false 1-5975 HUMANA INC DE 61-0647538 500 West Main Street Louisville KY 40202 502 580-1000 Common stock, $0.16 2/3 par value HUM NYSE Yes Yes Large Accelerated Filer false false false 120500635 5910000000 4694000000 16697000000 16626000000 85000000 88000000 3925000000 2035000000 6264000000 6631000000 32796000000 29986000000 2979000000 3030000000 380000000 382000000 730000000 740000000 9563000000 9550000000 3643000000 3377000000 50091000000 47065000000 11729000000 10241000000 6504000000 6569000000 333000000 353000000 301000000 266000000 822000000 1443000000 19689000000 18872000000 12390000000 10213000000 1826000000 1662000000 33905000000 30747000000 1 1 10000000 10000000 0 0 0 0 300000000 300000000 198690593 198690082 33000000 33000000 3369000000 3346000000 28173000000 27540000000 -1086000000 -999000000 78189958 76465862 14359000000 13658000000 16130000000 16262000000 56000000 56000000 16186000000 16318000000 50091000000 47065000000 28261000000 25550000000 1062000000 999000000 288000000 193000000 29611000000 26742000000 25124000000 21858000000 3042000000 2979000000 209000000 186000000 28375000000 25023000000 1236000000 1719000000 159000000 113000000 -63000000 8000000 1014000000 1614000000 251000000 359000000 -24000000 -17000000 739000000 1238000000 -2000000 -1000000 741000000 1239000000 6.13 9.91 6.11 9.87 741000000 1239000000 -114000000 188000000 -28000000 43000000 -86000000 145000000 1000000 -61000000 0 -15000000 1000000 -46000000 -87000000 191000000 654000000 1430000000 198690000 33000000 3346000000 27540000000 -999000000 -13658000000 16262000000 56000000 16318000000 741000000 741000000 -2000000 739000000 2000000 2000000 -87000000 -87000000 -87000000 723000000 723000000 723000000 108000000 108000000 108000000 45000000 45000000 45000000 1000 -22000000 22000000 0 198691000 33000000 3369000000 28173000000 -1086000000 -14359000000 16130000000 56000000 16186000000 198667000 33000000 3246000000 25492000000 -1304000000 -12156000000 15311000000 59000000 15370000000 1239000000 1239000000 -1000000 1238000000 4000000 4000000 5000000 5000000 191000000 191000000 191000000 94000000 94000000 94000000 112000000 112000000 112000000 38000000 38000000 38000000 -24000000 24000000 0 2000000 2000000 4000000 4000000 198667000 33000000 3262000000 26619000000 -1113000000 -12224000000 16577000000 57000000 16634000000 739000000 1238000000 1000000 -60000000 -24000000 -17000000 45000000 38000000 226000000 200000000 16000000 18000000 33000000 0 1890000000 1433000000 -97000000 907000000 1488000000 754000000 -422000000 -238000000 35000000 6934000000 33000000 6000000 423000000 6687000000 14000000 73000000 177000000 223000000 1259000000 1313000000 645000000 267000000 391000000 50000000 -414000000 -1292000000 -499000000 -2997000000 2232000000 1215000000 0 60000000 -644000000 -177000000 0 500000000 5000000 4000000 -20000000 108000000 717000000 94000000 109000000 100000000 -29000000 -106000000 1207000000 3279000000 1216000000 8674000000 4694000000 5061000000 5910000000 13735000000 158000000 97000000 1000000 6000000 22000000 73000000 8000000 5000000 0 -5000000 14000000 73000000 BASIS OF PRESENTATION AND SIGNIFICANT EVENTS<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employer Group Commercial Medical Products Business Exit</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value Creation Initiative</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges, primarily in asset impairments, of $29 million for the three months ended March 31, 2024 within operating costs in the consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. We did not record any charges for the three months ended March 31, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, accounts receivable related to services were $390 million. For the three months ended March 31, 2024, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at March 31, 2024.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.</span></div> <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employer Group Commercial Medical Products Business Exit</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.</span></div> 29000000 <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.</span></div> 390000000 RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Effective in Future Periods</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div> <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Effective in Future Periods</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div> ACQUISITIONS<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024 and 2023, respectively, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in the first quarter of 2024 and 2023, respectively, have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in the first quarter of 2024 and 2023, were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the quarter of acquisition, were not material for disclosure purposes.</span></div> INVESTMENT SECURITIES<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities classified as current and long-term were as follows at March 31, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:45.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $379 million and $397 million, respectively, at March 31, 2024. The book value and fair value were $379 million and $398 million, respectively, at December 31, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at March 31, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or more</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,704 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,564 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,367)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by Standard &amp; Poor's Rating Service, or S&amp;P, at March 31, 2024. Our remaining debt securities below investment-grade were primarily rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unrealized losses from all debt securities were generated from approximately 1,685 positions out of a total of approximately 2,100 positions at March 31, 2024. All issuers of debt securities we own that were trading at an </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized loss at March 31, 2024 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At March 31, 2024, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three months ended March 31, 2024 or 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detail of gains (losses) related to investment securities and included within investment income was as follows for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:81.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on investment securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on investment securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recognized gains (losses) on investment securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses related to equity securities for the three months ended March 31, 2024 and 2023 was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:81.480%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) recognized on equity securities during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized on equity securities sold during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized on equity securities still held at the end of the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of debt securities available for sale at March 31, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,402 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,199 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,485 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,077 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities classified as current and long-term were as follows at March 31, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:45.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2928000000 0 84000000 2844000000 3925000000 0 486000000 3439000000 850000000 0 24000000 826000000 462000000 0 68000000 394000000 1420000000 1000000 113000000 1308000000 1552000000 2000000 37000000 1517000000 7348000000 24000000 623000000 6749000000 18485000000 27000000 1435000000 17077000000 2717000000 1000000 51000000 2667000000 3946000000 1000000 425000000 3522000000 879000000 1000000 22000000 858000000 465000000 1000000 66000000 400000000 1471000000 0 126000000 1345000000 1813000000 2000000 44000000 1771000000 7011000000 28000000 594000000 6445000000 18302000000 34000000 1328000000 17008000000 379000000 397000000 379000000 398000000 <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at March 31, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or more</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,704 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,564 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,367)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2301000000 43000000 447000000 41000000 2748000000 84000000 862000000 15000000 2513000000 471000000 3375000000 486000000 261000000 1000000 508000000 23000000 769000000 24000000 9000000 0 365000000 68000000 374000000 68000000 0 0 1242000000 113000000 1242000000 113000000 447000000 2000000 787000000 35000000 1234000000 37000000 824000000 7000000 4702000000 616000000 5526000000 623000000 4704000000 68000000 10564000000 1367000000 15268000000 1435000000 1899000000 12000000 431000000 39000000 2330000000 51000000 958000000 12000000 2269000000 413000000 3227000000 425000000 160000000 1000000 523000000 21000000 683000000 22000000 0 0 373000000 66000000 373000000 66000000 18000000 0 1303000000 126000000 1321000000 126000000 120000000 1000000 1364000000 43000000 1484000000 44000000 466000000 2000000 4783000000 592000000 5249000000 594000000 3621000000 28000000 11046000000 1300000000 14667000000 1328000000 0.97 0.01 1685 2100 <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detail of gains (losses) related to investment securities and included within investment income was as follows for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:81.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on investment securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on investment securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recognized gains (losses) on investment securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2000000 0 1000000 61000000 0 1000000 0 0 1000000 -60000000 <div style="margin-bottom:9pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses related to equity securities for the three months ended March 31, 2024 and 2023 was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:81.480%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) recognized on equity securities during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized on equity securities sold during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized on equity securities still held at the end of the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 1000000 0 1000000 0 0 <div style="margin-bottom:9pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of debt securities available for sale at March 31, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,402 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,199 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,485 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,077 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1235000000 1229000000 5402000000 5199000000 3259000000 2954000000 1230000000 1037000000 7359000000 6658000000 18485000000 17077000000 FAIR VALUE<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our fair value measurements at March 31, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:49.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,077 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,851 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:58.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:58.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,590 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 assets had a fair value of $226 million, or 1.0% of total invested assets, and $218 million, or 1.0% or total invested assets, at March 31, 2024 and December 31, 2023, respectively. During the three months ended </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.946%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private Placements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains or losses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer out</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Swaps</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on SOFR, to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our condensed consolidated balance sheets at fair value as of the reporting date. Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $17 million at March 31, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheets, were approximately $20 million and $68 million at March 31, 2024 and December 31, 2023, respectively. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three months ended March 31, 2024. We did not enter into interest-rate swap agreements for the three months ended March 31, 2023. The following table summarizes the notional amounts at March 31, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:59.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000 million, 5.750% due April 15, 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt is recorded at carrying value in our condensed consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $13.0 billion at March 31, 2024 and $10.8 billion at December 31, 2023. The fair value of our senior notes debt was $12.6 billion at March 31, 2024 and $10.6 billion at December 31, 2023. The fair value of our senior notes debt is determined based on Level 2 inputs, </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our commercial paper borrowings. The commercial paper borrowings were $0.3 billion and $0.9 billion at March 31, 2024 and December 31, 2023, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Put and Call Options Measured at Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson &amp; Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $731 million and $22 million, respectively, at March 31, 2024. The put and call options fair values, derived from the Monte Carlo simulation, were $595 million and $18 million, respectively, at December 31, 2023. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.</span></div><div style="margin-bottom:9pt;text-align:right;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:59.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0% - 18.8%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1% - 17.8%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit spread</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0% - 1.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% - 1.1%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue exit multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average cost of capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 12.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 12.5%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets and Liabilities Measured at Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2024 and 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the assets and liabilities acquired during 2024 and 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2024 and 2023. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our fair value measurements at March 31, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:49.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,077 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,851 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:58.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:58.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,590 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5594000000 5594000000 0 0 2844000000 0 2844000000 0 3439000000 0 3439000000 0 826000000 0 826000000 0 394000000 0 391000000 3000000 1308000000 0 1308000000 0 1517000000 0 1479000000 38000000 6749000000 0 6564000000 185000000 17077000000 0 16851000000 226000000 22671000000 5594000000 16851000000 226000000 4582000000 4582000000 0 0 2667000000 0 2667000000 0 3522000000 0 3522000000 0 858000000 0 858000000 0 400000000 0 396000000 4000000 1345000000 0 1345000000 0 1771000000 0 1733000000 38000000 6445000000 0 6269000000 176000000 17008000000 0 16790000000 218000000 21590000000 4582000000 16790000000 218000000 226000000 0.010 218000000 0.010 During the three months ended <div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.946%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private Placements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains or losses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer out</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 218000000 101000000 0 0 -2000000 1000000 11000000 1000000 0 0 1000000 0 0 4000000 226000000 99000000 17000000 20000000 68000000 The following table summarizes the notional amounts at March 31, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:59.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000 million, 5.750% due April 15, 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 750000000 0.05875 650000000 650000000 850000000 0.05950 800000000 400000000 500000000 0.03950 450000000 450000000 750000000 0.05500 700000000 300000000 1000000000 0.05750 400000000 0 13000000000 10800000000 12600000000 10600000000 300000000 900000000 731000000 22000000 595000000 18000000 The table below presents the assumptions used for each reporting period.<div style="margin-bottom:9pt;text-align:right;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:59.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0% - 18.8%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1% - 17.8%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit spread</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0% - 1.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% - 1.1%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue exit multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average cost of capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 12.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 12.5%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.170 0.188 0.161 0.178 0.010 0.013 0.009 0.011 1.5 2.5 1.5 2.5 0.110 0.125 0.110 0.125 0.030 0.030 MEDICARE PART D<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at March 31, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:41.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.570%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,472)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,825)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,880)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net long-term asset (liability)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,880)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at March 31, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.<div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:41.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.570%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,472)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,825)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,880)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net long-term asset (liability)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,880)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 100000000 592000000 224000000 514000000 108000000 2472000000 232000000 1825000000 -8000000 -1880000000 -8000000 -1311000000 293000000 0 17000000 0 81000000 0 77000000 0 212000000 0 -60000000 0 204000000 -1880000000 -68000000 -1311000000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for our reportable segments for the three months ended March 31, 2024 were as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:55.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,563 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at March 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/<br/>    relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and <br/>    technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and <br/>    other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible <br/>    assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended March 31, 2024 and 2023, amortization expense for other intangible assets was approximately $16 million and $18 million, respectively. The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at March 31, 2024:</span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:88.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> <div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for our reportable segments for the three months ended March 31, 2024 were as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:55.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,563 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2663000000 6887000000 9550000000 0 13000000 13000000 2663000000 6900000000 9563000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at March 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/<br/>    relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and <br/>    technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and <br/>    other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible <br/>    assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at March 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/<br/>    relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and <br/>    technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and <br/>    other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible <br/>    assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1092000000 1092000000 1092000000 1092000000 288000000 288000000 288000000 288000000 P9Y4M24D 956000000 728000000 228000000 956000000 718000000 238000000 P6Y8M12D 139000000 111000000 28000000 139000000 109000000 30000000 P11Y10M24D 67000000 63000000 4000000 67000000 62000000 5000000 P8Y4M24D 85000000 46000000 39000000 84000000 44000000 40000000 P9Y2M12D 2627000000 948000000 1679000000 2626000000 933000000 1693000000 16000000 18000000 The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at March 31, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:88.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 44000000 58000000 43000000 33000000 29000000 27000000 BENEFITS PAYABLE<div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,104)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,729 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At March 31, 2024, benefits payable included IBNR of approximately $7.3 billion, primarily associated with claims incurred in 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development). </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> <div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,104)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,729 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10241000000 9264000000 25659000000 22380000000 -535000000 -522000000 25124000000 21858000000 16061000000 14203000000 7575000000 6901000000 23636000000 21104000000 11729000000 10018000000 7300000000 EARNINGS PER COMMON SHARE COMPUTATION<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detail supporting the computation of basic and diluted earnings per common share was as follows for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:77.872%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, except per common share results; number of shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available for common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average outstanding shares of common stock <br/>    used to compute basic earnings per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,978 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,005 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted earnings per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,268 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,564 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.91 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.87 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of antidilutive stock options and restricted stock <br/>    excluded from computation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detail supporting the computation of basic and diluted earnings per common share was as follows for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:77.872%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, except per common share results; number of shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available for common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average outstanding shares of common stock <br/>    used to compute basic earnings per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,978 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,005 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted earnings per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,268 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,564 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.91 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.87 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of antidilutive stock options and restricted stock <br/>    excluded from computation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 741000000 1239000000 120978000 125005000 6000 34000 284000 525000 121268000 125564000 6.13 9.91 6.11 9.87 1165000 538000 STOCKHOLDERS’ EQUITY<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/29/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/26/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Board declared a cash dividend of $0.885 per share payable on April 26, 2024 to stockholders of record on March 29, 2024. In April 2024, the Board declared a cash dividend of $0.885 per share payable on July 26, 2024 to stockholders of record as of the close of business on June 28, 2024. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.</span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. During the three months ended March 31, 2024, we repurchased 1.8 million shares in open market transactions for $702 million at an average price of $388.78 under the February 2023 and 2024 share repurchase authorizations. During the three months ended March 31, 2023, we repurchased 0.1 million shares in open market transactions for $67 million at an average price of $495.68 under the February 2023 share repurchase authorization.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining repurchase authorization was $2.96 billion as of April 23, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with employee stock plans, we acquired 0.04 million common shares for $15 million and 0.05 million common shares for $27 million during the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/29/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/26/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.8850 108000000 0.885 0.885 824000000 3000000000 1800000 702000000 388.78 100000 67000000 495.68 2960000000 40000.00 15000000 50000.00 27000000 INCOME TAXES<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The effective income tax rate was 25.3% and 22.5% for the three months ended March 31, 2024 and 2023, respectively. The year-over-year increase in the effective income tax rate is primarily due to a change in the mix of current year earnings between our Insurance segment and our CenterWell health services segment, as the latter incurs a higher effective domestic tax rate than the former. In addition, the prior year income tax rate was favorably impacted by the recognition of a non-taxable gain.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> 0.253 0.225 DEBT<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at March 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:60.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.850% due October 1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 4.500% due April 1, 2025</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.700% due March 13, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 1.350% due February 3, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.950% due March 15, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due March 1, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due December 1, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 3.700% due March 23, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.125% due August 15, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 4.875% due April 1, 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,250 million, 5.375% due April 15, 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 2.150% due February 3, 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250 million, 8.150% due June 15, 2038</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.625% due December 1, 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 4.950% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.800% due March 15, 2047</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000 million, 5.750% due April 15, 2054</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,390 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In March 2024, we issued $1.3 billion of 5.375% unsecured senior notes due April 15, 2031 and $1.0 billion of 5.750% unsecured senior notes due April 15, 2054. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $2.2 billion. We used the net proceeds for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on SOFR, to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $17 million at March 31, 2024.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Agreements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021) and entered into a 364-day $1.5 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2022, which expired in accordance with its terms). </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SOFR spread, currently 114.0 basis points under the 5-year revolving credit agreement and 116.0 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 11.0 basis points, under the 5-year revolving credit agreement and 15.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 45.1% as measured in accordance with the revolving credit agreements as of March 31, 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At March 31, 2024, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of March 31, 2024, we had $2.482 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the three months ended March 31, 2024 was $2.7 billion, with $0.3 billion outstanding at March 31, 2024 compared to $0.9 </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">billion outstanding at December 31, 2023. The outstanding commercial paper at March 31, 2024 had a weighted average annual interest rate of 5.46%.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Short-term Borrowings</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. </span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At March 31, 2024 we had no outstanding short-term FHLB borrowings.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at March 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:60.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.850% due October 1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 4.500% due April 1, 2025</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.700% due March 13, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 1.350% due February 3, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.950% due March 15, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due March 1, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due December 1, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 3.700% due March 23, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.125% due August 15, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 4.875% due April 1, 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,250 million, 5.375% due April 15, 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 2.150% due February 3, 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250 million, 8.150% due June 15, 2038</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.625% due December 1, 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 4.950% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.800% due March 15, 2047</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000 million, 5.750% due April 15, 2054</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,390 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 250000000 871000000 600000000 0.03850 572000000 572000000 572000000 572000000 822000000 1443000000 600000000 0.04500 599000000 598000000 500000000 0.05700 498000000 498000000 750000000 0.01350 688000000 688000000 600000000 0.03950 537000000 537000000 500000000 0.05750 495000000 495000000 500000000 0.05750 495000000 495000000 750000000 0.03700 590000000 590000000 500000000 0.03125 433000000 433000000 500000000 0.04875 496000000 496000000 1250000000 0.05375 1238000000 0 750000000 0.02150 744000000 743000000 750000000 0.05875 735000000 750000000 850000000 0.05950 826000000 840000000 250000000 0.08150 261000000 261000000 400000000 0.04625 396000000 396000000 750000000 0.04950 740000000 740000000 400000000 0.04800 396000000 396000000 500000000 0.03950 514000000 529000000 750000000 0.05500 720000000 728000000 1000000000 0.05750 989000000 0 12390000000 10213000000 12390000000 10213000000 1300000000 0.05375 1000000000 0.05750 2200000000 17000000 P5Y 2500000000 P5Y 2500000000 P364D 1500000000 P364D 1500000000 0.01140 P5Y 0.01160 P364D 0.00920 0.01300 P5Y 0.00940 0.01350 P364D 0.00110 P5Y 0.00150 P364D 0.00080 0.00200 P5Y 0.00060 0.00150 P364D 0.60 0.451 0 18000000 2482000000 P5Y 1500000000 P364D 750000000 2700000000 300000000 900000000 0.0546 0 COMMITMENTS, GUARANTEES AND CONTINGENCIES<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Contracts</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare products, which accounted for approximately 86% of our total premiums and services revenue for the three months ended March 31, 2024, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state-based Medicaid business, which accounted for approximately 7% of our total premiums and services revenue for the three months ended March 31, 2024 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At March 31, 2024, our Military services business, which accounted for approximately 1% of our total premiums and services revenue for the three months ended March 31, 2024, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2024, unless further extended. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract comprises 24 states, and Washington D.C., and covers approximately 4.6 million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is <span style="-sec-ix-hidden:f-1003">one</span> transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings and Certain Regulatory Matters</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States of America ex rel. Steven Scott v. Humana Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, currently pending in United States District Court, Western District of Kentucky, Louisville division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. During 2023, we accrued certain anticipated expenses in connection with this matter.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Lawsuits and Regulatory Matters</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.</span></div> 0.86 0.07 0.01 32 6000000 24 4600000 8 P9Y SEGMENT INFORMATION<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $3.7 billion and $4.0 billion for the three months ended March 31, 2024 and 2023, respectively. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $32 million and $33 million for the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our segment results were as follows for the three months ended March 31, 2024 and 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:52.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2024</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,906)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,801 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,962)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,762)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,666)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,023 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 3700000000 4000000000 32000000 33000000 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our segment results were as follows for the three months ended March 31, 2024 and 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:52.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2024</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,906)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,801 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,962)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,762)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,666)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,023 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 22448000000 0 22448000000 1989000000 0 1989000000 821000000 0 821000000 25258000000 0 25258000000 256000000 0 256000000 239000000 0 239000000 197000000 0 197000000 2311000000 0 2311000000 28261000000 0 28261000000 0 335000000 335000000 0 241000000 241000000 24000000 0 24000000 251000000 0 251000000 0 211000000 211000000 275000000 787000000 1062000000 28536000000 787000000 29323000000 1000000 1414000000 -1415000000 0 2617000000 -2617000000 1000000 4031000000 -4032000000 162000000 0 126000000 288000000 28699000000 4818000000 -3906000000 29611000000 25251000000 0 -127000000 25124000000 2364000000 4483000000 -3805000000 3042000000 186000000 53000000 -30000000 209000000 27801000000 4536000000 -3962000000 28375000000 898000000 282000000 56000000 1236000000 0 1000000 158000000 159000000 0 0 -63000000 -63000000 898000000 281000000 -165000000 1014000000 -2000000 -22000000 0 -24000000 896000000 259000000 -165000000 990000000 -2000000 0 0 -2000000 898000000 259000000 -165000000 992000000 19809000000 0 19809000000 1765000000 0 1765000000 616000000 0 616000000 22190000000 0 22190000000 1018000000 0 1018000000 254000000 0 254000000 179000000 0 179000000 1909000000 0 1909000000 25550000000 0 25550000000 0 314000000 314000000 0 201000000 201000000 71000000 0 71000000 171000000 0 171000000 0 242000000 242000000 242000000 757000000 999000000 25792000000 757000000 26549000000 14000000 1133000000 -1147000000 0 2615000000 -2615000000 14000000 3748000000 -3762000000 97000000 0 96000000 193000000 25903000000 4505000000 -3666000000 26742000000 21993000000 0 -135000000 21858000000 2418000000 4126000000 -3565000000 2979000000 165000000 49000000 -28000000 186000000 24576000000 4175000000 -3728000000 25023000000 1327000000 330000000 62000000 1719000000 0 0 113000000 113000000 0 0 8000000 8000000 1327000000 330000000 -43000000 1614000000 -3000000 -14000000 0 -17000000 1324000000 316000000 -43000000 1597000000 -1000000 0 0 -1000000 1325000000 316000000 -43000000 1598000000 false false false false